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Hepatitis C virus (HCV) uniquely requires the liver specific microRNA-122 (miR-
122) for replication, yet global effects on endogenous microRNA (miRNA) targets 
during infection are unexplored. In this body of work, we employed high-
throughput sequencing and crosslinking immunoprecipitation (HITS-CLIP) 
experiments of human Argonaute (AGO) during HCV infection. We demonstrate 
robust AGO binding on the 5' untranslated region of HCV RNA at known and 
predicted miR-122 sites, thereby establishing conclusive biochemical evidence of 
endogenous miR-122 action on HCV RNA that firmly agrees with previous 
genetic evidence. We further characterize novel AGO binding on HCV RNA to 
determine its dependence on miR-122, miRNAs generally, replication 
competence and time. These results establish an unbiased interaction landscape 
between HCV RNA and cellular miRNAs, mostly miR-122. 
On the human transcriptome, we observed reduced AGO binding and 
functional mRNA de-repression of miR-122 targets during virus infection. This 
miR-122 "sponge" effect was relieved and redirected to miR-15 targets by 
swapping the miRNA tropism of the virus. Single-cell expression data from 
reporters containing miR-122 sites showed significant de-repression during HCV 
infection depending on expression level and site number. Based on these results, 
we describe a quantitative mathematical model of HCV induced miR-122 
sequestration and propose that such miR-122 inhibition by HCV RNA may result 
in global de-repression of host miR-122 targets. This in turn may provide an 
environment fertile for the long-term oncogenic potential of HCV. 
This last point presented a fitting entree into miR-122 biology, given its 
known tumor suppressive activity in the liver. To conclude this work, we 
performed AGO-CLIP in miR-122 knockout mouse livers as well as in human 
liver samples, to determine the in vivo targetome for this miRNA across two 
species. Surprisingly, we discovered widespread and non-canonical miR-122 
binding throughout the transcriptome. Furthermore, a substantial fraction of this 
binding was not conserved between mouse and human transcriptomes, despite 
the fact that miR-122 is highly conserved. These results, in concert with AGO-
CLIP in HCV infected cells, point to a model where HCV may have evolved the 
use of miR-122 for its high abundance and its well buffered capacity to be 
inhibited with minimal detrimental effects to the host, and perhaps benefits for the 
virus. 
In sum, this thesis reveals how miR-122 is redistributed in the cell 
following HCV infection. As a molecular mechanism, chronic inhibition of miR-122 
by HCV RNA is proposed to impact, and may very well help induce, the complex 
constellation of liver diseases that characterize this infection in humans.
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To my grandparents 
Che non men che saper dubbiar m'aggrada 
"For doubting pleases me as much as knowing" 
-Dante, Inferno XI 
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Chapter 1: Introduction 
 In 1989, Qui-Lim Choo, Michael Houghton and colleagues at the Chiron 
corporation identified a positive sense, ~10kb RNA of exogenous origin that was 
closely associated with non-A, non-B hepatitis (NANBH) and renamed Hepatitis-
C Virus (HCV) (Choo et al., 1989). With a molecular handle for identifying HCV, 
work quickly progressed in establishing a causal role in NANBH, identifying anti-
HCV antibodies in NANBH patients, and linking HCV with end-stage liver disease 
and hepatocellular carcinoma (HCC) in humans (Alter et al., 1989; Kiyosawa et 
al., 1990; Kuo et al., 1989). Despite comprising its own genus among the 
flaviviridae family of viruses, HCV was later found to exhibit significant sequence 
heterogeneity and was grouped into at least seven major genotypes with 
numerous subtypes (Bukh et al., 1993; Smith et al., 2014). The domestication of 
HCV to enable detailed laboratory investigation in tissue culture was a long and 
laborious process that ultimately succeeded with the development of sub-
genomic replicons, the isolation of highly permissive cell lines, and the isolation 
of adaptive HCV variants that lead to the establishment of viral clones capable of 
producing infectious virus particles in cell culture (Blight et al., 2002; Lindenbach 
et al., 2005; Lohmann et al., 1999; Wakita et al., 2005). In the quarter century 
since its discovery, strategies to cure HCV have progressed dramatically from 
interferon therapy, with ~50% cure rates, to direct acting anti-viral agents (DAAs) 
with cure rates in excess of 95% across a variety of viral genotypes (Sadler and 
Lee, 2015). These stunning developments, only apparent in the past few years 
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and currently ongoing, were coincident and dependent upon breakthroughs in 
basic studies of HCV in virus labs the world over, to whom full credit as a field is 
due. For anyone who has borne witness to the discovery and cure of HCV within 
the span of one scientific lifetime, it is tempting to declare an end to this viral 
scourge in the age of highly effective curative therapy. And yet, much remains to 
be done. It is, in this student's eyes, only the beginning.  
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An overview of hepatitis C virus 
 As of 2014, HCV remains a major global public health burden with an 
estimated 185 million people ~(2.8% of the world's population) currently infected 
(Mohd Hanafiah et al., 2013). In the United States, between 3.4 and 4.4 million 
people are estimated to be infected with HCV (Chak et al., 2011). While most 
infections are asymptomatic, symptoms during an acute HCV infection include 
hepatitis and jaundice (Hoofnagle, 1997; Villano et al., 1999). Between 10-40% of 
HCV infections spontaneously resolve while the majority of cases result in a 
chronic infection (Figure 1.1) (Thomas et al., 2000; Thomas, 2013). Persistent 
HCV infections can result in an array of outcomes, including cirrhosis and HCC, 
which manifest over decades in 2-30% of patients (Bruno et al., 1997). 
Complications from cirrhosis and related end-stage liver diseases (ESLDs) 
combined with HCV-associated HCC have made HCV the primary cause of liver 
transplants in the U.S. (Davis et al., 2010). Moreover, HCV-induced cirrhosis 
constitutes a top risk factor for HCC (Herbst and Reddy, 2013).  
 While HCV infections are globally prevalent, they are unevenly distributed 
across regions and age groups. HCV is the largest proximal cause of liver 
transplantations in industrialized nations where infection prevalence remains 
highest among marginalized populations such as the incarcerated, injection drug 
users, and the homeless (Chak et al., 2011). Global prevalence is highest in 
developing nations, particularly in the Middle-East and Asia (Mohd Hanafiah et 
al., 2013).  
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Figure 1.1. HCV infection natural history. An acute infection may result in 
hepatitis and jaundice, which in 10-40% of cases resolves within 3-6 months. 
Unresolved infections persist for decades in 60-90% of cases and can result in 
extra-hepatic complications. A wide range of cases (2-30%) progress to end 
stage liver disease including cirrhosis and HCC. ALT: Alanine transaminase. 
Figure from (Thomas, 2013).  
 
Egypt is estimated to have the highest HCV prevalence among nations, where up 
to 50% of persons born before 1960 are affected. The history of HCV infection in 
Egypt exemplifies global HCV transmission in the era before mass blood 
surveillance: mass public health injection campaigns to eradicate schistosomiasis 
from the 1950s to 1970s resulted in millions of Egyptians unknowingly becoming 
infected with HCV. These mid-20th century surges in infection, in Egypt and 
elsewhere, were subsequently linked to unsafe injection and unsterile treatment 
practices that largely no longer occur (Thomas, 2013). Combined with routine 
blood screening in place since the early 1990s, incidences of HCV infection from 
contaminated blood products are exceedingly remote (Chak et al., 2011).  
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 Despite tremendous advances in stemming new HCV infections from 
blood products, the epidemiology of HCV in the 20th century presents a continued 
challenge given that the infection is largely asymptomatic and presents with liver 
disease decades after the initial infection (Thomas et al., 2000). It is estimated 
that in the U.S., persons born between 1946 and 1965, the so-called "baby 
boom" generation, will likely bear the brunt of HCV related complications. Peak 
projections estimate over a quarter million HCV liver-related deaths between 
2020 to 2029 (Davis et al., 2010). Concurrently, estimates on the need for liver 
transplantations are expected to sharply rise in the coming decade (Biggins et 
al., 2012). These sobering statistics combined with their projected economic and 
quality-of-life impacts, even in the age of curative DAAs, make continued 
scientific efforts at understanding the role of HCV in promoting liver disease all 
the more relevant (Thomas, 2013).  
 The uneven global distribution of HCV is reflected in the distribution of the 
various genotypes of the virus (Figure 1.2) (Messina et al., 2015). At both the 
nucleotide and amino acid level, genotypes differ around 30%, subtypes around 
20%, and isolates within a subtype between 2-10% (Simmonds et al., 2005). Of 
the six major known genotypes, Genotype 1 predominates in the Americas and 
western Europe, accounting for 70% and between 50-70% of cases in each 
region, respectively. Genotype 2 is prevalent in the Americas, sub-Saharan 
Africa, and Japan, where genotype 1 is also present.  
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Figure 1.2. Relative prevalence of each HCV genotype by Global Burden of 
Disease (GBD) region. Size of pie charts is proportional to the number of 
seroprevalent cases as estimated by (Mohd Hanafiah et al., 2013). Figure from 
(Messina et al., 2015).  
 
 
Genotype 3 is mostly found in Europe, southern and western Asia, while 
genotypes 4 and 5 are prevalent in central and South Africa. Genotype 6 mostly 
affects East and Southeast Asia. A recent and novel genotype 7, with only a few 
cases, appears to be present in central Africa (Murphy et al., 2014). While all 
genotypes appear to have similar pathogenic features, some differ in their 
association with certain complications and their abilities to be studied in the lab. 
For example, genotype 3 has been associated with an increased risk of liver 
steatosis and HCC compared to other genotypes (Adinolfi et al., 2001; Nkontchou 
et al., 2011; Rubbia-Brandt et al., 2000). Historically, Genotype 1 has been both 
the most prevalent and difficult to treat (Hoofnagle and Seeff, 2006). Genotype 2 
viruses have been the most proximate source of cell culture adapted HCVs: a 
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Japanese genotype 2 isolate (JFH-1) was the progenitor of fully infectious HCV 
cell culture systems (Lindenbach et al., 2005; Wakita et al., 2005).  
 With the advent of DAAs providing highly curative, interferon-free, 
treatment regimens that exhibit pan-genotypic effectiveness with minimal side 
effects, it is conceivable that viral genotyping will cease to be relevant for HCV 
therapy (Messina et al., 2015). And yet, with a plurality of outcomes for HCV 
infections, from asymptomatic to sever liver disease, environmental factors such 
as genotypic differences, combined with host-genetics in the dynamically 
regulated and aging liver only highlight how much there is to learn about HCV 
disease causation. For our purposes, this introduction will start small and at the 
source by turning our attention to the virus.  
 
The HCV life cycle 
 HCV is an enveloped, spherical virus particle between 50-80nm in 
diameter (Catanese et al., 2013b). The virion is studded with E1 and E2 
glycoprotein heterodimers embedded in the lipid bilayer, which encloses a 
nucleocapsid consisting of the core protein and a positive sense RNA genome 
approximately 9.6kb in length. The RNA genome consists of highly structured 5' 
and 3' untranslated regions (UTRs) that flank a single viral open reading frame 
(ORF) which encodes a single polyprotein of around 3000 amino acids that is 
processed into ten distinct components comprised of structural proteins (Core, 
E1, and E2), p7 channel, and the non-structural proteins (NS2, NS3, NS4A, 
NS4B, NS5A, and NS5B) (Figure 1.3) (Lindenbach and Rice, 2005).  
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Figure 1.3. HCV genome organization and polyprotein processing. The HCV RNA 
genome (top) contains highly structures 5′ and 3′ UTRs (red) which flank a single 
long ORF (blue). IRES-mediated translation of the ORF leads to a polyprotein 
(bottom) that is co- and post-translationally processed into ten viral proteins. Core 
protein maturation involves a cellular signal peptide peptidase cleavage of a C-
terminal signal peptide (white triangle) and cleavage from E1 by the cellular 
signal peptidase, which also cleaves E1, E2 and p7 from the polyprotein (gray 
triangles). In an autocleavage mechanism requiring a dimer to make up the 
composite active site, the NS2-NS3 protease cleaves itself (red triangle). The 
NS3 protease located in the first one-third of NS3, assisted by its membrane 
bound cofactor, NS4A, cleaves the remaining proteins NS3, NS4A, NS4B, NS5A 
and NS5B (green triangles). Glycosylation of the envelope proteins (black dots) 
and the functions of the individual HCV proteins are indicated. Figure adapted 
from (Scheel and Rice, 2013).  
 
 
HCV entry 
  Among the most well studied aspects of HCV biology, viral entry presents 
a multitude of unique features and outstanding questions (Lindenbach and Rice, 
2013). HCV particles typically exist as lipoviroparticles (LVPs) in infected hosts, 
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so described due to the association of the virion with low-density and very-low-
density lipoproteins (LDL and VLDL) (Andre et al., 2002; Merz et al., 
2011)(Figure 1.4). In addition to association with ApoE and ApoB, LVPs engineer 
a "Trojan horse" for HCV by coercing lipoprotein secretion and adsorption 
mechanisms for productive entry into cells, and may help shield the virus from 
neutralization (Bartenschlager et al., 2011). To present a summarized model of 
HCV entry (comprehenisvely reviewed by (Lindenbach and Rice, 2013)), LVPs 
are thought to first make contact with host cells via low affinity engagement of the 
LDL receptor (LDLR) and glycosaminoglycans (GAGs), before E1-E2 interactions 
engage co-receptors Scavenger Receptor class B member 1 (SR-B1) and 
Cluster of Differentiation 81 (CD81) with higher affinity promoted in part by 
epidermal growth factor receptor (EGFR) and ephrin receptor type A2 (EphA2). 
The CD81 bound HCV particles are then thought to traffic laterally to tight-
junctions where Claudin-1 (CLDN1) and Occluding (OCLN) play critical roles in 
late stages of entry thorough interactions with the NPC1L1 cholesterol absorption 
receptor.  
 At this point, LVP uptake occurs via clathrin mediated endocytosis, likely 
into endosomes wherein low pH alongside CD81 priming is sufficient to trigger 
fusion of the viral envelope with the host membrane (Sharma et al., 2011). 
Although E2 is predicted to be a class II fusion protein, recent structures on 
highly related pestivirus E2 has led to speculation that E1 may be fusogenic (Li et 
al., 2013e; Omari et al., 2013).  
 10 
 
 
Figure 1.4. The HCV life cycle. Interaction of extracellular HCV LVPs with cellular 
surface receptors initiates the entry process, which can also occur from direct 
cell-to-cell transmission. After pH-dependent fusion and uncoating, the incoming 
HCV genome is translated and the resulting polyprotein is processed (bottom 
inset and Figure 1.3). HCV NS proteins set up ER-derived membrane spherules 
(membranous web, bottom right inset) to initiate the process of RNA replication. 
The spatiotemporal contribution of miR-122 binding to the HCV genome is not yet 
fully understood, and miR-122 presence is indicated with '?'. In the assembly and 
release process (top right inset), core protein is transferred from cytoplasmic 
Lipid Droplets (cLD) to form nucleocapsids are loaded with viral RNA, with the 
help of NS5A, NS2, NS3-NS4A and perhaps p7. It is not clear whether the RNA 
is transiently located on the cLD. Virion morphogenesis is coupled to the VLDL 
secretion pathway through luminal lipid droplets (LuLD), and particles are 
produced as LVPs. EphA2, ephrin receptor type A2; GAG, glycosaminoglycans; 
PL, phospholipids; TG, triglycerides; MTP, microsomal transfer protein. Figure 
adapted from (Scheel and Rice, 2013).  
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Further work on the E2 ectodomain has recently resolved a novel IgG like fold 
that does not appear to undergo structural rearrangements in low pH (Khan et al., 
2014). The late stages of entry, especially fusion and viral uncoating remain 
poorly understood.  
 
HCV translation, protein processing and RNA replication 
 As mentioned above, the HCV genome is highly structured with critical 
RNA elements in the 5' and 3' UTRs (Lohmann, 2013). Following uncoating and 
release of viral genome into the cytoplasm, the pioneer round of translation of 
HCV RNA is initiated by an Internal Ribosome Entry Site (IRES) located in the 
5'UTR (Figure 1.3 and 1.4) (Fraser and Doudna, 2007). Translation begins on the 
IRES through direct and RNA structure-guided recognition of the 40S ribosomal 
and eukaryotic initiation factor 3 (eIF3), thus bypassing the need for the cap-
structure and related binding factors (Tsukiyama-Kohara et al., 1992; Wang et 
al., 1993). The AUG start codon is directly placed into the peptidyl (P) site of the 
40S subunit (Reynolds et al., 1995; Rijnbrand et al., 1996). The resulting HCV 
polyprotein is co- and post-translationally cleaved by the viral NS2-NS3 and NS3-
NS4A proteases and by cellular proteases (signalase and signal peptide 
peptidase), respectively into ten HCV proteins (Figure 1.3) (Lindenbach and Rice, 
2005). The NS4B and NS5A proteins are believed to induce ER rearrangements 
that result in membrane spherules which in aggregate are termed the 
"membranous web" (Figure 1.4) (Egger et al., 2002; Romero-Brey et al., 2012). 
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RNA replication occurs in this membranous web, which is thought to offer 
protection from dsRNA sensing and damaging reactive oxidants. As the RNA-
dependent RNA polymerase, NS5B forms the core of the HCV replicase 
complex, which in concert with the NS3 helicase, NS4A, and multi-functional 
NS5A, synthesizes anti-sense RNA genomes from sense templates (Lohmann, 
2013). Anti-sense genomes serve as the template for continual and successive 
production of sense genomes, which can then undergo translation, assembly and 
export, or RNA replication. The assembly, stability and decay of the replicase is 
thought to be a highly dynamic process, and so determining the precise 
spatiotemporal roles for replicase components has been difficult, and much 
remains to be explored (Lohmann, 2013).  
 
HCV assembly and release 
 Virus assembly and release is tightly coupled with host cell lipid 
biosynthesis (Lindenbach and Rice, 2013). Upon protease cleavage and 
liberation from the HCV polyprotein, the mature core protein critically relocates to 
cytoplasmic lipid droplets (cLDs) (Barba et al., 1997; Miyanari et al., 2007). 
Nucleocapsid formation involves the interaction of core with NS5A, though the 
precise mechanism for delivery of the RNA genome to sites of assembly is poorly 
understood (Lindenbach and Rice, 2013). Close juxtaposition of sites of RNA 
replication and virion assembly are thought to facilitate nucleocapsid formation 
alongside NS2 coordination of assembly through interactions with E1 and E2, p7, 
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NS3, and NS5A (Jones et al., 2007; Phan et al., 2009). E1 and E2, once 
processed, proceed through the ER where they assume a type 1 membrane 
topology. Further post-translational processing of E1 and E2 takes place to 
include the addition of N-linked sugar moieties and their trimming with 
glycosidases (Lavie et al., 2007). Nucleocapsids forming at cLDs link up with 
mature E1 and E2 by budding into luminal lipid droplets (luLDs) where the virion 
completes maturation and is secreted via the VLDL pathway (Gastaminza et al., 
2008). As virus particles transit through this secretory pathway, they are thought 
to be protected from low pH exposure by the p7 ion channel (Wozniak et al., 
2010). Once secreted from the cell as LVPs, the process then begins anew 
(Bartenschlager et al., 2011).  
 
HCV interactions with the innate immune response 
 HCV presents a thought-provoking case in that the standard of care prior 
to DAAs was interferon treatment, a central molecule in the innate immune 
response. And yet the mechanisms by which IFN therapy failed to work were 
mostly unknown and continue to be a major focus of current research (Horner 
and Gale, 2013). One theme centers on unique features of the HCV RNA 
genome. Unlike normal cellular mRNAs, the HCV genome lacks a 5' cap-
structure. And like all RNA viruses, HCV replication goes through an intermediate 
phase where double stranded RNA (dsRNA) is produced. As such uncapped 
RNAs or dsRNA products are rarely found in normal cellular cytoplasm, these 
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molecules constitute pathogen associated molecular patterns (PAMP) for which 
the cell has evolved sensing and effector mechanisms to mount an anti-viral 
response (Beutler et al., 2007). Early reports linking innate immunity to HCV 
infection focused on protein kinase R and RNAseL, two classical interferon 
stimulated genes (ISGs), as effector molecules counteracted by HCV proteins or 
RNA structures (Han and Barton, 2002; Taylor et al., 1999). Still, how HCV 
evaded innate immune sensing was a mystery. Clarity emerged in 2003, when 
Foy, Gale and colleagues established a role for NS3/4A protease activity as 
critical for preventing IRF3 activation and the downstream IFN response (Foy et 
al., 2003). A flurry of subsequent reports established that NS3/4A antagonizes a 
molecule dubbed the mitochondiral antiviral signaling protein (MAVS, aka IPS-1, 
VISA, and Cardif), a key player downstream of retinoid acid-inducible gene-I 
(RIG-I) (Meylan et al., 2005). In this manner, NS3/4A cleavage of MAVS blunts 
RIG-I activation of the interferon response. MAVS cleavage has been observed 
in patients where importantly, the presence of MAVS cleavage fragments 
correlated with lower levels of IFN activation (Bellecave et al., 2010).  
 The story of MAVS is presented here as one of a growing list, which 
includes TRIF (also cleaved by NS3/4A), a renewed interest in the sensing and 
effector activities of PKR, and the enigmatic clinical and predictive associations of 
HCV with IFNL4 (Horner and Gale, 2013; Prokunina-Olsson et al., 2013). The 
fact that HCV proteins have evolved functions that antagonize the host innate 
immune response is not surprising, particularly given what is known for other 
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viruses, notably HIV-1, for which each accessory protein seems all but tailor-
made to counter a host restriction factor (Malim and Bieniasz, 2012). Work 
utilizing ISG screens has provided a compelling platform to systematically 
address these issues in HCV and in other viruses (Diamond and Schoggins, 
2013; Dittmann et al., 2015; Schoggins et al., 2011; Wilson et al., 2012). What 
bears keeping in mind for HCV is that the complete picture of its regulation and 
subversion of innate immunity is unclear and that future surprises lie in store.  
 
HCV interactions with protein host factors 
 As detailed above, HCV depends extensively on the host cell to infect, 
replicate and spread, is subject to host innate immune control, and has evolved 
mechanism to evade innate immune detection. While too numerous to list here, a 
vast number of host factors influencing each aspect of the viral life cycle have 
been identified using RNAi-screening and mass spectroscopy methods (Shulla 
and Randall, 2012). HCV interactions with the host can be broadly classified as 
either pro- or anti-viral, on the basis of functional studies aimed monitoring the 
effect of factor perturbation on measureable virus outputs: RNA, protein and 
infectious virus. Many pro-viral factors have been the subject of detailed 
mechanistic investigation, as potential therapeutic targets complementary to DAA 
centered approaches. A few examples are highlighted here: 
 Cyclophilin A (CypA), a peptidyl-proyl cis-trans isomerase required for 
HCV replication through its interaction with NS5A, is a prime example, as it was 
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discovered after observing that the immunosuppressive drug cyclosporin A 
(CsA), which targets CypA, inhibited HCV replication in cell culture (Watashi, 
2003). While the precise role for CypA in HCV replication is still not clear, CsA 
derivatives are highly effective at antagonizing the critical NS5A-CypA interaction 
across all genotypes, and importantly, pose a high genetic barrier to drug 
resistance in vivo (Flisiak et al., 2012) 
 Diacylglycerol acyltransferase-1 (DGAT1) is an ER resident, triglyceride 
synthesizing enzyme, that was found to be critical for HCV particle formation 
(Herker et al., 2010). DGAT1 appears to regulate core trafficking via NS5A to lipid 
droplets, such that DGAT1 knockdown or pharmacologic inhibition prevents virus 
assembly (Camus et al., 2013; Herker et al., 2010).  
 Found in several siRNA screens, phosphatidylinositol-4 kinase III-α 
(PI4KIIIα) is an ER associated lipid kinase that hijacked by NS5A and seems to 
be essential for the integrity of the membranous web (Berger et al., 2009; Reiss 
et al., 2011). Later work identified that HCV inhibitors thought to target NS5A 
were actually directed to PI4KIIIα. While promising, transient ablation of PI4KIIIα 
lead to sever liver pathology in mice, so clearly more work is needed to 
determine if strategies aimed at inhibiting this enzyme are viable (Vaillancourt et 
al., 2012).  
 The mechanisms of how these host proteins facilitate HCV replication 
have been and are being worked squarely with therapeutic potential in mind. The 
overall motivation is that by developing host targeting agents (HTAs), problems 
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with viral resistance associated with prototypical DAAs can largely be 
circumvented, and in select cases perhaps eliminated (Scheel and Rice, 2013).  
 
Host protein interactions with HCV RNA 
 As the master blueprint for HCV, the viral RNA genome must interact with 
many host RNA binding proteins (RNABPs) to facilitate its tripartite role as 
template for replication, translation, and RNA packaging into virions. It also 
presents a central node whose targeted disruption theoretically presents an 
insurmountable barrier for virus resistance. A number of proteins bind the 3'UTR 
of HCV RNA to include heterogeneous nuclear ribonucleoprotein C (HNRNPC), 
ELA V-like RNA-binding protein 1 (ELAVL1, or HuR), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as well as polypyrimidine tract binding 
protein (PTBP1/2) (Ito and Lai, 1999; Luo, 1999; Petrik et al., 1999; Spångberg et 
al., 2000). As the latter would suggest, the poly-U/C tract of HCV RNA as well as 
the highly conserved 3' X-tail serve as binding sites for the above proteins though 
by and large, the functional importance of these protein-RNA interactions is far 
from clear. Most were found to interact with in vitro transcribed HCV RNA in cell 
lysates, so it's possible that many of these founding results are artifacts. Proteins 
binding the 5'UTR include poly(rC)-binding protein 2 (PCBP2), the La antigen, 
polypyrimidine tract binding protein (PTBP1/2), heterogeneous nuclear 
ribonucleoprotein L (HNRNPL), insulin-like growth factor 2 binding protein 1 
(IGF2BP1), and U6 snRNA-associated Sm-like protein (LSM1-7) (Ray and Das, 
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2011; Rosenfeld and Racaniello, 2005; Scheller et al., 2009; Weinlich et al., 
2009). These proteins may act as IRES-transactivating factors (ITAFs) as their 
specific depletion impairs HCV translation in cell culture and in general they are 
thought to be cofactors for a variety of IRESes (King et al., 2010). Some ITAFs 
bind the 3'UTR in addition, as shown for PCBP2, which may promote translation 
via circularization of the viral genome (Wang et al., 2011). Circularization of viral 
genomes is a common theme for regulating translation versus RNA replication in 
flaviviruses, however its role on HCV biology is unclear outside of in vitro 
systems. With the advent of CLIP methods to be discussed below, the functional 
genomic characterization of these and other protein-RNA interactions on a viral 
genome is increasingly within reach and represents a frontier ripe for 
advancement. For now, I focus your attention on one class of very well studied 
RNABPs, the Argonautes (AGOs), and their unique association with HCV RNA. 
But before that, we must explore a unique feature of this protein as being 
programmed by small snippets of RNA, called microRNAs, that allow AGOs to 
play critical roles in a multitude of biologic processes. 
 
MicroRNAs, small RNAs and silencing 
 MicroRNAs (miRNAs) are a class of small (~22nt) noncoding RNAs 
(ncRNAs) that regulate gene expression by sequence-specific targeting of 
mRNAs causing mRNA degradation or translational repression (Bartel, 2009). 
Initially identified as non-coding RNAs, lin-4 and let-7, which control the timing of 
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larval development in the worm C. elegans, miRNAs were soon found to 
represent an abundant class of small endogenous RNAs with a variety of 
regulatory roles throughout diverse metazoans (Lagos-Quintana et al., 2001; Lee 
and Ambros, 2001; Lee et al., 1993; Reinhart et al., 2000). In addition, miRNAs 
have also been found in plants, green algae, and viruses (Griffiths-Jones et al., 
2008).  
 In general, miRNAs are but one class of a number of small endogenous 
RNAs that include small interfering RNAs (siRNAs) and Piwi-interacting RNAs 
(piRNAs) (Ambros et al., 2003; Aravin et al., 2007). These small RNA types 
broadly contribute to the phenomena of RNA silencing, whereby small RNAs act 
as guides for PIWI domain containing RNA nucleases, predominantly the 
Argonautes (AGOs), to repress gene expression. However, miRNAs differ 
considerably from other small RNAs in their mode of biogenesis (Figure 1.5) 
(Bartel, 2004). miRNAs are transcribed by RNA polymerases II and III into 
primary miRNA (pri-miRNA), which undergoes processing into pre-miRNA 
hairpins through the action of the Microprocessor complex composed of the 
RNAse III enzyme Drosha and Di-George syndrome critical region 8 (DGCR8) 
proteins (Gangaraju and Lin, 2009). For a minority of miRNAs, Drosha 
independent pre-miRNA production can occur from miRNA genes present in 
introns, called "mirtrons", for which the spliceosome functions analogous to 
Drosha (Okamura et al., 2007; Ruby et al., 2007).  
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Figure 1.5. Canonical miRNA and siRNA biogenesis in metazoans. (A) 
MicroRNA (miRNA) genes are transcribed by RNA polymerases II and III into pri-
miRNAs. These are processed into pre-miRNAs in the nucleus by the 
Microprocessor complex, which contains the RNase III enzyme Drosha and the 
double-stranded RNA-binding protein DGCR8. Some miRNAs, called mirtrons, 
have also been shown to be generated from introns that bypass Drosha 
requirement. Pre-miRNAs are then transported into the cytoplasm by the 
karyopherin exportin-5 and RanGTP, where they are further processed by the 
RNAse III enzyme Dicer. This results in double-stranded 20–25nt intermediates 
with 2nt overhangs on the 3′ end. One of the RNA strands is then loaded by 
Dicer into an RNA-induced silencing complex (RISC), which contains an 
Argonaute family member, that then targets the 3′ untranslated region of the 
target mRNAs by an imperfect match between the miRNA and the mRNA, to 
induce mRNA degradation or repress translation. (B) The small interfering RNA 
(siRNA) pathway initiates with either bidirectional transcription or transcription of 
an inverted repeat that results in a double-stranded precursor. This precursor is 
also processed in the cytoplasm by Dicer and is loaded into a small interfering 
RISC (siRISC) complex intended for target mRNA degradation. Alternatively, 
dsRNA from an exogenous source (viral, transfected, careless graduate students, 
etc) can be processed directly from the cytoplasm. Figure modified from 
(Gangaraju and Lin, 2009).  
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 Pre-miRNAs are exported from the nucleus through the action of exportin-
5 and RanGTP (Bohnsack et al., 2004). Once in the cytoplasm, pre-miRNAs 
undergo processing by the RNAse III enzyme Dicer, generating a double 
stranded 20-25nt intermediate that gets loaded onto AGO to form a RNA-induced 
silencing complex (RISC) (Hutvágner and Zamore, 2002). The miRNA bound 
RISC represses through base pairing of the miRNA with the 3'UTR of the mRNA 
target, and subsequently promotes mRNA decay or translational repression, via 
partially understood mechanisms (Filipowicz et al., 2008).  
 The small interfering RNA (siRNA) pathway initiates with either 
bidirectional transcription or transcription of an inverted repeat that results in a 
double-stranded precursor. This precursor is also processed in the cytoplasm by 
Dicer and is loaded into a small interfering RISC (siRISC) complex intended for 
target mRNA degradation (Carthew and Sontheimer, 2009). Alternatively, dsRNA 
from an exogenous source can be processed directly from the cytoplasm and 
loaded onto RISC (MacKay et al., 2014). While this pathway is present in 
mammalian cells, it is not thought to compose an appreciable anti-viral response 
(see below). 
 In theory, the capacity for siRISC or miRISC to silence target mRNAs 
without nuclear control or input offers a highly flexible and rapid platform for an 
immune response to foreign nucleic acids (Carthew and Sontheimer, 2009). 
Indeed, RNA interference (RNAi) as described above forms that backbone of the 
innate immune response in both plants and invertebrates (Baulcombe, 2004). 
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Along similar lines, CRISPR systems in bacteria and archaea provide somewhat 
analogous protection mechanisms from invading bacteriophage DNA or RNA, 
with the added benefits of being both adaptive and heritable (Bondy-Denomy and 
Davidson, 2014). Given the above, vertebrates appear to be outliers with 
elaborate protein based immune responses, centered largely on interferon 
signaling, that induce the production of hundreds of effector proteins called 
interferon stimulated genes (ISGs) (Schoggins and Rice, 2011). The relationship 
between a robust protein based and an ancient, though ancillary RNA-based 
immune response in vertebrates will be discussed in a following section. It 
suffices here to mention that recent findings have only reinvigorated the 
discussion on the anti-viral functions of RNAi in mammalian cells (Burgess, 2013; 
Li et al., 2013c; Maillard et al., 2013; Sagan and Sarnow, 2013; Tanguy and 
Miska, 2013).  
MicroRNA target recognition, function and expression 
 At the simplest level, miRNA function is governed within the AGO protein. 
On AGO, a miRNA encounters its mRNA target via Watson-Crick base pairing to 
a "seed" region on the mRNA (positions 2-7 from the miRNA 5' end) (Figure 
1.6A) (Bartel, 2009). Each miRNA is predicted to regulate hundred of targets, 
primarily by engaging 3'UTRs (Lewis et al., 2005). With hundreds of known and 
predicted miRNA genes in the human genome, and comparable numbers in mice 
and other mammals, the array of possible regulatory events is astounding. 
However, three key principles are worth emphasizing.  
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Figure 1.6. miRNA seed characteristics and repression features. (A) Schematic 
of miRNA (miR-122) engagement of mRNA targets displaying all major classes of 
miRNA seed pairing: 8mer, 7mer-m8, 7mer-A1, 6mer, offset 6mer, and 3' 
supplementary or compensatory pairing, which can occur with all of the above 
seeds, but is illustrated here with 7mer-m8. The predicted frequency of each 
seed class for conserved mRNA targets for a prototypical and conserved miRNA 
is shown at right from calculations by (Friedman et al., 2009). (B) Target mRNA 
repression is schematized along the y-axis where repressive potential of seed 
site types, site number and positioning, and 3' supplementary pairing is displayed 
graphically. Panel B modified from (Bartel, 2009) 
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 First, binding energetics and the location of mRNA binding sites are 
important in terms of delineating functional repression. The strength of target 
mRNA repression is directly proportional to seed energetic stability, as 
summarized in Figure 1.6B. Practically, this means that 8mers are on average 
more repressive than 7mers, which are more repressive than 6mer seeds, and 
so on. 7mer-m8 seeds are typically more repressive than 7mer-A1 seeds, as the 
first miRNA position does not engage in base pairing with mRNA; instead the 
mRNA binding pocket in AGO structurally prefers an adenosine to allow seed 
binding to occur (Elkayam et al., 2012; Schirle et al., 2014). Supplementary 3' 
pairing of a miRNA to its target beyond nucleotides 10-12 can boost repression 
largely by increasing base pairing stability, though these are considered rare 
(Bartel, 2009). By and large, miRNA binding to 3'UTRs is more repressive than 
binding to coding exons, presumably due to competition of the translocating 
ribosome, though this has not been directly tested. As might be expected, 
multiple miRNA seeds per mRNA are more repressive than single seeds, where 
notably, cooperative repression is observed if miRNA sites are within 40nt of one 
another (Grimson et al., 2007; Saetrom et al., 2007).  
 Second, functional conservation tends to matter for both the miRNA and 
its mRNA binding seed targets. Many miRNA families−i.e. a collection of miRNAs 
that share the same seed−are broadly conserved throughout metazoans while 
others are found in only a few lineages (Altuvia et al., 2005). miRNAs related by 
family typically regulate the same sets of genes in various organisms, such as 
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miR-142-3p in myeloid cells or miR-1 in muscle, though this is not always the 
case (Lee et al., 2007). In broad terms, the conservation of a miRNA binding site 
on its target mRNA can be viewed as evidence for its functional selection. This is 
particularly true for miRNAs with critical roles in developmental transitions or 
stem cell maintenance (Gangaraju and Lin, 2009). 
 Lastly, one point that tends to be overlooked is that functional 
miRNA:mRNA interactions can only take place if both species are co-expressed. 
Like mRNAs, miRNA expression ranges dramatically from ubiquitous to highly 
tissue specific. In their current iterations, most miRNA prediction methods 
overwhelmingly fail to account for co-expression of a miRNA and its target, 
providing instead a static list of every possible interaction. In principle, 
miRNA:mRNA co-expression is highly related to the conservation status of a 
miRNA binding site, since a selected-for site will be most "functional" upon 
encountering its expressed cognate miRNA. Conversely, one can also think of 
the depletion of sites from messages co-expressed with miRNAs. For a 
prototypical transcriptome, 3'UTR targets contained on average about half as 
many conserved and non-conserved binding sites for expressed miRNAs as 
expected by chance. In other words, large swaths of the transcriptome appear to 
be selectively avoiding regulation by a co-expressed miRNA (Farh et al., 2005). 
Furthermore, the evolutionary pressure to avoid miRNA sites is specifically 
detected in "housekeeping genes" which might explain their shorter 3′UTRs in 
animals compared to the longer 3′UTRs of orthologous transcripts in plants and 
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fungi, which lack the same miRNAs (Stark et al., 2005). Considered a major 
driver of 3'UTR evolution, the phenomena of selective avoidance has given rise 
to the term miRNA "antitargets" to describe mRNAs lacking co-expressed miRNA 
sites (Bartel and Chen, 2004; Farh et al., 2005). This negatively impacts miRNA 
prediction in that many bona-fide, but tissue-specific or species-specific binding 
sites are missed as false negatives.  
 The situation described above makes it unsurprising that the bioinformatic 
emphasis on conservation of miRNA seeds has limits. While conservation of a 
miRNA or its target binding site has historically been a key predictive and 
computationally searchable hallmark for phenotype screening, more recently it 
has become clear that both non-conserved and non-canonical targeting are 
frequent occurrences with functional importance (Frankel et al., 2014; Loeb et al., 
2012). The emphasis on miRNA and target conservation is historically justifiable 
given the blind frequency of miRNA seeds on target transcripts (on average one 
7mer every 10kb, multiplied by ~1000 miRNAs). Reliance on conservation and 
strict seed definitions dramatically reduced the searchable space on a 
transcriptome and with it, the number of false positives. In this vein, the advent of 
CLIP based NGS methods, to be discussed later in this chapter, is a further 
refinement to target prediction, and arguably supercedes the reliance on 
conservation, seed definition and co-expression by providing direct biochemical 
evidence of a miRNA engaging its target in a native setting (Chi et al., 2009; 
Grosswendt et al., 2014; Hafner et al., 2010)(Moore, et al. 2015. Submitted). 
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 To sum, miRNAs likely influence the expression or evolution of nearly all 
mammalian mRNAs, via direct interactions or inversely through selective 
avoidance, as well as through a myriad targeting rules (Bartel, 2009). In so doing, 
we can readily appreciate the ability by which new regulatory events in 3'UTRs 
can rapidly emerge within organisms. As 3'UTRs drift to include or exclude 
miRNA seeds, or as miRNAs become expressed in certain conditions to regulate 
previously unperturbed gene networks, the stage is set for functional modulation 
in species and tissue specific realms towards the evolution of new regulatory 
features.  
Mechanisms of miRNA mediated control 
 But what of more proximal functions for miRNAs within individual cells? As 
strictly post-transcriptional modifiers of gene expression, miRNAs are unique in 
that they exert regulatory effects at the level of transcriptional noise (<2 fold 
repression in most cases) as defined by inter-individual variation in gene 
expression (Cheung et al., 2003). This modest regulation provides an added 
dimension to finely tune mRNAs to generate a rich palette of gene expression 
(Figure 1.7A-B). This concept is similar to a dimmer switch or rheostat, which 
forms an apt analogy to explore the various classes of miRNA targets under 
changing environments (Figure 1.7C) (Bartel and Chen, 2004). In the rheostat 
model, regulation can proceed in one of three ways: switch-like, tuning, and 
neutral. Switch-like regulation is the most familiar in that it is binary; the 
expression of a miRNA "turns off" the expression of its target protein by inhibiting  
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Figure 1.7. Mechanisms of miRNA control. (A) Transcriptional regulation can 
provide a variety of distinct expression levels, illustrated graphically as various 
shades of blue. (B) Additive miRNA action adds an additional and post-
transcriptional layer of control to produce a richer and more complex expression 
palette. (C) Three categories of miRNA targets are presented. Upper dashed line 
indicates the upper limit of desired protein expression, lower line demonstrates 
the threshold under which the protein is no longer active; in the top panels, these 
lines overlap indicating that these thresholds are one and the same and act in a 
binary on-off fashion. On the left, miRNA expression induction can engage like a 
switch and turn off the expression of a protein (top); can tune protein expression 
to within an ideal range (middle) or may have a neutral effect (bottom). On the 
right, target induction can be highly dampened by a constitutively expressed 
miRNA (top), can be titrated to an optimal expression (middle), or have a neutral 
effect (bottom). Panels A and B adapted from David Bartel's iBiology "Intro to 
miRNAs" Youtube series. Panel C is modified from (Bartel and Chen, 2004). 
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its mRNA. Similarly, a constitutively expressed miRNA can silence abherrent 
mRNA expression as a means to dampen transcriptional noise. In the tuning 
mode, miRNA expression can lower protein amounts to some desired level, or 
can dampen an overshooting transciptional event. Lastly, miRNA action can exert 
neutral effects where a protein is repressed but still within an optimal range for 
activity. Importantly, examples of each of these versions of miRNA targeting have 
been described (Bartel and Chen, 2004).  
 The optimal expression ranges for proteins whose mRNAs undergo 
miRNA regulation--the dashed lines in the figure--are crucial to the model of 
miRNA activity presented in Figure 1.7C. Numerous factors can influence the 
location of these lines, and by extension, the capacity for protein expression to be 
buffered from miRNAs. Here we focus on two related factors: the expression 
difference between a miRNA and its target, and the cumulative effect of all 
expressed targets of a miRNA (target abundance).  
 Single cell work from the van Oudenaarden and Sharp labs revealed that 
miRNA repression is not uniform across cells and is driven by the expression 
level and number of miRNA binding sites in target mRNAs (Mukherji et al., 2011). 
Consequently, miRNAs can generate gene expression thresholds. At one 
extreme, a target can be dramatically silenced if its mRNA is low relative to the 
expression of its regulating miRNA, i.e. it resembles switch-like behavior. At the 
other extreme, high target mRNA expression vastly overpowers the inhibitory 
effect of a low expressed miRNA (neutral). The middle ground, where miRNA 
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abundance and target expression converge, serves a tuning function by 
balancing mRNA abundance with repressive miRNA pressure. Adding multiple 
miRNA binding sites per transcipt shifts the threshold in mathematically 
predictable ways (Mukherji et al., 2011). In these manners, target expression and 
the number of miRNA sites appear to govern expression thresholds for individual 
miRNA regulated transcripts. 
 While the above considers the expression difference between one miRNA 
and one target, it is important to highlight the aggregate effects of all the targets 
of a particular miRNA, and their role in influencing the gene expression 
thresholds for one another. Also termed "target abundance" (TA), this parameter 
has been incorporated into miRNA target prediction methods to aid in discovering 
functional sites (Garcia et al., 2011). Nevertheless, TA implementation typically 
relies exclusively on counting the number of conserved miRNA targeting events 
in 3'UTRs; thus, real target abundance (the total number of miRNA sites 
expressed in a transcriptome) is likely under-estimated. Recent demonstrations 
that long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) bind 
miRNAs and impart no repressive function on a coding transcript would agree 
with TA under-estimation. Moreover, these data point to an entirely new layer of 
miRNA regulation by competing endeogenous RNAs (ceRNAs) (Hansen et al., 
2013; Liu et al., 2014b; Memczak et al., 2013; Salmena et al., 2011; Wang et al., 
2013b).  
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 ceRNAs (including miRNA sponges) will be discussed in Chapters 5. For 
now, it suffices to say that miRNAs have continued to reveal their mysteries in 
the age of high-throughput sequencing, proving that they are far from settled and 
predicable regulators. And as we'll see, their role in virus biology is only 
beginning to be revealed. 
 
miR-122  
 The liver specific miR-122 is the central miRNA player for our purposes. A 
confluence of events that lead to its discovery are worth mentioning. As a distinct 
miRNA entity, miR-122 was initially cloned in 2002 from a survey of small RNAs 
from mice and notably displayed expression only in the liver, where it was also 
the most abundant (Lagos-Quintana et al., 2002). At that time, the only known 
database sequence match for the miR-122 came from woodchuck liver, as a 
result of work done over a decade earlier. In the mid-1980's, Buendia and 
colleagues at the Pasteur Institute were studying genetic rearrangements that 
resulted in HCC from chronic woodchuck hepatitis virus (WHV) infections. 
Closely related to carcinogenic hepatitis B virus (HBV), WHV was and remains 
an excellent tractable model for studying hepadnavirus induced liver tumors 
(Tennant and Gerin, 2001). The Pasteur group found that the majority of tumors 
were the result of a rearrangement and enhanced expression of N- or c-myc, due 
to viral insertional mutagenesis (Moroy et al., 1986). In one unique case, they 
characterized a chromosomal translocation in which the 5' end of a previously 
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unknown gene recombined with the second exon of c-myc, resulting in a 50-fold 
increase in c-myc expression (Etiemble et al., 1989; Moroy et al., 1989). Termed 
the hcr locus, the unknown gene was found to encode a highly abundant 
polyadenylated RNA around 4.7kb in length (Moroy et al., 1989). Curiously, the 
RNA was essentially non-coding as the longest ORF was only 37aa in length. 
The link between the mature miR-122 sequence and its parent hcr gene was 
finally made in 2003-2004, while Chang, Taylor and colleagues were studying the 
effects of Dicer on hepatitis delta virus (HDV) infections and confirmed that miR-
122 was highly abundant in rodent livers and in human hepatoma (Huh-7) cells 
(Chang et al., 2003). Shortly thereafter, they confirmed hcr gene as the source 
for miR-122, and provided the first functional evidence of its ability to down-
regulate an mRNA target, cationic acid transporter protein (CAT-1, aka SLC7A1), 
with a clear seed dependence (Chang et al., 2004). Much has been learned since 
then about miR-122 in terms of its role in many, if not most, aspects of liver 
biology. While its association with HCV is most germane to the present work (see 
next section), a comprehensive account of all other miR-122 functions is 
presented here.  
Possible roles in liver development 
 miR-122 expression begins as early as e12.5 in mice where its expression 
is promoted by hepatocyte nuclear factor 6 (HNF6), a hepatocyte-specific 
transcription factor (Laudadio et al., 2012; Xu et al., 2010). miR-122, in turn, 
forms a positive feedback loop by enhancing the expression of HNF6 and other 
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liver-enriched transcription factors (LETFs) (Laudadio et al., 2012). HNF6 along 
with other LETFs participate in a network of transcriptional regulation essential 
for terminal hepatocyte differentiation (Kyrmizi et al., 2006). More directly, miR-
122 also downregulates CUTL1, a transcription factor that represses genes 
required for hepatocyte differentiation (Xu et al., 2010). It should be noted 
however, that these tissue culture based results are largely based on miR-122 
overexpression, and may be artifactual (Wang et al., 2010). Moreover, the miR-
122 knockout mouse, both total and liver specific, is viable and displays no major 
defects in anatomical or functional liver development (Hsu et al., 2012; Tsai et al., 
2012).  
Lipid metabolism 
 Studies in mice following miR-122 antagonism with anti-sense 
oligonucleotides (ASOs) or locked nucleic acids (LNAs) revealed altered lipid 
profiles characterized by reduced plasma cholesterol levels, increased hepatic 
fatty-acid oxidation, and a decrease in hepatic cholesterol and fatty-acid 
synthesis rates (Elmén et al., 2008; Esau et al., 2006; Krützfeldt et al., 2005). 
Interestingly, while a number of direct miR-122 targets were identified in these 
studies using microarrays, a substantial fraction of up and down-regulated genes 
did not contain miR-122 sites, indicating substantial and indirect roles for miR-
122 activity. Indeed several genes with crucial to lipid metabolism (ACC1, ACLY, 
SCD1, SREBP2 and HMGCR) were down-regulated (Esau et al., 2006; Krützfeldt 
et al., 2005). Consistent with these findings, miR-122 antagonism decreased 
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serum cholesterol levels in chimpanzees (Lanford et al., 2010). Recent work with 
the miR-122 knock-out mouse has linked AGPAT1 and CIDEC as direct targets 
of miR-122 (Hsu et al., 2012). CIDEC, also called FSP27, regulates triglyceride 
storage and fatty acid oxidation within lipid droplets (Keller et al., 2008; Vila-Brau 
et al., 2013). In the liver, CIDEC is induced during the initial stages of fasting, but 
decreases during late fasting (Vila-Brau et al., 2013); this oscillation is notable in 
light of circadian miR-122 activity (discussed below). AGPAT1 is mostly involved 
in regulating the energy state in adipose and muscle tissues by stimulating the 
conversion of fatty acids into triglycerides (Ruan and Pownall, 2001; Takeuchi 
and Reue, 2009). It is thought that miR-122 repression of CIDEC and AGPAT1 
inhibits the storage of triglycerides in liver tissue, and may account for the 
increased triglyceride secretion observed in miR-122 KO mice (Hsu et al., 2012). 
These two relatively well-studies examples are likely the tip of the iceberg for the 
role of miR-122 in hepatic lipid metabolism, as we shall soon see in our own work 
using CLIP in miR-122 knockout mice.  
Iron metabolism 
 miR-122 depletion was also observed to cause iron deficiency in mice 
where it was found that miR-122 directly targets the hemochromatosis (Hfe) and 
hemojuvelin (Hjv) mRNAs for suppression (Castoldi et al., 2011). These proteins 
activate hepcidin, a hormone that controls systemic iron levels, which in turn 
binds to and induces the degradation of ferroportin, an iron efflux channel 
expressed in hepatocytes (Castoldi and Muckenthaler, 2012; Nemeth et al., 
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2004). Consequently, by suppressing the activators of hepcidin, miR-122 
prevents the degradation of ferroportin, which permits proper iron uptake in the 
liver (Castoldi and Muckenthaler, 2012).  
Circadian rhythm inputs to metabolic control 
 In addition to being controlled by HNF transcription factors, expression of 
the miR-122 locus oscillates in a circadian manner and is under the control of two 
retinoid-related orphan receptor elements (ROREs) upon which the oscillating 
REV-ERBα transcriptional repressor acts to start and stop expression (Gatfield et 
al., 2009; Ueda et al., 2002). In the mouse liver, mature miR-122 levels remain 
relatively constant, but pre- and pri-miR-122 levels fluctuate such that levels of 
these intermediates are lowest at Zeitgeber Time (ZT) 8-12 and highest at ZT24. 
These periods correspond to the peak and minimal expression of REV-ERBα 
respectively; in REV-ERBα knock-out mice, near constant levels of pre- and pri-
miR-122 were observed (Gatfield et al., 2009). Many miR-122 targets also 
demonstrate circadian oscillations in expression that are consistent with miR-122 
expression, where a few targets, such a PPARb/d and Nocturnin play key roles in 
the liver circadian clock (Gatfield et al., 2009; Kojima et al., 2010). These results 
are particularly puzzling, given that mature levels of miR-122 do not fluctuate. 
Much remains to explore on this front.  
As a biomarker for liver damage 
 The world of serum miRNA profiling as non-invasive biomarkers for a 
variety of disease is vast, sometimes oversold, and often contradictory. While 
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comprehensive and rigorous studies to determine the utility of miR-122 as a 
biomarker for a variety of complex liver diseases has not yet been performed, 
one trend is seemingly apparent: in the many small scale studies, miR-122 levels 
are elevated in serum upon liver damage or disease. Correlating with disease 
scoring and severity, miR-122 levels were elevated in human and murine models 
of liver damage from alcohol and HBV (Zhang et al., 2010). Elevated serum miR-
122 has been identified as a potential biomarker for liver damage from many 
sources, including acute hepatotoxicity, chronic HBC and HCV infections, HCC-
associated liver damage, non-alcholic fatty liver disease, acetaminophen 
poisoning, and liver transplant rejection (Cermelli et al., 2011; Ding et al., 2012; 
Farid et al., 2012; Hu et al., 2013; Starkey Lewis et al., 2011). It should be noted 
however, that elevated alanine transaminase (ALT) in serum, a classic marker for 
liver injury, was observed in these studies alongside increased serum miR-122. 
Thus, it's likely that miR-122 in the blood reflects hepatic cytotoxicity more than 
anything else. Still, there is some evidence for miR-122 as a marker for specific 
liver injuries, which opens the door for delineating functional differences in miR-
122 secretion. A study using a mouse model of liver damage demonstrated that 
circulating miR-122 could be used to differentiate between causes of liver 
damage: drug-induced injury led to miR-122 partitioning to the protein fraction of 
mouse serum, while alcohol and inflammation-induced liver injury led to miR-122 
circulation in exosomes (Bala et al., 2012). 
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Tumor suppressor activities and loss in HCC 
 miR-122 has been implicated as a tumour suppressor in several different 
conditions and model systems, and is notably and typically lost in HCC (Bai et 
al., 2009; Coulouarn et al., 2009; Hsu et al., 2012; Kutay et al., 2006; Tsai et al., 
2009). In the HCC cell lines HepG2 and Hep3B, which express little miR-122, 
restoration of miR-122 promotes apoptosis and is thought to inhibit proliferation 
by suppressing Wnt/β-catenin signaling (Xu et al., 2012). Furthermore, loss of 
miR-122 expression in HCC cell lines correlates with increased cell migration and 
invasion, while restoration of miR-122 reversed these effects (Coulouarn et al., 
2009). Although a comprehensive evaluation of the role miR-122 targets in tumor 
suppression has not yet been performed (but is the focus of Chapter 5), 
numerous studies have begun to link miR-122 tumor suppressor activity to 
specific targets. miR-122 appears to stabilize the p53 tumor suppressor by 
regulating Cyclin G1, and consequently sensitizes cells to doxorubicin 
chemotherapy (Fornari et al., 2009). The muscle specific isoenzyme of pyruvate 
kinase, PKM2, is a miR-122 target that is upregulated in HCC, is inversely 
correlated with miR-122 expression, and is thought to contribute to altered 
energy metabolism in HCC cells (Jung et al., 2011). miR-122 knockout mice are 
prone to tumor development with age: after progressive liver pathology to include 
fibrosis and steatosis, many mice spontaneously develop HCC after a year in 
age, and phenocopy the higher male-to-female disease incidence observed in 
humans (Hsu et al., 2012; Tsai et al., 2012). These studies demonstrated altered 
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lipid metabolism consistent with findings with LNA or ASO treated mice and 
furthermore characterized increased liver inflammation and infiltration of IL-6 and 
TNF producing cells as well as linked a disregulation of a miR-122 target KLF6, 
to fibrosis (Hsu et al., 2012; Tsai et al., 2012). Importantly, both studies showed 
that miR-122 loss was reversible: a myc model of liver tumorigenesis could be 
rescued by over expressing miR-122, and miR-122 loss could be corrected by 
overexpressing microsomal triglyceride transport protein (MTTP), which largely 
restored lipid metabolism (Hsu et al., 2012; Tsai et al., 2012). It should be noted 
that these rescue experiments, especially in the myc system, were devoid of the 
chronic inflammation that usually accompanies and often precedes HCC 
development, thus it can be argued that miR-122 tumor suppressor activity is 
partially inflammation independent. Still, other studies suggest otherwise. A 
subset HCC patients bear a polymorphism (rs3783553) in a putative miR-122 
binding site in the 3' UTR of IL-1α. As IL-1α is implicated in carcinogenesis and 
tumour growth, as well as in controlling tumor immunity, miR-122 regulation of IL-
1α may provide a link to liver inflammation upon miR-122 loss (Gao et al., 2009). 
A similar argument has been made for the myeloid cell chemoattractant CCL2, 
also a miR-122 target, which when derepressed alters the immune cell profile of 
the liver (Hsu et al., 2012). The multi-valent role of miR-122 in liver cancer 
reflects its role in maintaining liver homeostasis, yet clearly there is much more to 
learn.  
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Roles in other cancers 
 Although miR-122 is not expressed in high levels in other tissues, it has 
been implicated in cancers of other tissue types. Compared to normal tissues, 
miR-122 was found to be downregulated in gastrointestinal primary tumours and 
cell lines (Wang et al., 2009). This study further linked miR-122 to APC-mediated 
growth inhibition, as miR-122 sequestration had promoted growth; a similar result 
to those mentioned above in HCC cell lines (Wang et al., 2009). In a rat model of 
colorectal cancer, lowered miR-122 in healthy tissues was predictive of 
carcinogenesis elsewhere in the colon, and could be monitored ex vivo from fecal 
colonocytes present in the stool (Kunte et al., 2012). In breast cancer, miR-122 
was identified in serum deep sequencing of stage II-III patients, with increased 
levels of miR-122, and presumably liver damage, correlating with and later 
predicting non-responsiveness to neoadjuvant chemotherapy and metastatic 
outcomes (Wu et al., 2012). More recent work has begun to establish a causal 
role for circulating miR-122 to reprogram glucose metabolism of the pre-
metastatic niche in breast cancer (Fong et al., 2015). Lastly, in anaplastic thyroid 
cancer, miR-122 levels increase in thyroid cancer cell lines that respond to 
treatment with a PAX8/PPARγ fusion protein, and subsequently are play a tumor 
suppressive role, both in vitro and in xenografts (Reddi et al., 2013). This would 
suggest that tumor suppressor activity for miR-122 might extend to other tissues, 
however, some caution is warranted in interpreting these findings given that miR-
122 levels in non-hepatic cells is very low.  
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Roles in HBV infection: a case for viral restriction? 
 In HBV infected patients, Wang et al. found a striking negative correlation 
between hepatic miR-122 levels and HBV viral load. Loss of miR-122 led to 
increased viral replication in HepG2 and Huh-7 cells, suggesting an anti-viral role 
for miR-122 in HBV (Wang et al., 2012b). Further work demonstrated that miR-
122 suppresses Cyclin G1 (also mentioned above), which forms a complex with 
p53, itself a negative regulator of HBV transcription. Thus, virus driven 
suppression of miR-122 leads to increased Cyclin G1, sequestering anti-viral 
p53, and permitting HBV transcription (Wang et al., 2012b). In addition, miR-122 
has been shown to directly bind to conserved HBV sequences, and is thought to 
directly suppress viral replication. In apparent response to this, miR-122 
expression in inhibited by the HBx viral protein by binding PPARγ, a 
transcriptional activator of miR-122 (Chen et al., 2011; Song et al., 2013). It has 
also been proposed that HBV transcripts harboring conserved miR-122 binding 
sites behave as miR-122 sponges, though some caution is warranted as these 
results are based solely on overexpression of HBV RNAs (Li et al., 2013a). As in 
HCV, miR-122 has been proposed as a serum marker for HBV associated liver 
damage and hepatocellular carcinoma, as a means of detecting active or occult 
HBV infections, and of predicting HBV disease progression in patients (Chen et 
al., 2012; Ding et al., 2012; Qi et al., 2011; Waidmann et al., 2012; Zhang et al., 
2010). While the lack of robust HBV infection systems currently presents a barrier 
to identifying the precise role of miR-122 in natural HBV infections, the general 
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and compelling evidence that miR-122 expression does appear to inhibit HBV 
replication reveals that there is much more to learn. 
 
HCV and miR-122: coming together as a fascinating outlier 
 And then there's HCV. In 2005, Jopling, Lemon, Sarnow and colleagues, 
mostly at Stanford, wondered why HCV replicons could grow in Huh-7 cells but 
not in HepG2 cells, despite the fact that both were HCC derived hepatoma cell 
lines. Starting with the observation by Chang et al. that miR-122 was found to be 
expressed in Huh-7 but not in HepG2 cells, the Stanford group posited that miR-
122 could be regulating HCV expression (Chang et al., 2004; Jopling et al., 
2006). After confirming miR-122 expression in liver and Huh-7, but not in HepG2 
or HeLa cells, they found that suppression of miR-122 using ASOs inhibited HCV 
sub-genomic replicons (SGRs) in Huh-7 cells (Jopling et al., 2005). They then 
searched the the HCV genome for miR-122 seeds and began a mutagenesis 
study, and found remarkably that a miR-122 site in the 5' UTR, when mutated at 
various seed positions (p3, p3,4, and p6), resulted in dead SGRs (Jopling et al., 
2005). The mutation could be rescued by transfected miR-122 variants bearing 
complementary mutations (Jopling et al., 2005). This genetic evidence formed 
the basis of subsequent studies of miR-122 and HCV, which from the outset 
represented a unique outlier on two fronts. Whereas miRNAs typically interact 
with the 3'UTRs of mRNAs to suppress gene expression, HCV engagement of a 
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miRNA at its 5'UTR was critical for viral RNA accumulation. Subsequent work to 
describe the unique mechanism at play is described here. 
miR-122 binding sites on the HCV genome 
 In addition to the original miR-122 site (termed S1), a second miR-122 site 
(S2) located 10nt downstream of S1 in the 5'UTR is also critical for viral RNA 
accumulation, and both sites engage with auxiliary pairing at nucleotides 2-3nt for 
S1 and 30-31nt for S2 (Jopling et al., 2008; Machlin et al., 2011). Importantly, S1 
and S2 sites are highly conserved across all known HCV genotypes (Jopling et 
al., 2006). Additionally, viruses closely related to HCV, such as GVB-V, and the 
recently identified non-primate hepacivirus (NPHV), retain two and one 
conserved miR-122 sites in their respective 5'UTRs (Burbelo et al., 2012; Kapoor 
et al., 2011; Sagan et al., 2013). The very recent isolation of additional rodent 
and perhaps bat hepaciviruses will likely add to this list, and may offer long 
sought after murine models of HCV infections (Drexler et al., 2013; Firth et al., 
2014; Kapoor et al., 2013).  
 For HCV, S1 and S2 sites were found to be simultaneously required for 
viral RNA accumulation, where interestingly, swapping the S1 seed for a miR-21 
binding site was non-viable (Jopling et al., 2008). More recent work has delved 
deeper into the base contacts proposed at S1/S2. Two studies have applied 
selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE) analysis to 
measure RNA nucleotide flexibility in the HCV 5'UTR with or without miR-122 in 
vitro. In both studies, SHAPE and gel shift assays revealed additional base 
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contacts at the S2 site, resulting in higher energetic stability (Mortimer and 
Doudna, 2013; Pang et al., 2012). While the functional consequences of 
differential S1 versus S2 binding have yet to be worked out, one recent study 
looking for HCV variants that would be resistant to miR-122 sequestration found 
that a G to A mutation at position 28, between S1 and S2, was partially resistant 
to miR-122 inhibition (Israelow et al., 2014).  
 In addition to increased contacts at the S2 site, Pang et al. observed miR-
122 dependent changes in SHAPE reactivity in the IRES domain 4, suggesting a 
3rd albeit very non-canonical miR-122 site in the IRES (Pang et al., 2012). The 
relevance of this site for a fully infectious virus is unknown. Other miR-122 sites 
on the virus genome can be found in the NS5B coding sequence and 
interestingly, one very highly conserved site in the 3'UTR; however, none of 
these sites appear to be functionally important, at least in cell culture system 
settings, as mutagenesis of these sites showed no major effects on viral 
replication (Jopling et al., 2008; Nasheri et al., 2011).  
Interactions of other miRNAs with the HCV genome 
 With the discovery of a positive role for miR-122 in HCV replication, much 
attention turned to the role, if any, of additional miRNAs on impacting HCV by 
directly engaging the viral RNA genome. In 2007, Pedersen, Chisari and 
colleagues reported that upon IFNbeta treatment in cell culture, miR-122 
expression was repressed and that surprisingly, a number of IFN stimulated 
miRNAs could antagonize HCV RNA directly and repress viral gene expression 
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(Pedersen et al., 2007). Furthermore, over-expression of the five IFN induced 
"anti-viral" miRNAs reduced HCV RNA replication in a manner that was seed 
dependent, as chimeric viruses of isolates containing natural mutations in 
putative seeds were no longer repressed (Pedersen et al., 2007). Not 
surprisingly, there was much excitement surrounding these findings, as they 
seemed to merge the protein based ISG response with one that included miRNA 
function in an ancient and anti-viral RNAi-like mode (Beard and Helbig, 2008). 
Enthusiasm was soon tempered as no correlation between miR-122 levels and 
HCV viral load was found in patients undergoing IFN therapy. Furthermore, the 
absolute expression of the "anti-viral" set of miRNAs was dramatically low in both 
mouse liver and in Huh-7 cells, even with IFN treatment (SarasinFilipowicz et al., 
2009). Despite these findings, numerous groups have continued to find additional 
miRNAs that antagonize the HCV genome (reviewed in (Singaravelu et al., 
2014)). It must be stressed however, that as these results are overwhelmingly 
based on the overexpression of small RNAs and reporter constructs, artifactual 
findings can be considered likely.  
miR-122 function on HCV: stabilizing RNA and promoting translation 
 As the HCV genome lacks a 5' cap structure, one early hypothesis was 
that the Ago:miR-122 complex may serve as a type of cap to protect the 5' end 
from exonuclease recognition. This appears to be the case. A study using 
replication defective genomes found that miR-122 transfection slowed the decay 
of HCV RNA, while miR-122 inhibition enhanced decay (Shimakami et al., 2012). 
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Furthermore, this activity was dependent on the presence of AGO2 (Shimakami 
et al., 2012; Wilson et al., 2011). AGO2:miR-122 complexes appear to protect 
HCV RNA from 5' exoribonucleases XRN1 and XRN2 , as knockdown of these 
factors largely rescues viral replication after miR-122 antagonism(Li et al., 2013d; 
Sedano and Sarnow, 2014).  
 In addition to protecting the 5' end of viral RNA, two studies have shown 
that miR-122 promotes translation, albeit somewhat transiently. Using HCV RNA 
in a non-premissive rabbit reticulocyte lysate system, Henke et al. observed a 
50% increase in HCV translation in the presence of miR-122 but not miR-124 
(Henke et al., 2008). Similar results were observed using replication defective 
reporter genomes in Huh-7 cells and measuring shortly after RNA electroporation 
(Jangra et al., 2010).  
miR-122 function on HCV: a replication and translation switch? 
 Very recent work from Masaki, Lemon and colleagues has posited a role 
for miR-122 as a regulator for positive strand replication versus translation. Using 
5-ethnyl uridine incorporation into nascent RNA, miR-122 transcfection was 
found to transiently increase HCV RNA synthesis and was dependent on protein 
synthesis (Masaki et al., 2015). Consistent with this, a small reduction in 
polysome associated HCV RNA was observed upon miR-122 transfection 
(Masaki et al., 2015). As the S2 miR-122 site overlaps with a PCBP2 binding site, 
thought to aid in the circularization of the HCV genome, a competition model has 
been proposed where miR-122 occupancy prevents PCBP2 induced 
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circularization, and subsequent translation in favor of RNA replication. How this 
effect on increased RNA replication squares with increased HCV translation 
observed with miR-122 in other HCV contexts remains to be determined.  
Making cells permissive: miR-122 expression engineering 
 The initial impulse to explain the HCV permissiveness of Huh-7 but not 
HepG2 cells highlights the importance of miR-122 as important for cell tropism 
(Jopling et al., 2005). With this in mind, miR-122 expression has been 
engineered to make cells permissive to HCV in HepG2 cells and in mouse cells 
with limited success (Israelow et al., 2014; Lin et al., 2010; Narbus et al., 2011). It 
is generally thought that miR-122, alongside entry factors, is a major determinant 
for the hepatotropism of HCV. In support of this, ectopic expression of miR-122 
can render numerous non-hepatic cell lines permissible for HCV infection, 
including 293T cells, Hec1B (uterus), MC-IXC (nerve), and RERF-LC-AI (lung) 
cells (Da Costa et al., 2012; Fukuhara et al., 2012). Whether the low levels of 
miR-122 in non-hepatic tissues might support an extra-hepatic reservoir of HCV 
is unknown at present. 
HCV exceptions to miR-122 
 Despite the fact that miR-122 seeds sites are conserved in all HCV 
genotypes, mutants have been isolated that are largely resistant to miR-122 
antagonism (Li et al., 2011). The most resistant variant in this study, called the 
U3 virus, replicated in the presence of miR-122 antagomir. This recombinant 
virus was found to have replaced stem loop I of the IRES with cellular U3 
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snoRNA, ablating the S1 site while maintaining S2 (Li et al., 2011). As mentioned 
above, the isolation of horse, rodent and bat hepaciviruses with between one and 
two miR-122 sites in various configurations raises the question as to their 
putative miR-122 dependence. Additional work has pinpointed miR-122 
independence for the hepatotropic GB virus B (GBV-B), a close relative to HCV 
(Sagan et al., 2013).  
Antagonizing miR-122 as an anti-viral therapy: a high resistance barrier 
 That HCV uses a small RNA as a critical host factor raised the immediate 
possibility that miR-122 antagonism could be a viable anti-HCV therapy (Jopling 
et al., 2005). Work has progressed systematically on this front, with the 
demonstration that miR-122 locked nucleic acid (LNA) inhibitors were well 
tolerated in in mouse livers and in HCV infected chimpanzees (Elmén et al., 
2008; Lanford et al., 2010). The resulting human compound, called miravirsen, 
represents a first-in-class therapy aimed at targeting a cellular miRNA (Scheel 
and Rice, 2013). Phase II studies in humans treated with miravirsen resulted in 
rapid drops in viral load for the duration of therapy and long-term follow-up has 
not resulted in any major adverse effects (Janssen et al., 2013; van der Ree et 
al., 2014). Importantly, no virus breakthrough or escape mutants were observed 
for the duration of treatment, highlighting the utility of targeting a small RNA host 
factor and furthermore suggestive of a high barrier to resistance (Janssen et al., 
2013). While miravirsen resistant HCV variants have been uncovered in vitro, 
none have yet to be reported in patients.  
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Viruses and miRNAs: a novel axis of host pathogen interaction 
 The story of HCV and miR-122 is illustrative but certainly not unique. Early 
speculation that other viruses, particularly large and complex dsDNA viruses, 
might manipulate the miRNA pathway was confirmed early on with the discovery 
that Epstein Barr Virus (EBV) encodes miRNAs (Pfeffer et al., 2004). Subsequent 
work revealed that the majority of herpesviridae family members encode multiple 
miRNA genes (Cullen, 2013). Generally, natural viruses that encode miRNAs 
have a DNA component to their replication cycle, have full access to host pri-
miRNA biogenesis machinery by replicating in the nucelus, and typically undergo 
long-term persistent infections (Kincaid and Sullivan, 2012). Viruses with DNA 
genomes (the Herpesvirus, Polyomavirus, Ascovirus, Baculovirus, Iridovirus, and 
Adenovirus families) and at least one member of the retrovirus family, bovine 
leukemia virus (BLV) have been shown to encode functional miRNAs (Kincaid 
and Sullivan, 2012). Most work has focused on the herpesviruses due to the 
sheer number (usually dozens) of miRNAs that each virus encodes as well as the 
relative ease by which miRNA expression can be measured.  
 In general, the functions of DNA virus encoded miRNAs are thought to 
relate to DNA virus lifestyles which, in the case of herpesviruses, have both latent 
and lytic phases. From the perspective of a latent herpesvirus infection, a miRNA 
presents a wonderfully subversive means to auto-regulate viral gene expression 
or to manipulate host gene expression, all in a non-immunogenic manner 
(Umbach and Cullen, 2009). This hypothesis has animated the herpesvirus field 
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to uncover such examples and in the process has helped shed light on long 
mysterious phenotypes. For instance, during latency, Herpes simplex virus 1 
(HSV-1) expresses one non-coding transrcipt called the latency associated 
transcript (LAT) and little else (Stevens et al., 1987). The precise role of the LAT 
was mysterious until it was found to encode numerous miRNAs that targeted the 
HSV reactivating transciption factors ICP0 and ICP4 (Umbach et al. 2008).Thus 
LAT expression represses leaky expression of ICP0 and ICP4 which would 
otherwise compromise latency if minimally expressed. Supporting this, 
suppression of LAT results in spontanous reactivation in ganglia (Du et al., 2011). 
 In addition to auto-regulation, herpesviruses have co-opted existing 
miRNA network for selfish ends. A notable example is Kaposi's sarcoma 
associated herpesvirus (KSHV), which encodes a miRNA called miR-K12-11 that 
acts as a miRNA analog to cellular miR-155 (Gottwein et al., 2007). In this 
manner, KSHV can subvert the miR-155 targetome in its native B-cell setting by 
expressing its own version, which in this case, appears to suppress innate 
immune, pro-apoptotic and transcription factors (Gottwein et al., 2007). 
Moreover, as miR-155 over-expression is thought to drive B-cell lymphomas, 
these data also provide compelling molecular evidence for the mechanism of 
KSHV induced B-cell transformation (Eis et al., 2005). Similar anti-apoptotic 
themes were also found among Epstein Barr virus (EBV) encoded miRNAs, in 
analyses for which I was able to take part (Riley et al., 2012a). As many EBV 
miRNAs have no host analog, these data were demonstrative of the unique 
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capabilitiy of a virus evolving a miRNA to target new sets of genes (Riley et al., 
2012a). Moreover, recent evidence suggests that EBV induced lymphoma critical 
requires viral miRNAs to suppress apoptosis (Vereide et al., 2013).  
 The story is quite different for RNA viruses and is currently evolving. It was 
not widely accepted that naturally occuring ssRNA or dsRNA genome viruses 
encode functional miRNAs (Cullen, 2010). To a degree, the arguments 
supporting this claim make sense: a miRNA hairpin or dsRNA precursor 
produced by an RNA genome should by definition undergo Drosha or Dicer 
cleavage of either the genome, anti-genome or subgenomic RNAs and is likely to 
result in reduced fitness. Additionally, dsRNA or extant hairpins are obvious 
targets for PAMP detection. One early study failed to show any miRNAs from six 
well characterized RNA viruses (Parameswaran et al., 2010). Emerging 
exceptions can be found among retroviruses, which package an RNA genome 
into virions but uniquely go through a DNA stage in their lifecycle via reverse 
transcription and and integration into the host genome. While early studies 
purportedly found small RNAs encoded in the HIV-1 genome in addition to a 
suppressor of RNA silencing, they could not be confirmed (Bennasser et al., 
2005; Lin and Cullen, 2007; Triboulet et al., 2007). A more recent renewed focus 
on retroviral miRNAs has centered on bovine leukemia virus (BLV), which clearly 
encodes a miRNA that interestingly acts as a cellular miR-29 mimic (Kincaid et 
al., 2012). Both simian and bovine foamy viruses (SFV and BFV) were shown to 
encode functional miRNAs (Kincaid et al., 2014; Whisnant et al., 2014). Notably, 
 51 
SFV possesses a unique mechanism for controlling Drosha processing by 
regulating RNA pol II versus pol III transcription of the viral miRNA; in this 
manner, the virus is thought to avoid the fitness penalty associated with Drosha 
cleavage (Kincaid et al., 2014). Moreover, one SFV miRNA appears to act as a 
mimic to miR-155, which is very reminiscent of the KSHV story presented above.  
 The emerging picture painted for retroviruses has not gone unnoticed by 
RNA virologists in re-evaluating the potential for other RNA viruses to encode 
miRNAs. While still too early to draw firm conclusions, miRNAs have been 
putatively discovered in flaviviruses such as West Nile virus (WNV) and Dengue 
virus (DENV) (Hussain and Asgari, 2014; Moon et al., 2012; Pijlman et al., 2008; 
Schnettler et al., 2012).  
 Perhaps the most interesting recent take on miRNAs as an "anti-viral" 
effector concerns the North American eastern equine encephalitis virus (EEEV), 
a highly virulent mosquito-borne alphavirus that results in a 30-70% mortality rate 
in humans. Unlike its South American counterpart, Venezuelan equine 
encephalitis virus (VEEV), EEEV is restricted from myeloid cells which in turn do 
not produce interferon. It was found that this EEEV restriction in immune cells 
was due to the presence of miR-142-3p sites, a myeloid specific miRNA, in the 
EEEV RNA genome (Trobaugh et al., 2013). By this mechanism, EEEV has 
evolved to be suppressed in myeloid cells specifically so as to evade the innate 
immune response. Moreover, the selective maintenance of miR-142-3p sites on 
the viral genome also seemed to confer a benefit for mosquito borne 
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transmission, so there appears to be a selective advantage for the miR-142-3p 
sequence in both host and vector backgrounds (Trobaugh et al., 2013). In sum, 
these findings turn the anti-viral miRNA hypothesis on its head, by placing the 
virus in control of its own tropism where miRNAs can be considered essential 
host factors required to negatively select virus replication from specific contexts.  
 
Uncovering host-viral interactions at the RNA level 
 As the above discussion highlights, the role of small RNAs in viral 
infections is far from complete and is under current, active investigation. 
Nevertheless, we can consider a comprehensive framework that attempts to 
address the possible roles by which a miRNA (or siRNA) can aid or inhibit a 
virus, taking into account the host or viral source of the RNA (Figure 1.8) 
(inspired by the discussion in (Cullen, 2009)). In this framework, we consider 
AGO as the protein stage for an unfolding drama between host and viral RNAs. 
In normal cells, miRNA:mRNA interactions take place as usual, but upon virus 
infection, switching and tuning of a host response (anti-viral or otherwise) can 
occur. Viral coercion can take place in three direct forms: by encoding viral 
miRNAs, by permitting miRNA targeting of viral transcripts, and by the complete 
viral re-programming of AGO. As highlighted above, examples of each of these 
forms of regulation have been documented, especially in DNA viruses. 
Importantly, it must be noted that each of these forms of regulation do not have to 
occur in isolation and can influence one another. For instance, a viral miRNA  
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Figure 1.8. A comprehensive scheme of AGO associated miRNA:mRNA 
interactions between host and virus. In this model, four main interactions are 
considered: host responses to virus infection (top left), viral miRNA targeting of 
host mRNAs (top right), host miRNA targeting of viral mRNAs (bottom left), and 
viral auto-regulation (botom right). Note that effects of one type of targeting may 
have effects on others. For instance, in miRNA sponging, an abundant viral 
transcript sequesters a cellular miRNA and would thus affect the normal host 
targeting of that miRNA. The obverse of this scenario are viral mimics of celluler 
miRNAs. For each scenario, relevant viruses that offer experimental support are 
highlighted (see text for details). 
 
sponge would resemble a host miRNA:viral mRNA regulation on AGO, but its 
effects would be functionally exerted on inhibiting normal cellular miRNA function 
and de-repressing specific targets. This is consistent with a few examples from 
herpesviruses, which encode non-coding RNAs that serve as decoys for miRNA 
activity: Herpesvirus saimiri produces RNAs that were found to sequester miR-
27, while human cytomegalovirus (HCMV) produces a stretch of intergenic RNA 
that functionally inhibits the miR-17 family (Cazalla et al., 2010; Lee et al., 2013). 
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Virus miRNAs that mimic a cellular miRNA are the obverse of this scenario 
(Kincaid et al., 2014). However, it must be stressed that these examples are all 
mostly anecdotal, relying on specific genetic characterization and reporter 
validation that misses the global picture of the RNA traffic on AGO in the infected 
cell. To circumvent this, we must turn our attention to genomics methods aimed 
at achieving a high resolution and unbiased map of global miRNA:mRNA 
interactions across the cell. 
 
HiTS-CLIP, a method for global interrogation of protein-RNA interactions 
 High-throughput sequencing crosslinking and immunoprecipitation (HiTS-
CLIP aka CLIP-seq) is a method that combines the stringent purification of RNAs 
bound to an immunoprecipitated RNABP and massively parallel sequencing of 
these RNAs by cDNA cloning and library construction (see Chapter 2). It is useful 
to consider HiTS-CLIP as a subset of total RNA-seq, where instead of purifying 
mRNA on the basis of a polyA tail (or negative selection of ribosomal RNAs), 
RNA is "filtered" through a protein. In this manner, the specific targets of an 
RNABP may be identified from the level of transcriptomes to nucleotides (Darnell, 
2010).  
 The motivation behind CLIP based methods owes much to work aimed at 
understanding DNA-protein interactions in living cells. Early attempts to isolate 
DNA-protein complexes, often weakly bound in vivo, harbored the major concern 
of ensuring that physiologic complexes were preserved and not artifactually 
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created upon cell disruption (Dedon et al., 1991). Improved biochemical 
purification methods in the mid 1980's that incorporated a chemical crosslinking 
step greatly enhanced signal to noise (Gilmour and Lis, 1984; Kuo and Allis, 
1999; Solomon and Varshavsky, 1985). In this manner, the DNA biochemists 
were able to ascertain physiologic DNA-protein complexes in a variety of 
systems, and thus underwrote the growth of the chromatin field.  
 The relative fragility of RNA relative to DNA is probably the most proximal 
cause for the lag between pioneering work with chromatin IP (or ChIP) and its 
protein-RNA equivalent in CLIP. Re-association artifacts in early RNA IP ("RIP") 
work were later confirmed to have confounded early work, presumably due to the 
"stickiness" of ssRNA relative to dsRNA (Brown et al., 2001; Darnell et al., 2001; 
2005). Compellingly, RNA-protein artifacts were shown to be a major driver for 
RIP experiments with ELAV and AGO (Mili and Steitz, 2004; Riley et al., 2012b).  
 Again, crosslinking came to the rescue, but unlike the chromatin field, 
which primarily uses formaldehyde as a general and reversible crosslinking 
agent, UV crosslinking became the method of choice for CLIP precisely for its 
specificity and irreversibility (Darnell, 2010). Although the mechanism is 
incompletely understood, UV-mediated crosslinking is thought to involve UV light 
absoprtion by nucleic acid bases (Brimacombe et al., 1988). This in turn raises 
their grounded energy state to enable the formation of a covalent bond with 
molecules very closely opposed, within the order of ångstroms (Fecko et al., 
2007). Importantly, UV light (at 254nm) only induces protein-RNA and RNA-RNA 
 56 
crosslinks, no protein-protein crosslinks are observed as they are with chemical 
reagents. Moreover, while the true figure is unknown, it does appear that the 
protein-RNA crosslinking reaction occurs on a minority of contact sites (estimated 
between 1-5%) (Darnell, 2010). The crosslink itself also does not appear to 
substantively interfere with the reverse transcription of RNAs with crosslinked 
amino acid moieties; instead RT tends to skip such bases, resulting in deletions 
that can be used to map RNABP binding sites to single nucleotide resolution 
(Zhang and Darnell, 2011). Most importantly, the covalent bond afforded by UV 
crosslinking enables the rigorous purification of protein-RNA complexes under 
stringent wash conditions.  
 The benefits provided by crosslinking RNA to protein enabled pioneering 
work by Ule, Jenson, Darnell and colleagues to map the RNA network regulated 
by NOVA in the mouse brain (Ule et al., 2003). What is prescient about this work 
is how clearly the idea was ahead of the sequencing technology: NOVA bound 
RNAs were cloned as a library (presumably with millions of individual binding 
events) but underwent TOPO cloning and Sanger sequencing. The result was a 
then heroic, but now measly ~340 CLIP "tags" from that mapped to NOVA 
regulated exons (Ule et al., 2003). Within three years, the "HiTS" was added with 
the adaptation of CLIP libraries for sequencing on early Illumina machines, in this 
way the NOVA regulated network expanded three orders of magnitude by tag 
number (>200K tags) (Licatalosi et al., 2008). Since then, numerous RNABPs 
have been studied at the systems level with CLIP to reveal transcriptome wide 
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roles in RNA regulation: HuC, Rbfox, RBM47, FMRP, MBNL2, FUS, PTBP2 to 
name but a few (Darnell et al., 2011; Ince-Dunn et al., 2012; Licatalosi et al., 
2012; Nakaya et al., 2013; Vanharanta et al., 2014; Wang et al., 2012a; Weyn-
Vanhentenryck et al., 2014).  
 Common among all of these studies is the study of "binary" protein-RNA 
interactions, that is, a protein bound to a single RNA target. Applying this method 
to a "ternary" interaction, namely AGO bound to miRNAs and mRNA targets, was 
achieved shortly before I joined the Darnell lab. Unequivocally, everything to be 
presented in this thesis is based on work done by Sung Wook Chi, Julie Zang, 
Aldo Mele & Robert Darnell, who in 2009 published results obtained from 
applying HiTS-CLIP to AGO (AGO-CLIP) and revealing a miRNA:mRNA 
interaction map in the mouse brain (Chi et al., 2009). It was immediately apparent 
to me, given the anecdotal and largely un-resolved role of small RNAs in virus 
infections that this could be a technique to steer towards questions in virology. 
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Aims of this thesis 
 The preceding sections build a case for studying virus infections with AGO HiTS-
CLIP and using HCV as a model system, given its well-known association with 
miR-122 as a positive control. The overall goal of this thesis has been to 
generate a physical and testable miRNA:mRNA interaction map for an HCV 
infection genome wide. Moreover, the study of HCV raises an intriguing 
possibility, given that HCV causes liver cancer and critically requires miR-122 for 
its replication. Combined with the observation that miR-122 knockout mice 
spontaneously develop liver cancer, a tantalizing hypothesis emerges: HCV 
might effectively lower miR-122 levels in hepatocytes, which in turn may 
constitute an oncogenic stress in chronically infected cells. In all honesty, 
presenting this as an a priori hypothesis is a bit misleading, since it constitutes 
both the main conclusion and the main question raised by the work to be 
presented. Thus, only with a bit of hindsight can the following aims be proposed: 
 
• Adapt and carry out AGO HiTS-CLIP analysis of HCV infected cells 
• Characterize and validate AGO binding events on the HCV RNA genome.  
• Characterize and validate AGO binding events on the host transcriptome. 
• Interrogate the miR-122 target network in mouse and human livers.  
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Chapter 2: Materials and methods 
 Far from being a dense recitation, this section provides a holistic view of 
the materials and methods used in this thesis. This will include the reasoning 
behind the selections of reagents and protocols, the justifications for 
modifications, and key optimization experiments not discussed in the main text. 
The scope of this section will range from wet to dry, that is, from experiments at 
the bench or tissue culture hood, to finished bioinformatic analyses and 
visualization. It is my goal to provide the reader with a deep view of the thinking 
behind how experiments were planned and performed, how assumptions were 
managed, and in the case of seemingly arbitrary decision-points (particularly 
informatics ones), what course of action was decided upon. Most importantly, this 
section is written with practitioners in mind, in the hope that any graduate student 
or postdoc who is engaged in similar work may find something useful.  
Selection, construction, and culture of cell lines 
 Huh-7.5 cells were clonally derived from Huh-7 cells that had been 
transduced with HCV subgenomic replicons (SGRs) and subsequently cured of 
HCV using IFN-alpha (Blight et al., 2002). These cells were found to exhibit 
enhanced HCV replication and virus production largely without inducing adaptive 
mutations, and resultantly have been a staple of HCV research in the Rice lab. 
Later work suggested that this enhancement in permissiveness was due to 
defective RIG-I signaling which abrogated an otherwise antiviral IFN response 
(Sumpter et al., 2005). With the observation that HCV NS3/4A specifically 
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antagonizes a key down stream component of RIG-I signaling, mitochondrial 
antiviral signaling protein (MAVS, a.k.a. IPS-1, VISA, and Cardif) (Meylan et al., 
2005), we reasoned that the Huh-7.5 context would illuminate small RNA:viral 
RNA interactions in a setting where the innate immune response has failed, in 
other words, when the virus had effectively disabled the protein-based IFN 
response. Ultimately, however, these cells were chosen for the practical concern 
of enabling high infection frequency, unlike parental Huh-7 cells. Such a large 
and homogenously infected population of cells was critical for interpretable 
genomics results due to the high sensitivity, though still population based, 
measurements provided by CLIP and RNAseq.  
 Huh-7.5 cells and related variants were maintained in Dulbecco's Modified 
Eagle Medium (DMEM) (Invitrogen, Life Technologies) supplemented with 5% 
heat inactivated fetal bovine serum (FBS, Hyclone, Thermo Scientific), and 
0.1 mM nonessential amino acids (NEAA, Invitrogen, Life Technologies). Cells 
were maintained at 37ºC in 5% CO2. For single cells plated for clonal expansion, 
cell conditioned media with 10% FBS was used to enhance cell viability. To make 
conditioned media, cell were incubated with media containing 10% FBS and 
serially harvested every 24 hours. This conditioned media was filtered through 
0.22µm Amicon filters (Millipore).  
Huh-7.5 TetON cell construction 
 These cells were a kind gift from Nick Takacs, who made them as follows: 
Huh-7.5 cells were transduced with retroviral particles made in 293T cells 
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following co-transfection with pRetroX-Tet3G (Clontech), MLV GagPol and VSVg 
plasmids. Transduced cells were selected using 500 μg/mL G418, plated in 96-
well format at 0.5-0.8 cells/well, and single cell clones were expanded. The 
clones were tested for permissiveness to HCV infection, growth rate, doxycycline 
dose-response of induction and timecourse of induction after transduction with a 
mCherry fluorescent protein reporter expressed from retroviral vector pRetroX 
TRE3G (Clontech). The clone deemed to have the optimal overall performance in 
these assays was re-named Huh-7.5 TetON and used in subsequent assays. 
Huh-7.5 TetON cells were maintained in DMEM with 10% FBS, 0.1mM NEAA, 
and 500µg/ml G418 (Gibco).  
CRISPR mediated deletion of miR-122 in Huh-7.5 cells 
 Guide sequences 122.sgRNA1 and 122.sgRNA2 (to remove 
approximately 38 nucleotides including the miR-122 seed and partial stem-loop 
(Figure 2.1A) were cloned into pX330-U6-chimeric_BB-CBh-hSpCas9 (pX330, 
Addgene plasmid #42230) following published protocols (Ran et al., 2013). After 
sequence confirmation, 1.25µg of each pX330-122.sgRNA1 and pX330-
122.sgRNA2 (2.5µg total) was used to electroporate 1x106 low passage Huh-7.5 
cells with an Amaxa Nucleofector 2b machine (Lonza) using program T-28 and 
Nucleofector Kit V reagents, following the manufacturers instructions. The 
supplied GFP plasmid was used as an electroporation control. Two days after 
electroporation, cells were seeded in 96 well plates at 0.5 cells / well for single 
cell clonal expansion. To genotype single cell clones and to approximate editing 
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Figure 2.1. A CRISPR based targeting strategy to delete miR-122 from Huh-7.5 
cells. (A) Guide RNAs were designed to delete a 38bp region encompassing the 
5' end of the miR-122 stemloop, including the entire miR-122 seed, and an 
adjacent DdeI restriction site. Approximate cut sites indicated with red triangles. 
PAM: protospacer adjacent motif. (B-C) Location of DdeI restriction sites and 
fragment sizes relative to the miR-122 PCR amplicon for WT (B) and the ΔmiR-
122 (C) mutant, used for genotyping. Targeted deletion of one DdeI site is 
expected to yield two fragments (190 and ~300bp respectively), while unedited 
clones should produce three fragments (190, 100 and 231bp). (D) Genotyping of 
GFP or CRISPR transfected and expanded clonal cell lines after DdeI digestion 
of PCR amplicons. Suspected ΔmiR-122 clones where one DdeI site has been 
deleted are indicated with black arrows. 
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efficiency in bulk cells, DNA was extracted using QuickExtract (Epicentre) and 
the miR-122 locus PCR amplified for 30 cycles. The resulting PCR products were 
purified, digested with DdeI (NEB), and underwent gel electrophoresis. As the 
deleted segment destroyed a DdeI restriction site, CRISPR deletions were 
identifiable on the basis of an altered restriction digest pattern (Figure 2.1B-D). 
Homozygous deletions, along with unedited and GFP only clones were expanded 
and used for subsequent studies. Guide sequences are in the Appendix.  
CRISPR mediated deletion of Drosha in Huh-7.5 cells 
 For Drosha deletion, guide sequences Drosha.sgRNA1 and 
Drosha.sgRNA2 were designed to excise exon 9 and force an out of frame 
splicing between exons 8 and 10 as reported previously (Chong et al., 
2008)(Figure 2.2). Guide RNAs were cloned into pX458-pSpCas9(BB)-2A-GFP 
(pX458, Addgene plasmid #48138). After sequence confirmation, transfection 
and single cell dilution cloning proceeded as above. To genotype single cell 
clones and to approximate editing efficiency in bulk cells, DNA was extracted 
using QuickExtract (Epicentre) and the Drosha exon 9 locus PCR amplified for 35 
cycles. The resulting PCR products underwent gel electrophoresis, where deleted 
cells yielded shorter amplicons. One homozygous deletion clone (ΔDrosha) was 
isolated, along with unedited clones. Western and northern analysis of ΔDrosha 
cells are described in the next chapter. Guide sequences are listed in the 
Appendix. 
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Figure 2.2. A CRISPR based targeting strategy to delete Drosha from Huh-7.5 
cells. (A) Guide RNAs were designed to delete a 166bp region encompassing 
exon 9 of the Drosha gene. Approximate cut sites indicated with red triangles. 
PAM: protospacer adjacent motif. (B) Genotyping of CRISPR transfected and 
expanded clonal cell lines after PCR amplification surrounding exon 9. One clone 
(#55) exhibited a deletion consistent with exon 9 homozygous removal. Plus sign 
indicates PCR from bulk transfected cells prior to single cell dilution cloning.  
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CRISPR mediated deletion of Dicer in Huh-7.5 cells 
 Initial Dicer deletion was attempted by following a similar scheme as 
Drosha, to delete a coding exon with an out-of-frame splice to force a frameshift 
and premature stop. Exons 1 and 2 was successfully deleted independently in 
this manner, yet full Dicer activity was observed in exon 1 deleted cells, and 
residual activity in exon 2 deleted cells, likely due to a downstream start codon 
that resulted in a tolerable N-terminal deletion (Ma et al., 2008)(see Chapter 3). 
To make a complete knockout, I focused on deleting exon 19 in both WT and in 
exon 2 deleted cells, to induce a frameshift whereby any downstream translation 
would make a fragment lacking the helicase domain, the domain of unknown 
function (DUF), and the Piwi Argonaut and Zwille (PAZ) domain, all known to be 
critical for dsRNA and miRNA processing by Dicer (Ma et al., 2012). Guide RNAs 
were cloned into pX458-pSpCas9(BB)-2A-GFP (pX458, Addgene plasmid 
#48138). After sequence confirmation, transfection and single cell dilution cloning 
proceeded as above. Genotyping was performed from QuickExtract (Epicentre) 
isolated DNA and the Dicer exon 19 locus was PCR amplified for 35 cycles. The 
resulting PCR products underwent gel electrophoresis, where deleted cells 
yielded shorter amplicons (Figure 2.3). Two homozygous deletion clones were 
isolated in WT cells (ΔDicerEx19) and one in exon 2 deleted cells 
(ΔDricerEx2.19), along with unedited clones. Western and northern analysis of 
ΔDicer cells are described in the next chapter. Guide sequences are listed in the 
Appendix. 
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Figure 2.3. A CRISPR based targeting strategy to delete Dicer from Huh-7.5 
cells. (A) Guide RNAs were designed to delete a 194bp region encompassing 
exon 19 of the Dicer gene. Approximate cut sites indicated with red triangles. 
PAM: protospacer adjacent motif. (B) Genotyping of CRISPR transfected and 
expanded clonal cell lines after PCR amplification surrounding exon 19. Four 
clones (12, 17, 19, 20) exhibited a deletion consistent with exon 19 homozygous 
removal. Plus sign indicates PCR from bulk transfected cells prior to single cell 
dilution cloning.  
 
 
Generation of recombinant HCV plasmids 
 The selection of which HCV to use in these studies has largely centered 
on genotype 2 viruses, due to their ability to generate relatively high titer stocks 
(by historical HCV standards), as well as the ability to generate the large and 
homogeneously infected population of cells needed for CLIP. Moreover, as the 
5'UTR miR-122 sites are completely conserved across all genotypes, results 
related to miR-122 studies with this virus are likely to be generalizable to other 
genotypes, though importantly, this has not been directly studied.  
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 pJ6/JFH1-Clone2, pJ6/JFH-Clone2-5AB-Ypet, and pJc1FLAG(p7-
nsGluc2A) are fully-infectious HCV non-reporter and reporter viruses 
respectively, that have been previously described (Catanese et al., 2013a; 
Horwitz et al., 2013; Marukian et al., 2008). Clone2 HCV is notable for efficient 
cell-to-cell spreading and is resistant to SR-BI antibody mediated inhibition, in 
this manner a high proportion of infected cells is thought to be achieved 
(Catanese et al., 2013a). To construct miR-15 dependent viruses in both 
backgrounds, we used overlap extension PCR. Briefly, pJ6/JFH1 Clone 2 
plasmid DNA was digested with EcoRI and KpnI to yield a 1298nt fragment 
encompassing the start of T7 transcription, both miR-122 sites, and reading into 
the E1 coding sequence. A 1.2kb region (Fragment A), upstream of miR-122 
sites, was PCR amplified from the parental 1298nt fragment with Accuprime Pfx 
Supermix (Invitrogen). Approximately 5ng of Fragment A was mixed with 5ng of a 
primer containing the EcoRI site, T7 start, 5' HCV sequence with miR-15 S1 and 
S2 sites and 20nt overlap with Fragment A, and the overlap product was 
amplified with 5μM of EcoRI and KpnI primers at either end. This PCR product 
was digested with EcoRI and KpnI, religated into the backbone, and sequence 
verified along the 1.3kb insert. The same strategy was used for miR-15 viruses in 
the Jc1FLAG2(p7-nsGluc2A) context but with EcoRI and BsiWI, resulting in a 
1373nt fragment), 1st PCR primers (Pos43_F and Pos1358_R), and overlap PCR 
primers (Pos12343_F and Pos1358_R). Similarly, fusion PCR was used to 
generate pJ6/JFH1-Clone2-U3, –U3S2p3 and –U3S2p3,4 mutants using primers 
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m122toU3_F and F S2p34, R S2p34, F S2p3 and R S2p3. All cloning oligos are 
listed in the Appendix.  
RNA transcription 
 In vitro transcripts were generated as previously described (Lindenbach et 
al., 2005). Briefly, plasmid DNA was linearized by XbaI and purified by using a 
Minelute column (Qiagen). RNA was transcribed from 1 μg of purified template 
by using the T7 RiboMAX Express RNA polymerase kit (Promega). Reaction 
mixtures were incubated at 37 °C for 30min to 1hr, followed by a 15-min digestion 
with 5U of RQ1 DNaseI (Promega). RNA was purified by using the RNeasy kit 
with DNAseI (Qiagen), and was quantified by absorbance at 260 nm and diluted 
to 0.5 μg/μl. Prior to storage at −80 °C, RNA integrity was determined by agarose 
gel electrophoresis and visualization by ethidium bromide staining. 
RNA electroporation 
 Huh-7.5 cells were electroporated with HCV RNA as previously described 
(Lindenbach et al., 2005). Briefly, Huh-7.5 cells were treated with trypsin, washed 
twice with ice-cold phosphate-buffered saline (PBS) (Invitrogen) and 
resuspended at 1.75×107 cells/ml in PBS. Then, 5 μg of each RNA was 
combined with 0.4 ml of cell suspension and immediately pulsed using a BTX 
ElectroSquare Porator ECM 830 (820 V, 99 μs, five pulses). Electroporated cells 
were incubated at room temperature for 10 min prior to resuspension in 15 ml or 
30 ml complete medium for non-reporter and reporter constructs, respectively. 
Resuspended cells were plated into 24-well, 6-well, and P150 tissue culture 
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dishes for reporter, RNA, and CLIP analysis respectively, at indicated timepoints. 
For U3 virus electroporations, cells were monitored until greater than 80% of cell 
were infected, then harvested (around 13-17 days post electroporation). 
Supernatants from electroporations meant for virus production were serially 
harvested and replaced starting at 48 hours, every 24 hours, for up to 5 days. 
Supernatants were filtered using 0.22µm filters to remove cell debris prior to 
concentration either under centrifugation in Amicon Ultracell 100kDa filters 
(Millipore), or concentration under N2 pressure using a Stirred Cell ultrafiltration 
device and membranes (Millipore, Model 8400).  
Two color miR-122 target fluorescent reporter construction 
 Construction of miR-122 fluorescent reporters largely mirrored previous 
work with miR-20 (Mukherji et al., 2011). In brief, a nuclear localization sequence  
(NLS: ATGGGCCCTAAAAAGAAGCGTAAAGTC) was appended to the N-
terminus TagBFP and TagRFP (Evrogen) open reading frames via overlap PCR. 
The resulting nlsTagBFP was cloned into the pTre3G-BI vector (Clontech, 
#631337) between EcoRI and NdeI restriction sites. nlsTagRFP was PCR 
amplified to add 3'UTRs with N=1 bulged, mutant, or perfectly complementary 
miR-122 sites before insertion between BamHI and EcoRV sites in the 
nlsTagBFP containing plasmid. The artificial 3'UTRs for N=4 and N=6 constructs 
were chemically synthesized as GeneBlocks (IDT) before undergoing Gibson 
Assembly (NEB) with the BamHI/EcoRV digested pTre3G-nlsTagBFP plasmid, 
nlsTagRFP, and the artificial 3'UTR. Gibson assembly was also used to 
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seamlessly append full-length 3'UTRs of cellular targets to nlsTagRFP, after 
amplifying miR-122 target 3'UTRs from human genomic DNA. While Gibson 
assembly was initially chosen due to problems with overlapping restriction 
enzyme sites that could not be resolved with traditional cloning methods, the 
ease, flexibility and power to "scarlessly" modify a DNA sequence using Gibson 
assembly quickly made it the method of choice. All cloning oligos are listed in the 
Appendix.  
HCV infection and LNA treatment assays 
 Infectious units were quantified by limiting dilution titration on naïve Huh-
7.5 cells and counted using the median tissue culture infective dose [TCID50] 
method (Lindenbach et al., 2005) or the focus-forming units (FFU) method 
(Gottwein et al., 2009). For infection experiments with WT or m15 Clone2 
viruses, cells were seeded in 6 well or P150 plates, infected at an MOI of 1-2 the 
following day, inoculum removed at 6 hours post-infection (hip) and harvested for 
RNA-Seq or CLIP at 72 or 96hpi. Samples harvested for CLIP from cells 
electroporated with WT Clone2 RNA were harvested at 48 hours post-
electroporation (hpe). 
 For miRNA and LNA experiments, cells were seeded the day before, and 
transfected with miRNA (Thermo Scientific) or LNA or miravirsen/SPC3649 (5'-
CcAttGTcaCaCtCC-3'; LNA in capitals, DNA in lower case, Exiqon) at indicated 
concentrations using RNAi/Max (Invitrogen) for 48 hours. For cultures that were 
subsequently infected, this was done 24 hours later with WT, U3 or m15 viruses 
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at an MOI of 1-2. Cells were harvested at indicated time points for RNA and flow 
cytometry, while supernatants were harvested for titer measurements. 
Replication of Gaussia luciferase expressing HCV genomes was monitored by 
measurement of secreted Gluc in supernatants using the Renilla Luciferase 
Assay System (Promega) on a Berthold LB960 luminometer (Bad Wildbad, 
Germany) or an Omega Fluorostar reader (BMG Labtech). Media was replaced 
at each time point measured. No significant cytotoxicity was observed from the 
applied concentrations of LNA and miravirsen/SPC3649, as determined using 
CellTiter-Glo (Promega).  
 For two color fluorescent reporter measurements, Huh-7.5 TetON cells 
were plated at 1.5x105 cells/well in 6 well plates. Infection with WT-Clone2-5AB-
Ypet virus was carried out 12 hours after plating at an MOI of 3. The inoculum 
was removed and replaced with fresh media after 6 hours. LNA and miR-122 
mimics were transfected at the indicated concentrations 24 hours after infection 
as outlined above. Media was replaced 48 hours after infection to include 1µg/ml 
doxycycline (Sigma) and reporter constructs were then transfected at 1.6µg/well 
using Lipofectamine2000 (Invitrogen) reagent. To harvest, cells were trypsinized, 
fixed in FACS fixation buffer (0.5% PFA, 1% FBS, in 1xPBS) on ice for 10 
minutes, and stored at 4°C in FACS buffer (1% FBS in 1xPBS). A small number 
of cells were harvested without fixation for RNA analysis. 
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RNA isolation and qPCR 
 Total RNA was prepared via Trizol extraction (Life Technologies, 
Carlsbad, CA), precipitation with ethanol, and yields determined by absorption 
spectroscopy using a NanoDrop (NanoDrop Products, Wilmington, DE). HCV 
genomes were quantified using the EraGen MultiCode-RTx method (EraGen 
Biosciences, Madison, WI) as described previously (Mulligan et al., 2009), and 
was run on the LightCycler 480 Real-Time PCR System (Roche Applied 
Sciences, Indianapolis, IN). MicroRNA qPCR was performed using the miScript 
RT II system (Qiagen) following the manufacturers instructions for absolute 
quantification. The resulting cDNA was used with the FastStart SYBR Green 
qPCR system (Roche Applied Sciences, Indianapolis, IN) following the 
manufacturers instructions and was run on a iCycler/IQ5 (BioRad). Synthetic 
miR-122, miR-21, miR-15a and miR-196 mimics (Dharmacon) were used to 
make a standard curves for each miRNA. The miscript RT II kit was also adapted 
to quantify HCV genomes (for Fig. 1G and Fig. S7) by using a sense HCV 
specific primer at the 3'end of the genome (JFH1-3UTR: 
CTGGTCTCTCTGCAGATCATGT). Previously determined amounts of in vitro 
transcribed HCV RNA were used to generate a standard curve. Per cell RNA 
amounts were determined by Trizol extracting RNA from 106, 105, and 104 Huh-
7.5 cells at 60-80% confluence, in duplicate, summing the total amount of RNA 
recovered, and dividing by the number of cells to reach a measurement of 
17.28±4.83pg RNA/cell. RNA measurements per nanogram were transformed to 
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per cell measurements with this number. For liver biopsy per cell estimates, we 
relied upon human hepatocellularity measurements of 139±25 million cells/gram 
of liver from (Sohlenius-Sternbeck, 2006). Four liver specimens of various 
weights (2-40mg of tissue) underwent RNA extraction with Trizol. The summed 
total of extracted RNA per sample was divided by specimen weight to arrive at an 
RNA/mg of tissue estimate, and transformed by 139000 cells/mg of tissue to 
reach a measurement of 1.27±0.39pg RNA/cell. Per nanogram qPCR results 
were transformed accordingly.  
Small RNA Northern analysis 
 Ten micrograms of Trizol extracted total RNA from Huh-7.5 cells was 
separated on a 15% acrylamide/7M urea gel. After transfer onto Hybond-N1 
membrane (Amersham Pharmacia Biotech), small RNAs were detected with 32P-
end-labeled DNA probes complementary to human miR-122-5p, miR-16-5p, miR-
21-5p, and U6 snRNA.  
Western blotting 
 Cells were lysed at the indicated times using 1X PXL (1X PBS, tissue 
culture grade; no Mg2+, no Ca2+, 0.1% SDS, 0.5% deoxycholate, 0.5% NP-40, 
sterile filtered), triturated and placed on ice for 15minutes. 15 μg of protein lysate 
was separated on 4–12% Bis/Tris NuPage polyacrylamide gels (Invitrogen). 
Proteins were transferred to nitrocellulose membranes and proteins of interest 
were detected using antibodies against NS5A (9E10; 1:5000) (Lindenbach et al., 
2005), AGO2 (ab32381, 1.3µg/mL, 1:1000) (Abcam), DICER (ab14601, 1:1000) 
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(Abcam), DROSHA (ab12286, 1:1000) (Abcam) or β-actin (AC15, 1:10000) 
(Sigma); secondary antibodies were AffiniPure Donkey-anti-Mouse IgG (H+L) 
(115-035-003, 1:10000) (Jackson Immuno Research), Goat-anti-Rabbit-HRP 
(31462, 1:10000) (Pierce), Goat-anti-rabbit IRDye 800CW (926-32211, 1:15000) 
(Licor Biosciences), or Goat-anti-rabbit IRDye 680RD (926-68070, 1:15000), 
(Licor Biosciences). Western blots were visualized using SuperSignal West Pico 
(Thermo Scientific) or the Odyssey CLx imaging system (Licor Biosciences). 
Fluorescence microscopy 
 Images were captured on an Axioplan 2 imaging fluorescence microscope 
(Zeiss, Thornwood, NY) using Metavue Software (Molecular Devices, Sunnyvale, 
CA). Images were processed using ImageJ software (NIH, Bethesda, MD). 
Luciferase reporter assays 
 Luciferase reporter vectors were cloned by inserting short oligonucleotides 
or PCR amplified target 3'UTRs into psiCHECK-2 (Promega) using XhoI and 
NotI. For luciferase reporter assays, 5x104 Huh-7.5 cells per well in 48-well plates 
were transfected over night with 2.56nM final concentration LNA122 (Exiqon) or 
miR-122 mimic (Thermo Fisher) using RNAi/MAX (Invitrogen). Alternatively, cells 
were infected with HCV (J6/JFH1-clone2), MOI=3 over night. 24 hrs later, cells 
were transfected with 1ng/well psiCHECK-2 reporter plasmid using 
Lipofectamine2000 (Invitrogen) and incubated over night before lysis in Passive 
Lysis Buffer and evaluation of luciferase levels using the Dual Luciferase 
Reporter Assay (Promega) on a Omega Fluorostar reader (BMG Labtech). 
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Flow cytometric analysis 
 For NS5A flow cytometry, cells were harvested using AccuMax 
(eBioscience) and fixed using Fixation/Permeabilization buffer (BD 
Biosciencesfor 10 min at 4 °C. Fixed cells were washed with BD Perm/Wash 
buffer (BD Biosciences), incubated 30 min at RT with AlexaFluor-647-conjugated 
9E10 antibody (1:4000 in BD Perm/Wash buffer), washed twice with BD 
Perm/Wash buffer and once with FACS buffer (PBS/3%FBS) prior to analysis 
using a BD FACS Calibur and BD FACSDiva software. Analysis was performed 
using FlowJo software.  
Two-color fluorescent miRNA reporter flow cytometry 
 For fluorescent protein reporter measurements, cells were run on a 
MACSQuant VYB flow cytometer (Miltenyi Biotec) after fixation to detect 
TagBFP, TagRFP, and Ypet signals. The raw FACS data were analyzed with 
FlowJo to gate single, intact cells according to their forward (FSC-A) and side 
(SSC-A) scatter profiles. HCV positive cells were gated on the basis of Ypet 
signal above uninfected background. Untransfected cells were used to 
characterize the cellular autoflourescence in BFP and RFP channels, from which 
we subtracted the mean plus two standard deviations of the autofluorescent 
signal for each channel in transfected cells. Cells with BFP and RFP 
fluorescence levels less than 0 after background subtraction were excluded from 
further analyses. Data were log-transformed and binned according to BFP levels, 
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and the mean RFP signal was calculated for each BFP bin. See Chapter 4 for 
details.  
High-throughput sequencing methods 
 The work presented in this thesis makes extensive use of high-throughput 
sequencing methods, many customized and invented in the Darnell lab. As such 
methods are constantly evolving, this section will outline the basic principles of 
experimental design using these techniques, describe the flow, aims and 
assumptions of these methods, as well as provide the finer details of their 
execution.  
Experimental designs 
 The proper design of experiments involving highly sensitive genomics 
methods is critical for minimizing technical or biologically spurious sources of 
variation that at best mask the variation between the intended biological variables 
tested, or at worse mislead to false conclusions. Long known to be an issue in 
many microarray studies, batch effects represent a major and sometimes 
unacknowledged source of technical variation in next-generation sequencing 
(NGS) studies (Leek et al., 2010). To minimize the sometimes impossible task of 
correcting for a batch effect after-the-fact, CLIP and RNAseq experiments were 
designed to account for and mitigate batch effects in the following ways: 
1. For all cell work, each well or dish from which a library was made is 
defined as a biologic replicate. One perturbed versus its un-perturbed sample 
(thus two biologic replicates) constituted one biologic replicate comparison.  
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2. For all animal and human work, all samples coming from the same donor 
are defined as a biologic replicate.  
3. All cellular perturbations (virus infections, LNA treatments, etc) were 
paired with un-perturbed controls under identical conditions. Comparisons across 
controls from different experiments were not used beyond as a measure for cross 
batch variation.  
4. Harvest of paired samples was carried out at the same time, in the same 
order (perturbed then control), and frozen in -80C. Subsequent CLIP and RNA 
library prep were initiated on paired samples on the same day.  
5. For timecourse measurements, paired samples were frozen at the time of 
harvest. All subsequent CLIP or RNaseq library prep was initiated for all 
biological replicates for all time points on the same day.  
6. Sample processing was done in separate tubes; where protein gels were 
concerned, all samples were separated by one empty lane. Where DNA gels 
were concerned, all samples were split by condition and run on separate gels. In 
other words, all perturbed biologic replicates were run on one gel, and all un-
perturbed samples on a separate gel. Samples were separated by one empty 
lane.  
7. Pooling of samples was performed to include both perturbed and un-
perturbed controls in the same lane of the same sequencing run. Splitting 
samples across lanes was avoided, unless a measure of technical variation was 
sought.  
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Sample generation  
 As stated above, Huh-7.5 cells were used for all HTS work. Cells were 
infected with virus or electroporated with viral RNA, the media replaced at 6 hpi 
or 24hpe, respectively, and harvested at time points indicated in the figures. In all 
cases, wells with identical numbers of cells were mock infected or mock 
electroplated with media or PBS.  
 For miR-122 knockout mouse studies, the livers form five floxed control 
mice and four liver specific miR-122 knockout mice, were provided by Kalpana 
Ghoshal at the Ohio State University. Dissected livers were wrapped in foil and 
flash frozen in liquid nitrogen before being shipped to RU on dry ice.  
 For human normal versus liver tumor, five samples from patients with HCC 
(all HCV negative) were flash frozen in liquid nitrogen after autopsy, in 
accordance with IRB approved protocols at the Ohio State University. 
Specifically, per patient approximately one gram of tumor and histologically 
normal adjacent tissue were frozen simultaneously before being shipped to RU 
on dry ice.  
Sample harvest 
 Cells growing in p150 plates were washed with cold PBS and irradiated 
over ice once for 400mJ/cm2 and once again for 200mJ/cm2 using a 
Spectrolinker XL-1500 (Spectronics Corporation). Cells were then trypsinzed (Life 
Technologies), pelleted, and stored at -80°C until use. One p150 plate would 
typically yield between 3 and 10 million cells per pellet.  
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 Mouse and human liver tissue was pulverized in a mortar and pestle with 
liquid nitrogen. A small portion (20-50mg) of the resulting powder was saved for 
RNA analysis. The remaining powder was crosslinked on a bed of dry ice with 
three irradations at 400mJ/cm2 using s Stratlinker XL-1500 (Stratagene). All 
samples were then stored in -80°C until lysis. 
Argonaute CLIP 
Argonaute CLIP was performed generally following previous work (Chi et al., 
2009) and is most comprehensively described in (Moore et al., 2014) with 
modifications listed here. The basic outline for AGO-CLIP consists two parts: 
from cells to autorad, that is, from cellular lysates to the isolation of AGO 
associated RNA fragments, and the DNA library preparation steps from small 
samples of isolated CLIPped RNA. For a schematic view of the standard AGO-
CLIP protocol with variations, see Figure 2.4 and Figure 2.5.  
Bead preparation 
 Protein A Dynabeads (Invitrogen) were washed 3x and resuspended in 
antibody binding buffer (AB: PBS, 0.02% Tween-20). Per p150 dish or liver 
sample, 100μl of beads was used. Beads were rotated with 12.5μl of bridging 
antibody (rabbit anti-mouse IgG, Jackson Immunoresearch) per 100μl of beads 
for 30 minutes at room temperature. Beads were then washed 3x with AB before 
adding 1μl of the pan-AGO antibody (2A8, ascetic provided by Dr. Zissimos 
Mourelatos and described in (Nelson et al., 2007)) per 100μl beads. For IgG only 
antibody controls, AGO antibody was omitted. Beads were rotated at for 30 min  
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Figure 2.4. Ago-CLIP schematic from cells to Ago associated mRNA isolation. 
Cells or tissues are crosslinked, undergo lysis and partial RNAse digestion before 
undergoing IP using anti-Ago (2A8) antibody coated magnetic beads. Following 
extensive wash steps, protein bound RNAs are enzymatically manipulated to 
enable down stream sequencing either by ligating a radiolabeled 3' RNA linker 
(left side) or direct radiolabeling with PNK (right). Radioactivity is indicated with a 
star. Following SDS-PAGE and proteinase K treatment, isolated Ago bound RNA 
is cloned. For RNA with 3' linkers, cloning proceeds with 5' linker ligation or BrdU-
CLIP. For RNA without linkers, poly-A or -G tailing CLIP is implemented.  
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Figure 2.5. Two cloning strategies for Ago-CLIP isolated RNA fragments. (A) In 
standard CLIP, RNA reads undergo sequential ligation of 5' and 3' RNA adapters, 
followed by RT-PCR. Note that the RNA input contains the 3' adapter, as this is 
done on bead prior to SDS-PAGE where the radiolabeled 3' RNA linker is used 
for auto-radiography. The 5' adapter contains a barcode (NNNNG) such that each 
RNA tag is uniquely labeled, thus cataloging a single Ago binding event. An index 
specific for each library is added with a 2nd PCR step to enable multiplexing. 
Reads are sequenced starting with the index. (B) In Poly-G (or A) CLIP, 
completely independent of RNA ligation, reads are first tailed with a homopolymer 
polymerase and undergo RT using an oligo that recognizes the poly-G stretch, 
and using BrdUTP in place of UTP. This RT oligo contains Illumina sequencing 
adapters separated with an APE1 site. The cDNA undergoes BrdU IP, on bead 
circularization, APE1 digestion, then is PCR amplified to create the library. As in 
standard CLIP, each RNA read is tagged with a unique barcode.  
 
 
at room temperature or overnight at 4°C. Just prior to IP, beads were washed in 
1X PXL lysis buffer (1X PBS tissue culture grade without magnesium or calcium, 
0.1% SDS, 0.5% Sodium-deoxycholate, 0.5% NP-40) with protease inhibitors 
(Roche, mini EDTA-free). 
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Cell lysate preparation and IP 
 Frozen lysates of crosslinked cells or powdered liver tissue were prepared 
by adding 1ml of 1X PXL (with protease inhibitors) and triturating to disrupt cells. 
Lysates treated with 10μl DNAse (RQ1, Promega) for 5 minutes, thermomixing at 
37°C at 1100rpm. Samples were then treated with RnaseA or RNaseI, first 
diluted to the indicated concentration by volume (e.g. 1:100, or 1:10,000) in lysis 
buffer and then added at 10μl per ml of lysate. Critical for interpreting CLIP 
autorads, the amount of RNAse to be added was empirically determined in pilot 
experiments using an RNase titration. Range concentrations that yielded a smear 
10-50kDa above the collapsed band were typically chosen, in some cases no 
RNase was required. Figure 2.6 shows an example of an RNase titration yielding 
a working concentration amenable for the partial RNAse digest needed for CLIP. 
Lysates underwent thermomixing again for 5 minutes at 37°C at 1100rpm before 
being treated with 10μl RNAsin RNase inhibitor (Promega) and spun at 4°C on 
max speed of a table-top micro centrifuge for 30 minutes. Supernatants, along 
with any lipid layer, were harvested and mixed with PXL equilibrated antibody 
bound beads for IP. A small amount of pre-IP lysate was kept to monitor Ip 
efficiency. Samples were rotated with beads at 4°C for 2-4 hours. Following IP, a 
small amount of post-IP lysate was kept. Beads were washed sequentially twice 
each with 1X PXL, 5x PXL (same as 1X but using 5X PBS), and 1X PNK buffer 
(50mM Tris-HCl, pH 7.5, 10mM MgCl2, 0.5% NP-40). 
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Figure 2.6. An RNAseA titration experiment for Ago-CLIP. Two mouse livers were 
processed for Ago-CLIP using 3' radiolabeled L32 linker under decreasing 
RNAseA concentrations (lanes 2-4), without RNAseA (lane 5), or without 
RNAseA plus RNAse inhibitors (lane 6). Minus crosslink control from similar 
amount of tissue is shown (lane 1). Ago:miRNA complex at 110kDa is highlighted 
with an arrow. Note that as RNAse concentration decreased the sharp 110 kDa 
band became more diffuse, indicating an RNAse dependence "collapse" of the 
radioactive signal to the modal size of Ago plus miRNA. On the basis of this 
experiment for mouse liver, lane 4, corresponding to 1:10K dilution of RNAse A 
was chosen for downstream processing, and became the RNAseA condition of 
choice for liver tissue studies in mouse and human.  
 
 
Removal of 3' phosphate, 3' linker ligation, and re-phosphorylation of 5' ends of 
AGO bound RNA 
 To prevent RNA circularization of RNA tags, IPs were treated with alkaline 
phosphatase. Beads were resuspended in 80μl containing 1x dephosphorylation 
buffer, 3U of CIAP (Roche), RNasin inhibitor (Promega), and thermomixed for 20 
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minutes at 37°C, shaking at 1100rpm for 15s ever 2 minutes. Samples were then 
washed as above sequentially in 1X PNK, 1X PNK plus 20mM EGTA, and twice 
with 1X PNK.  
 Radiolabeled linkers for 3' linker ligation per sample were set up by 
preparing a T4 phosphonucleotide kinase (PNK, NED) reaction according to the 
manufacturers instructions using 2.5μl 32P-γ-ATP and an RNA linker, either 
20pmol L32 or L34 RNA linker (Dharmacon or IDT) and incubating for 30 minutes 
at 37°C. To drive the reaction to completion, 0.5μl of 1mM ATP was added and 
incubated for an additional 5 minutes. Linkers were purified from free nucleotides 
using G-25 columns following the manufacturers instructions (GE Healthcare). 
Ligation reactions on bead were prepared using Rnl1 RNA ligase (Fermentas) 
and 12pmol radiolabeled linker following the manufacturers instructions. Samples 
were incubated for one hour at 16°C, shaking at 1100rpm for 15s every 4 
minutes. After this hour, 60pmol cold linker was added and the reaction allowed 
to go overnight. The next morning, beads were washed twice each with 1XPXL, 
5X PXL, and 1XPNK. A final PNK reaction was performed on bead to restore the 
5' phosphate. To each sample an 80μl mix containing 1mM ATP, 1X T4 PNK 
buffer, 4μl T4 PNK and RNasin inhibitor. Samples were incubated for 20 minutes 
at 37°C, shaking at 1100rpm for 15s ever 2 minutes.  
SDS-PAGE resolution of AGO:RNA complexes 
 Beads were washed twice each with 1XPXL, 5X PXL, and 1XPNK. Protein 
was eluted off the beads by incubating with in 30μl of 1X LDS loading buffer 
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(Invitrogen) with reducing agent for 10 minutes at 70°C, shaking at 1100rpm. 
Supernatants were run on Novex NuPAGE 8% Bis-Tris cels (Invitrogen) in SDS-
MOPS buffer (50mM MOPS, 50mM Tris Base, 0.1% SDS, 1mM EDTA, pH7.7) 
for 2.5 hours at 175V at 4°C. Radiolabeled protein RNA complexes were 
transferred to BA85 nitrocellulose (Whitman) using a Novel wet transfer 
apparatus for 1 hours at 30V. After transfer, the membrane was rinsed with 
RNAse-free PBS, and exposed to Biomax MR film (Kodak) at -70°C typically from 
3 hours to up to 5 days.  
Recovery of AGO-RNA complexes 
 Nitrocellulose membranes were aligned with the exposed film and regions 
of the membrane from low RNase IP lanes were excised. Typically, binary AGO-
miRNA complexes migrated at 110kDa, while AGO-mRNA and ternary AGO-
miRNA-mRNA complexes migrated between 130-150kDa. These two regions 
(110kDa and 130-150kDa) were excised and processed separately, though I 
noted no qualitative differences between the ability to clone miRNAs or mRNA 
targets from either region. Put another way, mRNAs could often be cloned from 
the 110kDa band, and miRNAs from the 130-150kDa bands. Parallel processing 
of these regions was often used as technical replicates. In general, the regions 
excised did not extend beyond 150kDa, due to the large length of the RNA 
recovered. Short mRNA fragments between 30 and 60nts were preferred to 
facilitate read clustering and peak finding; I note this only because most NGS 
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RNA protocols call for longer (100-300nt) reads, to more effectively leverage 
paired end sequencing and more accurate splice site identification.  
Proteinase K digestion, RNA recovery, and 5' linker ligation 
 RNA was liberated from membrane fragments using 200μl of a proteinase 
K solution (Roche) diluted in PK buffer (100mM Tris-HCl, pH 7.5, 50mM NaCl, 
10mM EDTA) to 4mg/ml and incubated for 20 minutes at 37°C, shaking at 
1000rpm. RNA was further denatured by adding 200μl of PK buffer with 7M urea 
and incubating for 20 minutes at 37°C, shaking at 1000rpm. RNA fragments 
underwent acid phenol:chloroform extraction and were precipitated overnight at -
20°C in 1ml of 1:1 ethanol:isopropanol and 50μl of 3M NaOAc, pH 5.2.  
 RNA was pelleted by spinning at max speed (>13,000rpm) in a table top 
centrifuge at 4°C, and washed twice with 75% ethanol. Following speedvac 
drying of the RNA, the pellet was dissolved in 6μl RNase-free water. The 5' linker 
was ligated using Rnl1 (Fermantas) and 20 pmol of the 5' linker following the 
manufacturers instructions and in a total volume of 10μl. Samples were 
incubated at 16°C for 5 hours with intermittent shaking. Ligated RNA was DNase 
digested by adding 30μl RNase-free water, 5μl 10X RQ1 buffer, 2.5μl RQ1 
DNase and 2.5μl RNasin inhibitor; and incubating at 37°C for 20 minutes. 
Samples then underwent phenol chloroform extraction as above.  
Reverse transcription and 1st PCR 
 RNA was pelleted by spinning at max speed (>13,000rpm) in a table top 
centrifuge at 4°C, and washed twice with 75% ethanol, and dried. Following 
 87 
speedvac drying of the RNA, the pellet was dissolved in 10μl RNase-free water. 
8μl RNA was mixed with 10pmol DP3 primer, 3μl 3mM dNTPs, and incubated for 
5 minutes at 65°C in a thermocycler; the remaining RNA from all samples was 
pooled and 8μl of this was used for the -RT control. Samples were ramped down 
to 50°C, after which RT was added: 1μl 0.1M DTT, 4μl 5x Superscript buffer, 1μl 
RNasin and 1μl Superscript III (Invitrogen ) or 1μl water for -RT controls. 
Samples were incubated in a thermocycler at 50°C for 45 minutes, 55°C for 15 
minutes, 90°C for 5 minutes then chilled to 4°C. PCR was performed immediately 
after using 27μl Accuprime Pfx (Invitrogen), 0.15μl DP5 primer (at 100 pmol/μl), 
0.15μl DP3 primer (at 100 pmol/μl) , and 4μl of the RT reaction, for a total of 4 
reactions per sample. PCR conditions were 95°C for 2 minutes, 20-35 cycles of 
95°C for 20s denature, 58°C for 30s anneal, and 68°C for 30s extension. 
Typically, miRNA plus linker fixed products arose around 20-24 cycles, mRNA 
plus linkers from 22-30 cycles. Reactions were taken out the the thermocycler 
following extension starting at 22 cycles, every two or three cycles. RT negative 
samples were taken out 4-5 cycles after the last +RT sample.  
 The entire PCR reaction was loaded with an equal volume of 2x loading 
buffer (95% formamide, 5% 100mM EDTA pH 8.0, and a dash of bromophenol 
blue and xylene cyanol) and run on 10% denaturing PAGE gels in 1X TBE for 1 
hour at 300V. Amplify molecular rulers (Biorad) were used as markers. To 
visualize DNA, gels were stained in 1X SYBR Gold (Molecular Probes) in 1X TBE 
for 10 minutes. PCR products corresponding to miRNAs flanked by adapters 
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(~55-60bp) or adapter flanked mRNAs (80-150bp) were cut from the gel. DNA 
was extracted by soaking gel slices in DNA diffusion buffer (0.5M ammonium 
acetate, 10mM Mg-acetate, 1mM EDTA, 0.1% SDS) and incubating at 50°C for 
30 minutes, shaking at 1200rpm. Gel slurry was filtered through Whitman glass 
filters in Nanosep columns (VWR). DNA was recovered from the filtrate using 
Qiaquick gel purification (Qiagen) and resuspended in 30μl.  
Multiplexed AGO-CLIP 
 To enable cost-effective multiplexing of standard CLIP libraries as well as 
compatibility with sequencing on MiSeq machines, we adapted the 2nd PCR step 
of the standard CLIP protocol to add sequencing adapters and 5' indices. This 
strategy uses the DP5 and DP3 sequences of the 1st PCR product as priming 
sites to add 5' indices and 3' adapters for a short (4-10 cycles) 2nd PCR step 
(Figure 2.5A). PCR was performed using 27μl, Accuprime Pfx (Invitrogen), 0.5μl 
MSFP5 5' primer (at 20 pmol/μl, each sample with different indexed primer), 0.5μl 
MSFP3 3' primer (at 20 pmol/μl) , and 3μl of the 1st PCR product, in triplicate. 
PCR conditions were 95°C for 2 minutes, 4, 7 or 10 cycles of 95°C for 20s 
denature, 58°C for 30s anneal, and 68°C for 30s extension. The 2nd multiplexed 
PCR product was separated on a 2% Metaphor agarose gel (Lonza) and the 
lowest cycle number visible purified Qiaquick gel purification (Qiagen) and 
resuspended in 30μl. Following DNA concentration and integrity analysis using 
TapeStation (Agilent), each individual sample was diluted down to 10nM, pooled 
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in equal parts with all other samples containing unique indices, and submitted for 
high throughput sequencing. All cloning oligos are listed in the Appendix.  
Poly-G CLIP 
 Poly-G CLIP is a direct adaptation of the single linker ligation BrdU CLIP 
protocol (Weyn-Vanhentenryck et al., 2014) and was inspired by ribosomal 
profiling methods (Ingolia et al., 2009). In contrast to standard CLIP, which relies 
on two sequential RNA linker ligation steps, and BrdU CLIP, which relies on one 
RNA ligation step, the poly-G CLIP protocol relies on tailing CLIP'ed RNA, 
performing RT with a primer capable of circularization and subsequent cleavage 
to generate a cDNA library amenable for high-throughput sequencing (Figure 
2.5B).  
 Regarding the choice of nucleotide for tailing, we chose G for a few 
practical but mostly empirical reasons. As poly-A tails can range in size from 
>100nt to >1kb, working out conditions for uniform poly-A tail lengths became 
impractical. Aldo Mele in the Darnell lab took an unbiased approach and tested 
two polyA polymerases, from E. coli or S. cerevesiae, and monitored their ability 
to generate homopolymeric tracts that could be used for priming. ATP yielded 
long tails for both enzymes as expected, but only yeast polyA polymerase 
created short, 12-15nt G tails on any input RNA (Figure 2.7). Moreover, the yeast 
enzyme most efficiently added tails to completion such that little input RNA was 
left untailed. On this basis of these experiments, I adapted Aldo's findings to aid 
in miRNA cloning efforts using polyG tailing.  
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Figure 2.7. Ribonucleotide incorporation comparison between poly-A polymerase 
enzymes from E. coli (E-PAP) and S. cerevisiae (Y-PAP). Exactly 20 pmol RL5D 
RNA linker was radiolabeled with 32P-γ-ATP in a PNK reaction and underwent 
poly A polymerase reactions with 5U E-PAP (left, NEB) or 300U Y-PAP (right, 
USB) in manufacturer recommended buffer conditions supplemented with 1mM of 
the indicated rNTP. Reactions proceeded for 20 minutes at 37°C, before stopping 
via heat denaturation at 65°C for 10 minutes. Samples were run on 20% 
denaturing Urea-PAGE gels and exposed to film. E-PAP readily incorporated 
ATP as expected forming products with median polyA lengths of 150-200nt, and 
was unable to incorporate an other rNTPs. Y-PAP synthesized polyA tails greater 
than 1kb in length and was largely incapable of incorporating UTP or CTP, but 
interestingly incorporated short well defined tails of polyG, between 12-15nt in 
length. Experiment performed by and data courtesy of Aldo Mele.  
 
 The standard CLIP protocol was followed to directly PNK label AGO 
bound RNA with 32P-γ-ATP (Moore et al., 2014); the 3' RNA linker ligation steps 
were skipped. Following autorad exposure, 100-110kDa regions were excised 
from the membrane for RNA isolation as described above. The resulting RNA 
was tailed with yeast poly-A polymerase (USB Affymetrix 74225Y) using GTP 
with the final concentrations: 1X Y-PAP buffer, 1mM GTP, 7.5U RNAsin 
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(Promega N261), and 300U Y-PAP. The reaction was incubated at 37°C for 20 
minutes, then 65°C for 10 minutes. After tailing, reverse transcription was carried 
out using 5μl polyG tailed RNA, 1μl 0.752M Tris, 1μl 8.2mM dATP, 1μl 8.2mM 
dCTP, 1μl 8.2mM dGTP (all Invitrogen), 1μl 8.2mM Br-dUTP (Sigma), 1μl 25μM 
RT Primer and 1μl H2O. This mix was incubated for 3min at 75°C then ramped 
down to and held at 48°C. To this reaction, 1μl 82mM DTT, 1μl 10U/μl RNasin 
and 1μl SuperscriptIII (or H2O for –RT) pre-warmed to 48°C was added to the 
original mix, then incubated for 45 minutes at 48°C, 15 minutes at 55°C, and 5 
minutes at 85°C then held at 4°C. Following RT, 1μl of 2U/μl RNaseH 
(Invitrogen) was added to destroy RNA and incubated at 37°C for 20 minutes, 
after which 10μl RNase-free H2O was added and the cDNA purified by spinning 
through a G-25 column. 
cDNA purification and BrdU IP 
 The cDNA was then purified using Protein G dynabeads (Invitrogen) 
coupled with an anti-BrdU antibody (Santa Cruz). Briefly, 50μl of ProteinG 
dynabeads per sample were washed in AB buffer and resuspended in 25μl of AB 
buffer along with 25μl 50X Denhardt's Solution (Sigma) and rotated at room 
temperature for 1hr. Beads were then washed three times with 1X IP buffer (0.3X 
SSPE (Ambion), 1mM EDTA, 0.05% Tween-20), resuspended in 25μl IP buffer 
plus 25μl of anti-BrdU antibody (5g, Santa Cruz, sc-32323) and rotated at room 
temperature a minimum of 45 minutes for antibody binding, then washed and 
equilibrated in 1X IP buffer. The equivalent of 25μl starting volume of beads were 
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used per BrdU IP. The volume of cDNA was brought up to 40μl with H2O and 
10μl 50X Denhardt's solution before adding 50μl of 2X IP buffer (2X IP 
buffer:0.6X SSPE (Ambion), 2mM EDTA, 0.1% Tween-20). The mix was 
incubated for 5 minutes 70°C, 2 minutes 25°C, spun down and added to the 
equivalent of 25μl starting volume of the prepared anti-BrdU beads. Tubes were 
rotated at room temperature for 30mins and washed once with 1X IP buffer plus 
5X Denhardt's, twice in low salt buffer (15 mM Tris- HCl, pH 7.5, 5 mM EDTA), 
and twice with 1X IP buffer. cDNA was eluted from the beads via BrdU 
competitive elution by adding 50μl 100μM BrdU (Sigma) in 1X IP buffer, rotating 
for 30min and collecting the eluate. Eluted cDNA was purified by spinning 
through a G-25 column, the volume adjusted to 97.5μl with H2O, after which 
37.5μl 4X IP buffer and 15μl Denhardt's solution was addedadded. The anti-BrdU 
IP was repeated as above with the remaining 25μl of prepared beads, and 
washed. The final two washed consistent of 1X CircLigase Wash Buffer (33mM 
Tris-acetate, 66mM KCl, pH7.8). 
On-bead cDNA Circularization and ApeI Linearization 
 On bead, cDNA was circularized by incubation for 1 hour, 60°C, 1300rpm 
thermomixer mixing for 15 seconds, every 30 seconds, with 2μl CircLigase 10X 
Reaction Buffer (Epicentre), 4μl 5M betane, 1μl 50mM MnCl2, 0.5μl CircLigase 
ssDNA Ligase II (50U, Epicentre) and 12.5μl H2O. Beads were washed by 
rotating for 5min, two times each with 1X IP buffer and ApeI buffer (50mM 
potassium acetate, 20mM Tris-acetate, 10mM magnesium acetate, pH7.9). 
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cDNA was then linearized on bead by adding 2μl 10X NEB Reaction Buffer 4, 
1.25μl ApeI (10U/μl NEB) and 16.75μl H2O, and incubating for 1 hour, 37°C 
1300rpm thermomixer mixing for 15 seconds, every 30 seconds. Beads were 
washed twice with low salt buffer, and twice with Phusion wash buffer (50mM 
Tris, pH8.0). 
PCR amplification  
 To elute cDNA off of beads, 10μl 5X Phusion HF Buffer (NEB), 1μl 10mM 
dNTPs and 37.5μl H2O were added, the mix transferred to a thin walled PCR 
tube and incubated at 98°C for 45 seconds. Superntatants from beads after 
agent capture were transferred to a fresh PCR tube. To this was added 0.5μl 
20μM P5 primer, 0.5μl 20μM P3 primer, 0.5μl Phusion DNA polymerase and 
0.5μl 50X SYBR Green I (Invitrogen).  
 PCR amplification was carried out on iQ5 or CFX real-time PCR machines 
(Biorad) in order to monitor amplification, with the samples being removed when 
the RFU signal reached ~800-1000. PCR cycle conditions were as follows: 1X 
98°C 30s, 15-20 cycles as necessary 98°C 10s, 60°C 15s, 72°C 20s. PCR 
products were run on 2% metaphor agarose gels (Lonza), purified using Qiaquick 
gel purification (Qiagen) and resuspended in 30μl. Unlike standard CLIP, each 
RT primer contained it's own index for multiplexing, and thus only one PCR 
reaction was ultimately performed to append Illumina sequencing linkers. 
Following DNA concentration and integrity analysis using TapeStation (Agilent), 
each individual sample was diluted down to 10nM, pooled in equal parts with all 
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other samples containing unique indices, and submitted for high throughput 
sequencing. All cloning oligos are listed in the Appendix.  
mRNA-seq library construction 
mRNA-seq libraries were prepared from Trizol extracted RNA following Illumina 
TruSeq protocols for poly-A selection, fragmentation, and adapter ligation. 
Alternatively, total RNA underwent RiboZero purification (Epicentre) to negatively 
select ribosomal RNA sequences. Multiplexed libraries were sequenced as 100nt 
single-end or paired-end runs on HiSeq-2000 sequencers.  
Illumina sequencing 
 CLIP library next-gen sequencing was carried out on HiSeq2000 (RU 
genomics Core) or Hiseq2500 (NYGC) machines, set up for 100nt single-end 
(SE) sequencing and typically run between 2-5pM per lane, using v2 or v3 
chemistry. Unless noted, the Illumina Read 1 primer was used. For RNAseq, 
samples were processed under 100nt paired-end sequencing, using standard 
Read1 and Read2 primers.  
Bioinformatic analysis 
Argonaute-CLIP 
 Analysis of AGO-CLIP data was carried out similar to previous work (Chi 
et al., 2009; Moore et al., 2014; Riley et al., 2012a). Data processing was carried 
out using the Galaxy suite of bioinformatics tools (Goecks et al., 2010) and the 
UCSC genome and table browsers (Kent et al., 2002), in addition to in-house 
tools developed by Chaolin Zhang. A schematic of data processing for CLIP is 
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presented in Figure 2.8. Using FASTX tools in Galaxy, FASTQ sequence files 
were first filtered for quality such that 80% of the read contained a mean PHRED 
score of 20. Reads were then collapsed on sequence to remove sequencing and 
PCR duplicates. The fold coverage, that is the raw reads divided by the collapsed 
reads, as a rough estimate of sequencing saturation, was typically as low as 5 
but up to 100 fold depending on the presence of multiplexed samples and was 
used as a rough proxy for sample complexity. 
 In theory, a CLIP-seq library from an mRNA binding protein can be 
thought of as a sparsely sampled subset of a full mRNA-seq library since 
RNABPs by definition bind transcribed RNA. Thus it follows, especially for 
RNABPs with defined binding sites, and for which exon exon junctions play a 
minor role, that CLIP-seq libraries will be less complex than their parent RNA-seq 
libraries, due to the reduced sequence "space" that can be cloned. As a 
consequence, one should expect that fold coverages on average will be higher 
for CLIP than RNAseq. In practical terms this means that a far greater number of 
CLIP experiments can be sequenced per lane than RNAseq experiments. For 
instance, in singlet libraries, a Hiseq2000 lane will typically yield approximately 
100M reads, for which AGO-CLIP will collapse to around 1-2M reads, a coverage 
of 50-100X; the parental RNAseq library would collapse to between 10-30M 
reads (3-10x coverage). Ten multiplexed AGO-CLIP libraries in the same 
scenario on average will yield around 1M reads per sample (10M total) for a per 
sample coverage of 10X, in line with one RNA-seq library.  
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Figure 2.8. An analysis pipeline for CLIP data. Key raw and finished files in blue 
denoted by format where applicable. Data processing, calculation, and 
visualization steps in green boxes.  
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 Barcoded samples, if any, were split after exact sequence collapse using 
the barcode splitter. 5'-degenerate linker sequences were removed for later 
estimation of unique binding events, where applicable (Licatalosi et al., 2012). 
The 3'-adapter sequence was also removed if present using the clip adapters tool 
while for poly-G tailed samples, an "adapter" sequence of GGGGGGG was 
clipped from the 3' end. Reads shorter than 18nt were discarded for linker ligated 
samples, 15nt for poly-G samples. This final set of groomed reads represented 
the input for subsequent alignment. 
 Alignment of mRNA sample reads to either the human (hg18) or J6/JFH1-
Clone2 (WT, U3 or m15) genome was carried out using the Bowtie (Langmead et 
al., 2009) or Novoalign (Novocraft) mapping programs allowing at most 2 
mismatches (or indels) and discarding reads with multiple hits. Alignment of 
miRNA samples was performed similarly, but allowing for zero mismatches. After 
mapping, we collapsed reads on coordinates such that only those reads with 
sufficiently different degenerate linkers were kept; this distinguished unique 
binding events (tags) from PCR duplicates (Darnell et al., 2011; Licatalosi et al., 
2012). Coordinates for mature miRNAs were constructed from mirBase (v18) for 
annotation and counting of miRNAs based on uncollapsed mapped reads. 
 Clustering of mRNA reads to genomic loci was carried out as in (Chi et al., 
2009) where we typically specified a minimum biologic complexity (BC) of at least 
half of the libraries in the comparison (3 for 6 libraries, 5 for 10, etc). Reads at a 
particular cluster from different experiments were normalized to the read-depth of 
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their respective libraries for cross comparison. The resulting clusters were 
intersected with UCSC genes (a union of RefSeq, Uniprot, and Genbank gene 
definitions) to determine the genic identities and positions of AGO binding sites. 
Seed searches were carried out within robust AGO clusters (+/- 32nts) for all 
miRNA families identified from miRNA-CLIP specifying perfect base pairing for 
miRNA seeds to targets following 8mer, 7mer-A1, 7mer-m8, and 6mer(2-7) 
pairing rules (Bartel, 2009).  
 Log2 fold changes comparing conditions were calculated as follows. A 
pseudo-count of 1 was added to all summed clusters per condition to allow for 
incorporation of conditions with zero clustered reads. After binning by BC, the 
sum total number of reads per cluster per condition was normalized to the read 
depth for that condition. Dividing these normalized CLIP abundance 
measurements per condition, we arrived at estimates over mock or controls for 
change in CLIP binding due to HCV, LNA and KO conditions.  
 Significant peaks on HCV RNA were called based on using scan statistics 
as described previously (Licatalosi et al., 2012). Gene wise p-values underwent 
Bonferroni multiple test correction where the significance cut-off on HCV RNA 
was set at 0.001. CIMS analysis on viral RNA was performed as described 
previously (Zhang and Darnell, 2011).  
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Figure 2.9. An analysis pipeline for RNAseq data. Key raw and finished files in 
blue denoted by format where applicable. Data processing, calculation, and 
visualization steps in green boxes. 
 
 
RNA-Seq bioinformatics 
 Figure 2.9 outlines the pipeline for RNAseq analysis. Analysis of these 
data was carried out by first filtering FASTQ reads such that 80% of the read 
contained a mean score of 20. Reads were then directly mapped to hg18 using 
 100 
Bowtie, allowing up to 2 mismatches and discarding reads with multiple hits. 
Mapped read coordinates were then intersected with a meta-transcript file of the 
longest isoform of every coding gene in UCSC genes and then counted. The 
resulting reads per gene count, for each RNA-Seq replicate then underwent 
statistical analysis and quantification using EdgeR (Robinson et al., 2009).  
Conservation analysis 
 Interval coordinates of miRNA seed target sites within CLIP clusters were 
intersected with PhyloP scores (Pollard et al., 2010) for available mammalian 
nucleotides from the UCSC table browser. The resulting per-nucleotide scores 
were averaged across the core 6mer. The same procedure was performed for 
miRNA seed target coordinates from TargetScan6.2 (Lewis et al., 2005) 
predictions.  
Statistical tests 
 Statistical analysis was carried out in Graphpad Prism or in R. Two-sided 
KS-Test were employed for CDFs to test both for goodness of fit and a difference 
in means. Mann Whitney U test (non parametric t-tests) were used for datasets 
for which no normality assumption could be made, Student's t-test were used 
otherwise. Where multiple ad-hoc or post-hoc comparisons were made, care was 
taken to account for multiple testing correction using one-way ANOVA and 
bonferroni correction.  
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Meta-analysis of published array data 
 Microarray datasets from the chimpanzee miravirsen study (Lanford et al., 
2010) were processed by computing the log2 fold change across each gene for 
each paired chimp array (post- versus pre-treatment) and then averaged. Liver 
biopsy datasets were obtained from Gene Expression Omnibus (GSE15331, 
(Peng et al., 2009); GSE14323, (Mas et al., 2009)) and processed with GEO2R 
to remove non-median centered datasets. For GSE15331, a total of 96 HCV 
positive datasets representing 24 individuals in technical quadruplicate were 
compared to 20 HCV negative datasets representing 5 individuals in technical 
quadruplicate. For GSE14323, a total of 19 normal liver datasets were compared 
to 41 datasets from HCV infected patients with pre-malignant cirrhosis but no 
hepatocellular carcinoma. The above processed datasets from three independent 
studies were intersected with all conserved 8mer and 7m8 miR-122 or miR-15 
predictions from TargetScan, or with CLIP derived miR-122 targets (7-8mers) 
from at least two miR-122 perturbation conditions. 
Gene Ontology analysis  
 Gene ontology analysis was perforemd with unranked lists using the 
DAVID suite of bioinformatics tools (Huang et al., 2008) or the GOrilla suite for 
GO term enrichment (Eden et al., 2009). Gene list comparisons were carried out 
between the list of interest and a background set of AGO bound transcripts.  
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Conservation analysis 
 Interval coordinates of miRNA seed target sites within CLIP clusters were 
intersected with PhyloP scores (Pollard et al., 2010) for available mammalian 
nucleotides from the UCSC table browser. The resulting per-nucleotide scores 
were averaged across the core 6mer. The same procedure was performed for 
miRNA seed target coordinates from TargetScan6.2 (Lewis et al., 2005) 
predictions.  
Statistical tests 
 Statistical analysis was carried out in Graphpad Prism or in R. Two-sided 
KS-Test were employed for CDFs to test both for goodness of fit and a difference 
in means. Mann Whitney U test (non parametric t-tests) were used for datasets 
for which no normality assumption could be made, Student's t-test were used 
otherwise. Where multiple ad-hoc or post-hoc comparisons were made, care was 
taken to account for multiple testing correction using one-way ANOVA and 
bonferroni correction.  
Quantitative modeling of miR-122 sponging by HCV RNA 
 Our mathematical model expands upon a previously developed model for 
miRNA regulation (Mukherji et al., 2011) by adding the behavior of HCV and its 
interaction with miR-122. The mathematical model we developed describes the 
concentrations of a target mRNA species (r), an HCV mRNA species (h), and 
binding of miRNA (m) to form complexes with target or HCV mRNA species, 
respectively (r*, h*), see Figure 2.10.  
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Figure 2.10. Illustration of model reactions for miR-122 dynamics, including 
transcription and translation of a target mRNA, binding to miR-122 and decay of 
mRNA species. HCV RNA can replicate, be degraded, or bind miR-122, 
functionally sequestering miR-122 and leading to de-repression of mRNA targets. 
See text for details.  
 
 
Production of a target mRNA comes from transcription of a gene at a rate (kr) 
with a corresponding degradation rate (γr). We assume the miRNA-mRNA 
complex (r*) does not undergo translation and degrades at a rate allowing for 
recycling of the miRNA species into the pool. The total amount of miRNA is 
assumed to be constant and can bind to either target mRNA (r) or HCV mRNA 
(h). HCV RNA also decays at a particular rate (γh). We assumed a model where 
HCV RNA is only degraded in its unbound form, consistent with previous data (Li 
et al., 2013d; Shimakami et al., 2012). 
 From the schematic presented in Figure 2.10, from the mass-action 
equations for this system, we have the following set of equations:  
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where the total pool of miRNA is defined be: 
   
Initially we performed numerical simulations of the full model, however to provide 
insight into the sponging effect of HCV we made simplifications to the model for 
analysis. Free miRNA (m) can be bound to either target mRNA (r) or HCV mRNA 
(h). At equilibrium, the amount of miRNA bound to the two species is proportional 
to the relative binding strengths as given by rearranging the equilibrium relations 
for these two species. Thus, the proportion of miRNA bound to each target is 
given by: r*	   /	   h*	   =	   Kr	   /	   Kh , where Kh	   (k+h/k-­‐h) and Kr	   (k+r/k-­‐r) are the 
equilibrium constants for the binding-unbinding reactions.  
 To simplify further, if we assume that the proportion of unbound miRNA is 
low in comparison to miRNA bound to HCV or mRNA target, then our 
conservation relation becomes mT	  =	  r*	  +	  h* and we can estimate the amount of 
miRNA bound HCV RNA combining the above relations to be: 
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Solving for steady states in our full model as in Mukherji et al., the solution for r is 
given by the equation below:  
 
where, 
  
With HCV RNA present, the difference in this relation is a reduction in the total 
miRNA pool (mT) such that the parameter theta is changed to: 
 
Examining this relation, it is evident that as the binding strength of miR-122 to 
HCV RNA gets stronger, the available miR-122 pool is reduced. As the HCV 
binding strength approaches zero, then all of the original mT pool is available. We 
can also approximate the effect of the number of binding sites and stoichiometry 
by assuming that N binding sites produces a similar effect to a single binding site 
with N * the binding strength. Simulating and fitting our data to values theta, we 
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used this formula to estimate the reduction in the pool of miRNA's caused by 
HCV mRNA.  
  Data fitting was initially performed on the N = 4 construct by 
simultaneously fitting the lambda and theta parameters to the steady-state 
equation for r	  =	  f(r0) above using a least-squares error fitting algorithm. In Figure 
4.24C, lambda was scanned and fit to the different experimental N constructs' 
curves. In contrast to Mukherji et al., we found there to be inherent basal 
expression differences between the variable number of miR-122 sites as 
observed in the LNA data curves. We corrected the basal expression differences, 
which resulted in the alignment of the data sets at high BFP expression. In Figure 
4.24 D-E, fitting was performed while changing only the value of theta 
representing a change in the available free miRNA but not in the binding strength 
parameter lambda. For N = 4 curves in both cases, we noted experiment-to-
experiment variability in theta fits, though the relative changes within each 
experiment were consistent. For all fits, the inherent signal bias between RFP 
and BFP was corrected by using the difference in a group of approximately 10 
data points at the high signal end for each curve, since they are expected to fall 
on a line of x=y.  
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Chapter 3: Argonaute HiTS-CLIP studies of HCV RNA 
 
This chapter describes the overall scheme of studying HCV interactions 
with small RNAs using the AGO-CLIP method, and considers how these 
functional genomics techniques were used to address many questions in HCV 
RNA virus molecular biology in an unbiased manner. As CLIP permits the 
empirical observation of AGO binding sites with minimal technical perturbation, 
and is adaptable for in vivo work, we will define the interaction landscape 
between AGO and HCV RNA during infection in Huh-7.5 cells. Following this, we 
will demonstrate how AGO-CLIP profiles change in response to a variety of 
perturbations to include time, perturbing or removing miRNAs, utilizing miRNA 
independent viruses, and swapping the miRNA tropism of the virus. The impact 
on virus biology will be considered throughout.  
The positive interaction of miR-122 with HCV RNA presents a unique 
outlier for miRNA function as it contradicts the canonical function of miRNAs as 
repressors of gene expression. A major goal of the current work is determining 
whether the miR-122 interaction with HCV RNA represents the predominant 
small RNA interaction with the viral genome, or is one of many. Moreover, with 
the HCV genome harboring multiple and conserved miR-122 sites beyond those 
in the 5’UTR, the timing and amount of binding at these and potentially other 
sites offers a window on the dynamics of small RNA usage by the viral genome.  
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Experimental setup 
 The first task for AGO-CLIP in virus infected cells is deciding the number 
of cells needed per CLIP sample. The initial AGO-CLIP paper obtained results 
from miR-124 transfected HeLa cells in 10cm dishes, which assuming 80% 
confluence at the time of harvest would correspond to ~8x10^6 cells per sample 
(Chi et al., 2009). A similar cell number was selected for work done in Clone2 
HCV infected Huh-7.5 cells, initially starting from electroporation, and later 
switching to infection. Importantly, independent electroporations or infections 
were performed, both in separate plates, but also on separate days and always 
with paired mock treated samples.  
 The experimental setup, as mentioned in the methods, was to 
electroporate HCV RNA or infect with virus approximately 5x10^6 cells per 
sample in a 15cm dish, allow for growth for between 48 and 72 hours, when most 
cell are infected and proceed with CLIP. Post electroporation, we measured 
infection frequency by flow cytometry of NS5A expression or by using the IPS-
RFP reporter cells (Jones et al., 2010) and observed 80-90% infection frequency 
that was stable between 48 and 72 hours (Figure 3.1).  
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Figure 3.1. Infection frequency measurements for Huh-7.5 cells infected with 
Clone 2 HCV. (A) FACS analysis of NS5A stained cells at indicated timpanist 
post-electroporation, showing >80% infection frequency. (B) IPS-RFP cell 
reporter analysis of HCV infection, showing >90% infection frequency. In these 
cells an RFP with an NLS sequence is fused to the mitochondrial targeting 
domain of IPS1 (aka MAVS). HCV NS3/4A protease expression cleaves IPS-
RFP, thus relocalizing fluorescence to the nucleus (Jones et al., 2010). In 
general, this assay for measuring HCV replication is slightly more sensitive than 
NS5A staining, due to the enzymatic nature of NS3/4A. Consequently, slightly 
higher infection frequency (or at the very least protein translation) can be 
measured with this method compared to NS5A FACS. Overall, both methods 
approximately agree.  
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 Following crosslinking and harvest, cells were processed for CLIP as 
described in the methods, using a pan-AGO antibody that recognizes all four 
known mammalian AGOs (Nelson et al., 2007). A typical autoradiogram is shown 
in Figure 3.2A. Here, 32P-labelled RNA crosslinked to AGO was run on an 8% 
Bis-Tris gel, transferred onto nitrocellulose and exposed for 2 days. An IgG 
antibody was used as a non-specific antibody control. Additionally, a no crosslink 
control is shown where only a faint band around 105-110kDa is apparent. This 
would correspond to tightly associated AGO:miRNA complexes (Lima et al., 
2009). UV crosslinking results in a dramatic increase in signal, where importantly, 
130-150kDa "smears" corresponding to AGO:mRNA or AGO:miRNA:mRNA 
complexes appear alongside a more apparent 110kDa band. High RNAse 
conditions tend to collapse the signal to the model size of the protein plus a 
protected RNA fragment, though this is not always the case. In this experiment, 
regions from mock or HCV infected lanes were cut corresponding to 110, 130 or 
150kDa as a first size selection step for the isolation of AGO bound miRNAs and 
mRNAs.  
As a measure of IP efficiency, pre- and post-IP lysates were probed via 
western blot to monitor the extent of AGO depletion (Figure 3.2B). In both 
uninfected and infected cells, approximately 60% of total AGO protein was 
depleted in lysates, indicating that the majority of AGO:RNA complexes were 
recovered for CLIP.  
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Figure 3.2. Autoradiogram of AGO bound RNA and measure of AGO depletion. 
(A) Autoradiogram of 32P-labelled RNA bound to AGO after IP using the pan-
AGO 2A8 antibody. AGOs migrate at 97kDa, which shifts by RNA species bound 
by approximately 1kDa/3nt, thus AGO bound to ~22nt miRNA should be around 
105kDa. IgG used as a non-specific control. Minus crosslink control shows the 
stringency of washes in that only a faint Ago:miRNA complex remains. High 
RNAse and low RNAse conditions indicated. Regions excised corresponding to 
110, 130 or 150kDa are highlighted. (B) Pre and post IP lysates were probed for 
Ago, NS5A and Actin. Percent of Ago depletion from mock or HCV infected cells 
is indicated and are based on normalizing to actin.  
 
 
 Excised membrane regions underwent proteinase K treatment to liberate 
the RNA, which then underwent 5' adapter ligation and RT-PCR for DNA library 
generation (see Methods). The "first" PCR provides the next size selection step 
after the autorad, and yields a key measure of success or failure for library 
cloning (Figure 3.3). Here, the cDNA derived from each membrane fragment 
(110,130 or 150kDa) underwent PCR for various cycle numbers. Importantly, 
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care was taken to catch the earliest cycle number for which an amplified signal 
could be detected on a 6M Urea-PAGE gel, to preserve the maximum library 
complexity and minimize the long known non-uniformity of PCR amplification of 
cDNA libraries (Patanjali et al., 1991). Adapter flanked miRNAs of ~60nt could be 
observed with as few as 20 cycles of PCR. Target mRNAs typically migrated as 
"smears" owing to the partial RNAse digest, ran between ~80-180nt, and were 
observed in as few as 24 cycles. In general, PCR from the 110kDa membrane 
fragments tended to yield miRNA+adapter sized products, though this was not 
always the case, as some mRNA smears could be observed. 130-150kDa 
regions almost always yielded mRNA "smears."  
 After isolation of miRNA or mRNA "smears," a second PCR step was 
performed to append 4mer indices (one per sample) to enable multiplexing, and 
to add Illumina sequences for NGS. This PCR step was typically very short 
(between 4-10 cycles). In the end, libraries with miRNA sized fragments were 
~150nt; mRNA between ~175-250nt. These libraries were concentration 
normalized, pooled such that each index was represented once, and submitted 
for high-throughput sequencing.  
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Figure 3.3. 1st PCR results from cloning AGO bound RNAs. Each panel depicts 
the results for excised membrane fragments (110, 130 or 150 kDa) after PCR 
amplification for indicated number of cycles. Minus reverse transcriptase (-RT) 
and minus template (-Temp) PCR controls are shown. Bands corresponding to 
miRNA + adapters (~60nt) and mRNA targets + adapters" smears" (~80-180nt) 
are indicated. Note that while 110kDa bands predominantly yield miRNA sized 
products, this is not exclusive. mRNA smears are more common in 130 and 
150kDa bands, where miRNAs can also be seen. Regions selected for 2nd PCR 
multiplexing steps were chosen such that no "bandiness" was evident for mRNA 
smears.  
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Figure 3.4. Multiplex adapter 2nd PCR results from cloning AGO bound RNAs. 
After amplification with muliplexed primers at indicated cycle number, mRNAs 
from 150 and 130kDa regions yielded products between 180 and 200bp as 
expected. Cloned miRNAs plus adapters from 100kDa regions yielded a sharp 
band at ~150bp. Libraries from Mock or HCV infected libraries were qualitatively 
identical at this stage.  
 
 
An AGO binding map of HCV RNA confirms extensive miR-122 engagement 
Three matched experiments were prepared and sequenced in the above 
manner, resulting in a total of six libraries. After processing reads for quality and 
trimming adapters, reads were mapped on to the input Clone2 HCV RNA 
genome, and collapsed on the basis of a degenerate linker sequence introduced 
during RNA linker ligation (see Methods). Thus, each resulting unique read 
("tag") can be considered an individual AGO binding event. Approximately 1-2% 
of input reads mapped to the HCV genome. The resulting AGO binding map is 
presented in Figure 3.5, where tags from independent experiments are 
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delineated by color and are displayed across a linear representation of the HCV 
genome.  
 
 
Figure 3.5. An Argonaute binding map on HCV RNA. (A) Mock-subtracted 
binding map of Ago-CLIP reads across HCV genomic RNA, from three biological 
replicates, denoted by read color. Statistically significant peaks above a uniform 
background are indicated by asterisks. Bottom CIMS track shows location of all 
deletions (gray) and statistically significant CIMS deletions (red). (B) Schematic 
of a miR-122 binding model to S1 and S2 highlighting locations of CIMS 
deletions. (C) Zoom in view of Ago binding from (A) across the viral IRES into the 
coding sequence. IRES domains (II-IV), associated stemloops (a-d) and the 
pseudoknot (pk) region are indicated. Upper track displays seeds for the top 50 
miRNA seeds from CLIP data, seed types denoted by colors. A proposed non-
canonical miR-122 site is highlighted in red (Pang et al., 2012).(D) Zoom in view 
of Ago binding from (A) across the NS5B peaks. Known stem loops in the NS5B 
coding sequence are indicated.  
 
Not displayed is the negative strand or alignments to mock infected cells, where 
in either case a vastly low percentage of reads mapped to HCV (not shown). This 
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not only presents a relief in terms of experimental success (no HCV mapping 
reads in the mock), but it also gives a sense of the high strand asymmetry 
exhibited by AGO binding. After removing reads mapping to the polyU tract 
(which is polyA on the negative strand and upon which mapped reads are 
indistinguishable from Illumina sequencing artifacts), >98% of reads mapped to 
the positive strand, and no peaks for the remaining low number of reads were 
observed on the negative strand. This would be consistent with AGO exclusively 
binding the positive strand, and playing little role, if any, on anti-sense genomes. 
Moreover, it also likely indicates that no RNAi-like response is occurring, given 
that this would imply Dicer activity on dsRNA in a manner that would generate 
siRISCs that target both strands of HCV.  
By far, AGO binding to positive strands at the extreme end of the 5'UTR, 
overlapping with S1/S2 miR-122 sites, and is the most frequent binding event on 
the HCV genome, accounting for 50% of all HCV mapped tags (Figure 3.5A). The 
high sequencing depth achieved at S1/S2 sites enabled nucleotide resolution of 
AGO crosslink sites, based on the observation that RT tends to skip crosslinked 
amino-acid-RNA adducts and thus results in deletions at the site of crosslinking 
(Zhang and Darnell, 2011). The resulting crosslink induced mutation analysis 
(CIMS) revealed a statistically significant enrichment of deletions in areas of 
close proximity to, but not within, the miR-122 S1 and S2 binding sites (Figure 
3.5B). Interestingly, the most significant crosslink site was at the G in position 28 
of the HCV genome. A recent report described G28A mutations as natural HCV 
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variants resistant to miR-122 antagonism: the G28A mutant was attenuated in 
WT cells, but could replicate in cells with reduced miR-122 levels (Israelow et al., 
2014). While the significance of this crosslink site remains to be determined, one 
possibility is that AGO binding to HCV RNA is tuned by contacts outside of the 
seed regions which structurally remain flexible in the AGO binding pocket in the 
absence of base-paring with the miRNA (Schirle et al., 2014). A G28A mutation 
might favor tighter miR-122 binding given that the opposed base on miR-122 is a 
U. Moreover, its position, between S1 and S2 auxiliary pairing may be relevant 
for the simultaneous AGO:miR-122 occupancy, though the precise contribution is 
unknown.  
Returning to the CLIP map, additional peaks of AGO binding were 
observed. To identify which peaks were "significant", we employed scan statistics 
to test if a peak was above a hypothetical background where all tags were 
uniformly distributed across the HCV genome (Darnell et al., 2011; Licatalosi et 
al., 2012). In this manner, the S1/S2 peak was significant as were peaks in the 
IRES, E1, E2, NS5A and NS5B regions of the genome. 
The second largest peak in the viral IRES specifically overlapped with the 
pseudoknot and the coding start site (Figure 3.5C). We noted no canonical 7mer 
or 8mer binding site for the top 50 miRNA families expressed in these cells, 
opening the possibility that some type of non-canonical or miRNA independent 
AGO binding is occurring. Interestingly, a non-canonical miR-122 site in the IRES 
was proposed based on SHAPE analysis of the HCV 5'UTR with miR-122 in vitro 
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(Pang et al., 2012). Our results with AGO could be consistent with miR-122 
engagement. Alternatively, as the 5'UTR is highly structured, the rather broad 
IRES peak could be due to crosslinking with AGO:miR-122 bound at S1/S2, but 
on the outer surface of the AGO protein. This would imply that the IRES peak is 
dependent on AGO binding to S1/S2, which is an idea that we will return to. 
Additionally, a role for AGO in regulating IRES translation, however minor, cannot 
be ruled out (see below). 
Along with S1 and S2 binding, four additional miR-122 sites are known on 
the HCV genome, notably in the NS5B coding sequence and in the 3'UTR 
(Jopling et al., 2005; Nasheri et al., 2011). Consistent with previous data, no 
significant AGO binding was observed on the 8mer miR-122 site in the 3'UTR 
(Figure 3.5D). The largest peak outside of the 5'UTR, in NS5B, overlapped with 
two miR-122 7mer seeds, one of which has been shown to be very slightly 
repressive (Nasheri et al., 2011). While reports have suggested numerous 
miRNAs that interact with HCV RNA (reviewed in (Gupta et al., 2014)), among 
these we only observed expression of let-7 and miR-196 families in our miRNA-
CLIP data (see next chapter), and no seeds from either of these families were 
observed within significant Ago binding peaks. Taken together, these data 
suggest that miR-122 constitutes the predominant miRNA interaction with HCV 
RNA in these cells, and is largely confined to the 5'UTR. 
We can only speculate as to the nature of the low-level amount of AGO 
binding across the HCV coding sequence. Given the high abundance of HCV 
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RNA in Huh-7.5 cells, it's possible that the low level binding reflects AGO-CLIP 
"noise" of rare binding events that are likely to survive filtering because they 
uniquely map. Still, it remains possible that some biology is at play. AGO was 
initially cloned as eukaryotic initiation factor 2C (EIF2C), which remains the root 
game name for AGOs 1-4 (Zou et al., 1998). As the name suggests, the initial 
phenotype for AGO suggested a role in translation, specifically in the ternary 
complex formation between eIF2, Met-tRNA, and GTP, known to be the first step 
in translation initiation (Roy et al., 1988). In this work, AGO (refered to in this 
study as Co-eIF-2A) was found to be important for stabilizing ternary complex 
formation on an mRNA prior to its transfer to the 40S ribosomal subunit (Roy et 
al., 1988). This literature has been largely superseded by emphasis on post-
transcriptional gene silencing by AGO, but it raises the possibility that AGO may 
be "moonlighting" with a role in HCV translation. The HCV IRES is unique in that 
it can bind to the 40S subunit in the absence of any initiation factors; it appears 
that only after 40S subunit engagement do eIF3 and the ternary complex bind to 
initiate translation (Ji et al., 2004; Pestova et al., 1998). If AGO plays a role in 
stabilizing the ternary complex and is already in the neighborhood by binding at 
miR-122 sites, then perhaps its primary function extends beyond protecting the 
uncapped genome, and is required to get translation initiation going efficiently. 
The observed CLIP map on the IRES may be consistent with this.  
In a general sense, the overall view of the AGO-CLIP map, with a large 
peak at the 5' UTR and AUG start, broad coating along the CDS and basically 
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zero signal from the stop codon into the 3'UTR, looks very similar to ribosomal 
profiling on a highly expressed gene. A prototypical example is FMRP, an 
RNABP known to be associated with translating risbosome such that CLIP with 
this protein reveals broad coating of coding exons (Darnell et al., 2011). Could 
this be evidence of a role for AGO ahead of the translocating ribosome or in 
association with it? Clearly, more work is needed to resolve this.  
The above are but a few interpretations drawn from the AGO-CLIP map on 
the HCV RNA genome and I hope they raise more questions than answers. It 
bears keeping in mind that a map constructed from cells infected for two days, 
undoubtedly reflects the AGO binding of a mixture of viral genomes at various 
stages of the viral life cycle. Thus we cannot conclude based on this static map 
which binding events are linked and therefore dependent on one another. Nor 
can we assign a weight to each binding event, assuming that they are 
independent: does the 50% engagement at the 5'UTR mean that 50% of viral 
RNAs are engaged with miR-122? This is perhaps the wrong question. But we 
can begin to address the dynamics of AGO binding on HCV RNA by turning our 
attention toward a timecourse.  
 
AGO binding to miR-122 sites on HCV RNA occurs early and is replication 
independent 
 The motivation behind this experiment was to manipulate as little as 
possible. Unlike work aimed at overexpressing or knocking down AGO or miR-
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122, we aimed to use CLIP to measure how endogenous AGO:miR-122 
complexes would react to a flood of incoming HCV genomes. We tested three 
genomes: the WT Clone 2 HCV genome which could launch an infection; a viral 
polymerase defective mutant (GNN) in the same background which could be 
translated, but could not undergo RNA replication; and a miR-122 null binder with 
S1 and S2 sites mutated at position 3 (p3). We reasoned that replication 
dependent and independent AGO binding could be distinguished in addition miR-
122 dependent binding with these mutants. We performed CLIP at 6, 12, 24, and 
48 hours post-electroporation in these contexts. We observed comparable AGO 
binding at the 5'UTR miR-122 sites of WT and GNN mutants as early as 6 hours 
post electroporation and not at all for the p3 mutant (Figure 3.6A-C). AGO 
binding to miR-122 sites in particular remained stable throughout the WT 
timecourse, but decreased steadily for the GNN mutant. Interestingly, in all three 
contexts we observed some AGO association with the IRES, suggesting miR-122 
and replication independence. AGO binding to regions outside the 5'UTR 
emerged after 24 hours of replication, and were not observed in the GNN or p3 
mutants. The overall amount of Ago binding for all three genomes' RNAs 
correlated with RNA abundance as measured by qPCR (Figure 3.6D-E), 
suggesting replication or abundance dependent Ago targeting of the viral ORF. 
This would not be inconsistent with sequencing noise. The persistence of IRES 
binding can be interpreted in at least two ways. As previously hypothesized, a 
non-canonical miR-122 site may be responsible (Pang et al., 2012).  
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Figure 3.6. Ago binding timecourse of WT and replication deficient (GNN) HCV 
RNA genomes. (A-C) Cells were electroporated with WT, and replication 
defective GNN, or p3 genomes and harvested for CLIP at indicated timepoints. 
The p3 mutant contains a C→G mutation at the third position for both S1 and S2 
binding sites and is considered a miR-122 null binder. Data are displayed across 
the HCV genome as a density plot of raw peak height. The maximum peak height 
for S1/S2 binding is indicated if beyond scale. (D) Normalized percentages of 
HCV mapping unique reads for WT, GNN and p3 mutants across the timecourse. 
(E) qPCR measurements of HCV RNA copies / ng of total RNA across the 
timecourse for WT, GNN and p3 electroporations. Dashed line indicates the limit 
of detection. All data are mean ± SD.  
 123 
Alternatively, AGO may be playing a miRNA-independent role in regulating the 
IRES. Future work using replication defective genomes that cannot undergo 
translation due to poor eIF2 ternary complex recruitment might help shed light on 
this. Overall, these data indicate that while HCV RNA is bound by endogenous 
AGO at S1/S2 miR-122 sites early upon infection, additional replication or 
abundance dependent Ago binding of the viral ORF can occur at a lower level.  
 
An HCV resistant to miR-122 antagonism engages miR-122 
 In 2011, Li, Bukh, and colleagues described an interesting HCV that was 
resistant to locked nuclei acid (LNA) based miR-122 antagonism (Li et al., 2011). 
After passaging HCV genomes lacking stem-loop I (SL1) of the 5'UTR, a 
replication competent recombinant virus was isolated where SL1 was replaced 
with part of cellular U3 snoRNA (Figure 3.7A). Interestingly, this "U3" virus lost 
the S1 miR-122 site but retained the S2 site. Based on U3 virus' ability to 
replicate despite miR-122 inhibition, we reasoned that CLIP with the U3 virus 
could yield insight on miR-122 independent binding with a replicating virus. We 
additionally hypothesized that this virus would generally behave as a miR-122 
null binder.  
 Surprisingly, CLIP revealed extensive AGO binding to the 5'UTR, 
specifically overlapping with the S2 miR-122 site (Figure 3.7B). CIMS analysis 
corroborated the likely engagement of miR-122 at S2 as significant crosslinking 
was observed 1nt upstream of S2 auxiliary pairing, mirroring results with WT 
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Figure 3.7. An HCV mutant resistant to miR-122 antagonism engages Ago and 
miR-122. (A) Schematic of the U3 virus 5'UTR with proposed S2 miR-122 
binding. U3 snoRNA sequence is shown in green, adapted from (Li et al., 2011). 
For reference, the WT HCV end with stem loop I is shown. (B) Ago binding map 
(top track) and CIMS locations (bottom track) across the U3 virus 5'UTR 
corresponding to miR-122 binding at S2. Relevant CIMS deletions sites are 
shown in gray (not significant) and red (significant). U3 snoRNA sequence is 
shown in green. (C) Ago binding map across the U3 virus genome after treatment 
with increasing doses of LNA122. Significant peaks are named by location and 
are indicated by asterisks. Bottom CIMS track shows location of all deletions 
(gray) and statistically significant CIMS deletions (red) for the untreated dataset. 
(D) Ago binding in significant peaks from untreated U3 datasets in (C) shown as 
normalized read densities calculated per dataset. **** P<0.0001, * P<0.05, one-
way ANOVA with bonferroni correction. Error bars, ± SD. This CLIP experiment 
was performed with Troels Scheel.  
 
virus presented earlier. To verify the LNA resistance of this virus, we performed 
CLIP in U3 virus infected cells after treatment with 3nM or 30nM LNA-122. Here 
we observed a sharp dose dependent decrease in AGO engagement of the 
5'UTR, and a less extensive decrease across the genome, consistent with a pro-
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viral effect for miR-122 binding to S2 (Figure 3.7C-D). Thus, it appears that miR-
122 is capable of residually engaging the U3 virus genome by binding S2, 
despite its relative miR-122 independence. One possible reason for this might be 
that miR-122 makes many more base contacts with the U3 virus, as modeled in 
Figure 3.7A, and as a result miR-122 bound to the U3 viral genome may be less 
susceptible to LNA based antagonism. Attempts to make S2 p3 mutants of the 
U3 virus were all inviable (not shown), which at first glance argues that miR-122 
binding to S2 remains required for viability. And yet, it's also possible that the S2 
sequence has overlapping functions, such as PCBP2 binding (Masaki et al., 
2015). Thus a bit of caution is warranted. Despite the preponderance of evidence 
that the U3 virus still binds miR-122, we cannot firmly conclude that this binding 
plays the same critical role that it does with WT virus. Most importantly, the 
striking miR-122 independence of this virus points to a potential avenue of 
resistance to LNA based therapeutics in the form of recombinant viruses with 
similarly large 5'UTR stem-loops.  
 
CRISPR disruption of small RNA biogenesis, part I 
 The results so far have primarily drawn upon the introduction of RNA 
genomes into the cell and rely upon CLIP of endogenous AGO:miRNA to reveal 
the binding landscape of miRNAs on the HCV genome. As a followup, we 
wondered what would happen upon perturbing the miRNA content of the cell as a 
complementary means of exploring miRNA:HCV RNA interactions. The approach  
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Figure 3.8. A CRISPR based targeting strategy to delete miR-122 and Drosha 
from Huh-7.5 cells. (A) Guide RNAs were designed to delete a 38bp region 
encompassing the 5' end of the miR-122 stemloop, including the entire miR-122 
seed, and an adjacent DdeI restriction site. DNA cleavage sites indicated with red 
triangles. miR-122-5p highlighted in gray. PAM: protospacer adjacent motif. (B) 
DNA chromatogram indicating the precise genomic location (red triangle) for non-
homologous end joining following CRISPR cleavage, resulting in miR-122 
deletion. (C) Guide RNAs were designed to delete a 166bp region encompassing 
exon 9 of the Drosha gene, highlighted in gray. DNA cleavage sites indicated with 
red triangles. (D) DNA chromatogram indicating the precise genomic location (red 
triangle) for non-homologous end joining following CRISPR cleavage, resulting in 
Drosha exon 9 deletion. (E) Western blot analysis of ΔmiR-122 and ΔDrosha 
Huh-7.5 cells for Drosha, Dicer, and Actin. (F) Small RNA northern blot analysis 
of ΔmiR-122 and ΔDrosha Huh-7.5 cells for miR-122, miR-21, miR-16, and U6 
RNA as a control. Mature and pre-miRNA bands are indicated. (G) HCV 
susceptibility of ΔmiR-122 and ΔDrosha Huh-7.5 cells supplemented with 3nM 
miR-122 mimic, assayed via flow cytometry 72hrs after Clone2-Ypet infection. 
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using LNAs, as in the U3 virus experiments, has the main benefit of being 
transient and simple to carry out, yet is not without confounding factors. Quite 
simply, no one really knows how LNAs inhibit miRNAs, beyond the basic 
mechanism of behaving like a very stable and tightly binding nucleic acid analog 
that can hybridize to a target sequence. Do LNAs inhibit pri-, pre-, mature, and/or 
AGO loaded mature miRNAs? Can we assume that results obtained with LNAs 
preclude ANY activity for the miRNA being inhibited? The same concerns 
surround the alternative approach of inhibiting small RNA biogenesis by siRNA or 
shRNA knockdown of Drosha or Dicer, with the added theoretical wrinkle of 
relying on circular logic that is self-limiting. The very enzymes required to 
generate silencing RNAs are themselves the targets of silencing.  
 To avoid these issues, we opted for an approach using CRISPR genome 
engineering to delete the miR-122, Drosha, and Dicer genes from Huh-7.5 cells. 
The scope of small RNA disruption enabled by these CRISPR mutants ranges 
from the minimal to the drastic: from the targeted deletion of one miRNA to the 
removal of all miRNAs. Schematized in Figure 3.8A, we targeted the miR-122 
locus with transfected Cas9 to delete a 38bp stretch encompassing the miR-122 
seed and a DdeI site used for genotyping (see methods). For Drosha deletion, 
we targeted exon 9 in a manner that would result in an out-of-frame splice 
between exons 8 and 10 resulting in a nonsense mediated decay substrate 
(Figure 3.8B). This was the same strategy used to generate the Drosha knockout 
mouse (Chong et al., 2008). Single cell dilution and expansion yielded ΔmiR-122 
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and ΔDrosha clones harbored the intended deletions (Figure 3.8C-D). We 
observed the specific loss of Drosha protein only in ΔDrosha cells via western 
blot (Figure 3.8E). Functional characterization of miRNA processing via Northern 
blot showed that both pre- and mature miR-122 was specifically lost in ΔmiR-122 
cells, but not other abundant miRNAs such as miR-21 or miR-16. In ΔDrosha 
cells, all three of these Drosha-dependent miRANs were lost (Figure 3.8F). The 
successful creation of both of these cell lines, despite altered miRNAs, suggests 
that miR-122 and miRNAs in general are not critically required for cell viability. 
However, some differences in proliferation rate were noted: while ΔmiR-122 cells 
grew no differently than WT cells, ΔDrosha cells proliferated at half the rate (not 
shown). This is consistent with known role for miRNAs in regulating the cell cycle 
(Bueno and Malumbres, 2011).  
 We next tested HCV susceptibility of ΔmiR-122 and ΔDrosha cells. As 
expected, HCV could not replicate in either cell line, but importantly, replication 
could be rescued with miR-122 mimic transfection (Figure 3.8G). In ΔmiR-122 
cells, this rescue was complete at 3nM, and not significantly different from 
unedited cells. In contrast, HCV replication could not be fully rescued in ΔDrosha 
cells. In this context, ΔDrosha cells lack all miRNAs with the exception of miR-
122, thus it's possible that either additional miRNAs are directly or indirectly 
required for HCV replication, or that global miRNA suppression is toxic to virus 
for non-specific and pleiotropic reasons. Nevertheless, the ability to launch HCV 
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infection in these cells after miR-122 mimic transfection opens the possibility of 
exploring the role of all miR-122 independent binding on the HCV genome.  
 
Probing non miR-122 dependent AGO binding on HCV RNA 
 With HCV permissive cell lines lacking miR-122 or all canonical mature 
miRNAs, we next decided to pursue CLIP in these contexts after HCV infection. 
ΔDrosha cells were first transfected with 3nM miR-122 mimic and then infected 
with WT HCV for three days before CLIP. Importantly, no HCV replication was 
observed in these cells without miR-122 supplementation (Figure 3.8G). We 
reasoned that compared to WT cells, CLIP in HCV infected ΔDrosha cells 
supplemented with miR-122 would only retain or enhance miR-122 dependent 
peaks, and that peaks lost in ΔDrosha might be indicative of other miRNA 
binding. We observed that the S1/S2, IRES, E1.2 and NS5B peaks remained 
significant in ΔDrosha+miR-122 cells, but the low level background generally 
persisted (Figure 3.9A). Ago binding to E1 and E2 peaks was reduced in 
ΔDrosha cells, suggesting that a minor proportion Ago binding on HCV RNA is 
due to other miRNAs, however no canonical seeds were found for these peaks. 
As a means of quantifying the relative amounts of Ago binding across peak 
regions between cell types with different infection frequencies, the density of 
reads under each peak region was normalized to total read depth and plotted per 
dataset.  
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Figure 3.9. Argonaute binding maps on HCV RNA in the absence of miRNAs. (A) 
Mock-subtracted binding map of Ago-CLIP reads across HCV genomic RNA in 
WT or ΔDrosha Huh-7.5 cells. Data were normalized to total cellular and virus 
read depth for cross track comparison. Statistically significant peaks per track are 
named by location and are indicated by asterisks. Bottom CIMS track shows 
location of all deletions (gray) and statistically significant CIMS deletions (red) 
from the WT track. (B) Ago binding in significant peaks from WT Huh-7.5 cells in 
(A) shown as normalized read densities calculated per dataset. Data were 
normalized to background read density of non-peak regions and set to one 
(dashed line). Asterisks, ** P<0.01, * P<0.05, Student's t-test. Error bars, ± SD.  
 
We can appreciate the relative amount of AGO binding per peak region and 
determine the extent of signal loss or gain upon removal of miRNAs (Figure 
3.9B). Clearly, S1/S2 and IRES binding are unaffected, and peaks in NS5B 
(mainly 5B.2 and the emergence of 5B.3) were enhanced in ΔDrosha cells, all 
suggesting miR-122 dependence. The 5B.3 peak is truly novel, and is perfectly 
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conserved among consensus HCV genotypes (Figure 3.10). The proximity of the 
remaining peaks to the read density of regions not in peaks (aka, the 
background) suggests AGO-CLIP noise as mentioned previously. Based on 
these results, we can be more confident that miRNAs other than miR-122 play 
little, if any, role in binding HCV RNA, at least in the context of an Huh-7.5 cell.  
 
 
 
Figure 3.10. miR-122 binding sites in the NS5B coding sequence and 3'UTR of 
HCV RNA. (A) Ago binding map in HCV infected WT cells across the NS5B 
coding sequence, from three experiments. (B) Sequence alignments for indicated 
major HCV genotypes (1-6) of bound miR-122 sites presented in (A). miR-122 
seed highlighted in red. Third codon positions shaded in gray; amino acids are 
colored according to physiochemical properties and are presented as the Clone2 
sequence with deviations in other genotypes below. Conserved nucleotides are 
marked with asterisks. 
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The U3 virus replicates in the absence of miR-122 and miRNAs 
  Given the seeming miR-122 independence of U3 virus replication, we 
decided to test U3 replication in ΔmiR-122 and ΔDrosha cells, and if possible, 
perform AGO-CLIP to resolve the miRNA dependence of the unique AGO binding 
pattern on this viral genome. We hoped to address the paradox observed with 
this virus: the U3 virus is resistant to miR-122 antagonism, and yet retains the S2 
site that is clearly and specifically bound by AGO. 
 Starting with ΔmiR-122 cells, we compared WT versus U3 virus infection 
in these cells measuring HCV RNA over a timecourse. As expected, WT virus 
was completely abolished in ΔmiR-122 cells, but could be rescued with 3nM miR-
122 supplied in trans (Figure 3.11A). Notably, no difference was observed in U3 
virus replication in WT versus ΔmiR-122 cells, and miR-122 supplementation had 
a mild enhancing effects for the U3 virus, that was only significant in the last 
timepoint (Figure 3.11B). These results strongly suggest that U3 virus replication 
is independent of miR-122. This was further corroborated by AGO-CLIP in U3 
infected ΔmiR-122 and ΔDrosha cells. U3 virus replication was slower in 
ΔDrosha cells compared to ΔmiR-122 cells (Figure 3.11C), however, we 
achieved sufficient percentages (>30%) to enable AGO-CLIP. The U3 virus 
displayed no notable AGO binding in both ΔmiR-122 and ΔDrosha contexts 
(Figure 3.11D). These data alongside our LNA results confirm that the S2 site 
engages miR-122, but that this binding is somewhat dispensable. Furthermore, 
this suggests that S1 and S2 might have distinct non-overlapping functions. In 
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the case of the U3 virus, the S1 site appears to have been replaced with a large 
stem loop. The recent observation that the S2 site also binds to PCBP2 and may 
compete with miR-122 binding points to a different role beyond RNA stabilization 
(Masaki et al., 2015). 
 
 
 
Figure 3.11. Timecourse qPCR measurements of WT-Clone2 virus (A) or U3-
Clone2 virus (B) in WT cells or in ΔmiR-122 cells with or without 3nM miR-122 
supplementation. Error bars, ± SD. AGO-CLIP with U3 virus in ΔmiR-122 and 
ΔDrosha cells. (C) Percent cells ΔDrosha cells infected with U3 virus over time. 
(D) U3 virus AGO-CLIP in WT Huh-7.5 cells (top), ΔmiR-122 (middle), and 
ΔDrosha Huh-7.5 cells (bottom). These experiments performed by Troels Scheel.  
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Swapping miRNA tropism of HCV: an attempt with miR-21 
 The results thus far have focused on the WT virus and the U3 virus, which 
no longer critically requires miR-122, but can still bind it. To get around the 
confounding factors of the U3 virus, such as its large SL1 and its loss of the S1 
miR-122 site, we opted to swap the miRNA tropism of WT virus as a means of 
minimally creating a miR-122 independent, but not miRNA independent, virus. 
This idea was first explored with miR-21 as a miRNA expressed in Huh-7 cell 
derivatives, but with a sufficiently altered seed compared to miR-122 (Figure 
3.12A-B) (Jopling et al., 2008). The added benefit of starting with miR-21 was 
that there was some interesting negative data worth revisiting. In an early report, 
the S1 miR-122 site in an HCV replicon system was mutated to a miR-21 site and 
found to be inviable in Huh-7 cells (Jopling et al., 2008). Based on this result, it 
was argued that the AGO:miR-122 complex might be unique in its engagement 
with HCV RNA, and that mutation of S1 may be interfering with an overlapping 
function. With the discovery of critical auxiliary pairing at positions 2-3 and 30-31 
of the HCV genome with miR-122, the issue was revisited using a chimeric 
miRNA that consisted of the miR-21 seed (positions 1-8) and the remainder as 
miR-122 (positions 9-22). This miRNA was not capable of rescuing replicons 
bearing tandem miR-21 S1 and S2 sites, despite the fact that this chimeric 
miRNA should have been able to bind the auxiliary sites (Roberts et al., 2011).  
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Figure 3.12. Exchanging miRNA tropism for HCV to use miR-21. (A) WT HCV 
RNA in complex with miR-122 based on extensive genetic and SHAPE data 
(Jopling et al., 2008; Machlin et al., 2011; Mortimer and Doudna, 2013). (B) A 
proposed model for miR-21a engagement with a miR-21 family dependent HCV 
("m21"). (C) A proposed model for miR-122 engagement with a S1/S2 miR-21 
HCV. Note that G:U wobbles are capable at positions 2 and 6. (D) Full length 
mono-cistronic secreted luciferase reporter virus (Jc1 background) timecourse of 
various mutants on the way to a miR-21 depdendent virus. WT and GNN mutants 
were contained miR-122 S1 and S2. Variations in swapping S1 or S2 seeds, or in 
mutating positions 2 or 29 to accomodate miR-21 are noted. Samples were 
washed at 24 and 48 hours after supernatant harvest. (E) Luciferase reporter 
virus measurements as in (D) with additional mutants. Samples were washed 
after all timepoints measured. All samples plotted as means ± SD. 
 
 Additionally, an important HCV seemed to be missing: a miR-21 
dependent virus that incorporated the appropriate base changes at positions 2 
and 30 to enable endogenous miR-21 recognition in a manner analogous to miR-
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122 (Figure 3.12B). We set out to make this virus, reasoning that individual S1 
and S2 miR-21 swaps would not be viable, and that the full miR-21 swap mutant 
with additional C to U mutations at positions 2 and 29 would replicate.  
 To our surprise, both S1 and S2 seed mutants were individually viable 
when swapped for miR-21, each exhibiting one log attenuation compared to WT 
genomes (Figure 3.12D). The S1/S2 double mutant was viable though attenuated 
by closer to three logs compared to WT (Figure 3.12E). These results with full-
length virus contradict earlier reports and showcase a tolerance for seed 
mutations. Interestingly, the full miR-21 binding mutant shown in Figure 3.12B 
was not viable (in black, Figure 3.12D-E). Working backwards from this mutant, 
we uncovered a high sensitivity for mutations at nucleotide 2 of the HCV genome. 
In all cases, mutations to U at this position were either inviable or very highly 
attenuated. A complete S2 swap (including a C29U mutation) was as viable as 
an S1 swap, however combining these mutations did not result in any viral 
replication (in gray, Figure 3.12E). That miR-21 S1/S2 swaps were viable, but 
when combined with C2U or C29T mutations had lost this viability, suggested 
that miR-21 was not rescuing this virus as thought and that perhaps, miR-122 
was still engaging this genome. Following the observation that S1/S2 virus 
replication could be boosted with miR-122 mimic (not shown), we settled on a 
model whereby this virus represented a maximal deviation from canonical miR-
122 binding in that many G:C base pairs were replaced by G:U wobbles (Figure 
3.12C). Furthermore, the drastic inhibition of the C2U mutation hinted at an 
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overlapping function beyond miRNA pairing that was perturbed upon 
mutagenesis.  
Swapping miRNA tropism of HCV to use miR-15 
 Perhaps the biggest lesson of our experience with miR-21 was that the C 
at position 2 of the HCV genome likely has an overlapping function beyond 
binding a miRNA. A likely candidate for this additional function is a role in RNA 
replication. Learning from this, we reasoned that a viable replacement for miR-
122 would need to maintain a GG at analogous positions to pair at auxiliary sites, 
should not allow for G:U wobbles in the seed, and should be expressed at similar 
levels to miR-122. Taking this candidate approach over a literature based 
approach, we settled on the miR-15 family. In particular, miR-15a/b satisfied the 
above criteria, with five non-G:U changes in the seed compared to miR-122, 
maintenance of GG at positions 15-16, and present as ~4.8% of miRNAs in the 
cell compared to ~8.3% for miR-122 (Figure 3.13).  
 While miR-16 dependent viruses were inviable (not shown), an 
electroporated miR-15a/b dependent HCV luciferase reporter virus (m15) was 
viable, and replicated to within one log of the WT virus after 72hrs (Figure 3.14A). 
Notably, the miR-15 virus was resistant to increasing concentrations of LNA122 
(IC50 > 50nM) but susceptible to LNA15a/b (IC50 = 10nM) (Figure 3.14B). Unlike 
WT virus, the m15 virus was also viable in ΔmiR-122 cells (Figure 3.14C).  
Taken together, these data strongly support miR-122 independent virus 
replication by exchanging miRNA tropism to use miR-15a/b.  
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Figure 3.13. Exchanging miRNA tropism for HCV. (A) WT HCV RNA in complex 
with miR-122 based on extensive genetic and SHAPE data (Jopling et al., 2008; 
Machlin et al., 2011; Mortimer and Doudna, 2013). (B) A proposed model for 
miR-15a engagement with a miR-15 family dependent HCV ("m15"). (D) 
Conservation of miR-122 (the sole family member) with the miR-15 family reveals 
extensive differences in the seed (6 changes with no possibility for G:U wobble 
pairing), maintenance of seed GC content, and importantly, the preservation of 
the GG at positions 15-16, critical for the 3' supplementary pairing shown in (C). 
Note that GG is not preserved in miR-161. Percent abundances of these miRNAs 
on AGO as measured by polyG-CLIP (see next chapter) are indicated.  
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Figure 3.14. Functional characterization of a miR-15 dependent HCV. (A) 
Luciferase measurements of supernatants from WT and m15 HCV reporter virus 
electroporations (± SD). Non-replicating GNN control is shown. Media was 
replaced at each time point measured. (B) Dose response of WT and m15 
reporter viruses following pre-treatment with LNA inhibitors of miR-122 or miR-
15a/b at indicated concentrations, measured at 96 hours post-infection (± SD). 
(C) Time course post infection of ΔmiR-122 Huh-7.5 cells with indicated viruses 
(± SD). These experiments were performed with Katharina Shaw.  
 
 
 We expanded these analyses with the non-reporter viruses in the Clone2 
background and measured sensitivities to 50nM LNA122 or LNA15 prior to virus 
infection. As expected WT HCV RNA levels were reduced 20-fold with LNA122 
treatment but were resistant to LNA15, the converse was true for the m15 virus, 
though with less attenuation (Figure 3.15A-B). We noted that the expected 
inhibitory LNA treatment for either WT or m15 virus reduced infected cell 
frequency (Figure 3.15C-D). Lastly, as expected, WT virus infectivity was 
severely reduced in LNA122 treated cells but was unaffected by LNA15 (Figure 
3.15E). The infectivity for the m15 virus presented an interesting result in that it 
was reduced in the presence of LNA15 as expected, but also in the presence of 
LNA122 (Figure 3.15F).  
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Figure 3.15. LNA sensitivity assays comparing WT HCV and m15 HCV. (A-B) 
qPCR measurements for WT (A) or m15 (B) viruses were performed at indicated 
timepoints post infection, after mock treating, or treating with LNA inhibitors to 
miR-15a/b (blue) or miR-122 (red) at 50nM, from duplicate experiments. Data 
presented as Genome Equivalents (GE) / ng of total cellular RNA (± SD). (C-D) 
Percent NS5A positive cells (± SD) in WT (C) and m15 (D) virus infections 
following LNA treatment as above, measured by flow cytometry. (E-F) Infectivity 
titer measurements of virus released from LNA or mock treated cells as above for 
WT (E) and m15 (F) virus infections, as FFU/mL (± SD). These experiments were 
performed with Troels Scheel and Eiko Nishiuchi.  
 
 At least two possibilities might explain the apparent reduction in m15 virus 
titer upon treatment with LNA122. Conceivably, miR-122 may have direct pro-
viral roles on HCV RNA beyond S1/S2 sites, such as the putative IRES binding 
site, or sites in NS5B. Alternatively, and not mutually exclusively, the miR-122 
regulated transcriptome if globally de-repressed may alter the intracellular 
environment such that it is "less pro-viral." I hesitate to use the term "anti-viral" for 
LNA122 treatment in this indirect context, since this would imply some level of 
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cellular intent. For example, consider a miR-122 target that if de-repressed would 
signal the cell to mount an anti-viral response or initiate cell-cycle arrest. Such 
scenarios have been recently proposed with limited experimental support (Xiong 
et al., 2014; Zhao et al., 2013). Arguably, such a target could constitute a sensor 
for miR-122 levels. However, if de-repressing miR-122 targets inhibits m15 virus 
due to a passive indirect effect, such as altering the lipid composition or 
trafficking, but playing no selected for role in detecting or combatting virus, this 
would be evidence of a non-specific "anti-viral" effect. In any case, as the above 
two scenarios are simultaneously possible and are completely dependent on the 
underlying host transcriptome, we will revisit them in the next chapter. What is 
common to both perhaps, is that the virus faces a miR-122 defined ceiling that 
limits its replication.  
 Refocusing on the virus, the ability of the m15 virus to replicate in ΔmiR-
122 cells offers an alternative means to explore miR-122 dependent binding as 
an obverse experiment to that presented in Figure 3.9. Recall how that 
experiment was performed with WT virus in ΔDrosha cells supplemented with 
miR-122, thus only miR-122 binding was expected to be observed. In the 
experiment presented in Figure 3.16, we performed CLIP in m15 virus infected 
WT and ΔmiR-122 cells. Here we expect a specific loss of miR-122 dependent 
binding where no change should be observed at S1/S2 sites since these depend 
on the miR-15 family.  
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Figure 3.16. AGO binding maps on m15 HCV reveal extent of miR-122 
dependent targeting. (A) Ago binding map of m15 virus infection in WT Huh-7.5 
(top panel) or ΔmiR-122 Huh-7.5 cells (bottom panel). Data were normalized to 
total cellular read depth for cross track comparison. Statistically significant peaks 
per track are named by location and are indicated by asterisks. (B) Ago binding in 
significant peaks from (A) shown as normalized read densities calculated per 
dataset. Two-sided Student's t-test used. Error bars, ± SD. 
 
The AGO-CLIP pattern on m15 virus was similar to that observed with WT virus, 
indicating that the S1/S2 swap can recapitulate the previously observed binding 
pattern (Figure 3.16A, top panel). In ΔmiR-122 cells we noted the reductions in 
AGO binding in the viral IRES and in the NS5B peaks, strongly supporting miR-
122 dependent binding at these sites (Figure 3.16A, bottom panel). Quantification 
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of read density within peaks revealed statistically significant reductions in putative 
miR-122 dependent sites (Figure 3.16B). These data offer confirmation for 
endogenous miR-122 dependent binding outside of S1/S2.  
  The above discussion on the apparent reduction of m15 virus to LNA122 
suggests a miR-122 defined ceiling for viral replication. While it remains to be 
determined if miR-122 binding on the viral RNA, outisde of S1/S2, plays a direct 
role in augmenting HCV RNA levels, the ΔmiR-122 cell context offers a platform 
to address the general ceiling question. In this experiment, we re-introduced miR-
122 at various concentrations into ΔmiR-122 cells, and infected with m15 virus. If 
the ceiling hypothesis holds, then we could expect to see a miR-122 dependent 
enhancement of m15 virus. Comparing untreated ΔmiR-122 cells or cells treated 
with 3nM or 30nM of miR-122, we noted a two-fold enhancement of viral RNA 
and infectious titer levels in the presence of miR-122 (Figure 3.17A and C). We 
also detected a slight increase in the percentage of infected cells (Figure 3.17B). 
These data, combined with the observations of LNA122 inhibition of the m15 
virus, lend support for a replication ceiling that is in some measure dictated by 
miR-122 levels. Moreover, as we'll see in the next chapter, this ceiling appears 
modified by the virus to functionally reduce the miR-122 levels in the cell.  
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Figure 3.17. Effect of miR-122 reintroduction to m15 virus infected ΔmiR-122 
cells. (A) qPCR measurements for m15 virus RNA in ΔmiR-122 cells 
supplemented with miR-122 mimic at indicated concentrations, from 
quadruplicate experiments. (B-C) FACS analysis of infection frequency (B) and 
infectivity measurements (C) as in (A). Asterisks: ****P<0.0001, ***P<0.001, 
**P<0.01, one-way ANOVA with Bonferroni multiple comparison correction. 
 
 
CRISPR disruption of small RNA biogenesis, part II  
 In contrast to Drosha, which is required for miRNA biogenesis but plays no 
role in RNAi, Dicer represents a critical node for both miRNA and siRNA 
biogenesis. Successful deletion of Dicer in Huh-7.5 cells would thus enable an 
unbiased exploration of any role for RNAi in HCV infected cells. In combination 
with ΔDrosha cells, we also reason that these reagents may also prove useful in 
revealing the respective contributions of miRNAs or siRNA in other virus 
infections. 
 More proximally, ΔDicer cells have the potential to resolve seemingly 
contradictory data regarding miR-122 usage by HCV RNA. One study found that 
Dicer knockdown reduced HCV RNA accumulation and could be rescued by 
adding back mature miR-122 duplexes (Zhang et al., 2012). Based on these 
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results, the authors concluded that mature miR-122 produced by Dicer activity on 
pre-miR-122 was key for maintaining HCV RNA abundance. And yet, mounting 
evidence suggests that pre-miR-122 may play an active regulatory role, 
especially in liver, where pre-miR-122 oscillates in a circadian manner and 
correlates with oscillating miR-122 target repression despite invariant (and high) 
levels of mature miR-122 (Gatfield et al., 2009). This work suggests an 
interesting hypothesis whereby mature miR-122 levels may not necessarily 
explain the full regulatory potential of this miRNA. Conceivably, newly 
synthesized miR-122 or the pre-miR-122 intermediate itself, may play a 
regulatory role distinct from "old" miR-122 (Gatfield et al., 2009). Starting from 
this premise, Cox, Doudna, Sarnow and colleagues tested the abilities of pre-
miR-122 molecules to maintain HCV RNA abundance. By using pre-miR-122 
hairpins with DNA bases at known positions of Dicer processing, they were able 
to make hairpins refractory to Dicer cleavage in vitro (Cox et al., 2013). These 
Dicer resistant hairpin molecules were observed to function in miRNA and siRNA 
assays, and in addition appeared to maintain HCV RNA abundance. Further 
testing of a bulged pre-miR-122 that exhibited poor Dicer processing and not able 
to function in miRNA and siRNA assays was also able to maintain HCV RNA 
abundance (Cox et al., 2013). Overall, these results suggest a role for pre-miR-
122 in binding and stabilizing HCV RNA.  
 The above two studies present somewhat contradictory findings. The first 
essentially argues that mature miR-122 is required for HCV RNA maintenance, 
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and thus implies a critical need for Dicer enzymatic activity. The second argues 
that pre-miR-122 can function to maintain HCV RNA, and therefore could imply 
that Dicer is largely dispensable. So which is it? Note that the results of the first 
study do not entirely rule out pre-miR-122 function so much as provide clear 
evidence that mature miR-122 functions on HCV RNA.  
 
 
Figure 3.18. Functional characterization of CRISPR engineered Dicer mutants in 
Huh-7.5 cells. (A) Western blot of Dicer in WT, ΔEX1, ΔEX2, ΔEX19 and 
ΔEX2.19 cells. Drosha served as a loading control. (B) Small RNA northern 
analysis of each of the above Dicer mutants probing for miR-122, miR-15a, miR-
16 and miR-21. U6 RNA served as a loading control.  
 
 To address this unambiguously, we decided to delete Dicer in Huh-7.5 
cells and test their susceptibility to HCV. Our initial attempt focused on deleting 
the first coding exon, where we reasoned that removing the start codon would 
prevent Dicer translation. Exon 1 was successfully deleted, but to our surprise, 
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Dicer protein was made at near WT levels and miRNA processing proceeded 
normally (Figure 3.18). In some experiments we also noticed that the loading 
control U6 RNA appeared degraded specifically in these cells (not shown). The 
nearest in-frame methionine is in exon 4, which would result in a protein missing 
149 amino acids from the N-terminus, corresponding to approximately a 17kDa 
reduction in size (from ~220kDa to 203kDa). In terms of protein structure, this 
would result in a Dicer mutant with a non-functional DEXDc helicase domain. 
Such mutants have been extensively characterized in vitro and are known to 
exhibit WT reaction velocities for miRNA processing but intriguingly, were found 
to be dramatically enhanced in siRNA processing (Ma et al., 2008; 2012). In this 
manner, the Dicer helicase domain is thought to be an inhibitor of Dicer siRNA 
but not miRNA processing. More recent work has revealed a curious form of 
Dicer active in mouse oocytes that essentially lacks the helicase domain (Flemr 
et al., 2013). This oocyte specific Dicer, called Dicero, arose from a retro-
transposon inserted alternative first exon between exons 6 and 7 of the Dicer 
gene. Found only in mice and rats, this Dicer also exhibits enhanced siRNA 
biogenesis and is thought to promote endogenous RNAi in the mouse germline 
for reasons that are still not yet clear (Flemr et al., 2013). Could our DicerΔEX1 
Huh-7.5 cells be used to illustrate an antiviral RNAi response in somatic cells? 
Experiments are currently underway to address this. 
 Taking a cue from ΔDrosha cells, where an exon was deleted to promote 
an out-of-frame splice to generate an NMD substrate, we next deleted exon 2 of 
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Dicer, thinking that by preserving translation in exon 1, no truncated Dicer would 
be made. DicerΔEX2 cells exhibited a a near complete absence of Dicer protein 
levels; however a very faint band could still be detected in long exposures and 
resembled DicerΔEX1 in seize (Figure 3.18A). These cells also displayed a 
marked increase in pre-miRNAs, suggesting a major defect in Dicer processing. 
Unlike pre-miR-15a, pre-miR-16 and pre-miR-21, the precursor for miR-122 
yielded additional unprocessed bands (Figure 3.18B). And yet, a small amount of 
mature miRNA could clearly still be made from miR-122 and miR-16, likely due to 
residual truncated Dicer activity (Figure 3.18A). Total Dicer knockouts these cells 
were not.  
 As a last attempt, I deleted exon 19, which is immediately upstream of the 
RNAse III domain coding exons, and whose deletion would induce an out-of-
frame splice (DicerΔEX19). Protein made any upstream start codon would 
encounter a stop before RNAseIII domains and thus would not function, if it 
happened to survive NMD. Additionally, any start downstream would make 
protein consisting only of the RNAseIII and the dsRNA binding domains, and also 
would not function (Ma et al., 2012). Exon 19 was also deleted DicerΔEX2 cells 
as an additional redundant strategy (making DicerΔEX2.19 cells). This third 
targeting strategy finally worked. Dicer protein levels were completely abolished, 
as was pre-miRNA processing in cell lines lacking exon 19 (Figure 3.18).  
 CRISPR mediated genome engineering is rightfully lauded as a superior 
alternative to traditional knockdown and knockout approaches for its ease and 
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flexibility. As the above exercise shows, targeting a few regions in the same gene 
largely bears this out, with the important caveat that not all knockout engineering 
attempts will yield the same results. In this instance, we fortuitously achieved a 
few very interesting mutants: a putative "super" Dicer expressing cell, a cell 
expressing very little Dicer, and true Dicer knockouts. 
Testing HCV dependence on Dicer: a role for pre-miR-122? 
 Now with a panel of endogenous Dicer mutant Huh-7.5 cells, we next 
tested their permissiveness to HCV. If pre-miR-122 can function to stabilize HCV 
RNA as posited by (Cox et al., 2013), we would expect to see HCV replication in 
DicerΔEX19 and DicerΔEX2.19 cells, were only pre-miR-122 is made. On the 
other hand, these cells should be refractory to HCV replication if only mature 
miR-122 is required.  
 We observed no replication in both DicerΔEX19 and DicerΔEX2.19 cells 
after infection with Jc1 luciferase reporter virus (Figure 3.19B). Virus replication 
could be rescued in these cells by transfecting 30nM miR-122 mimic, largely 
bypassing the Dicer requirement. We also tested DicerΔEX1 and DicerΔEX2 
cells, and found that virus replication was attenuated by one log in both contexts. 
This was notable in light of the fact that DicerΔEX1 cells expressed WT levels of 
protein, while DicerΔEX2 cells expressed 95% less Dicer (Figure 3.19A). This 
may reflect more promiscuous Dicer activity in ΔEX1 cells, though this has yet to 
be fully confirmed. Overall, these data preliminarily suggest that endogenous pre-
miR-122 cannot promote HCV replication. As this conclusion disagrees with 
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previous work, there are alternative hypotheses to consider in reconciling these 
disparate findings. Conceivably, Dicer may play a role in loading pre-miR-122 
molecules apart from its RNAse activity. Restoration of Dicer mutants that cannot 
cleave miRNA stem loops will need to be tested to see if HCV replication can be 
rescued in this context. Additionally, we've yet to test if transfected pre-miR-122 
can rescue HCV replication in DicerΔEX19 and DicerΔEX2.19 cells. This is 
important considering that the increase in pre-miR-122 yielded multiple RNA 
species, in contrast to miRs -15a, -16, and -21 in which a single pre-miRNA was 
unregulated (Figure 3.18B). Taken together, these data bring up many 
fascinating questions to explore using genome engineered manipulations of small 
RNA activity in the cell.  
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Figure 3.19. HCV replication timecourse measurements in various Dicer CRISPR 
mutants. Jc1 luciferase reporter virus was used at an MOI of 1 to infect WT Huh-
7.5 cells, or Huh-7.5 cells harboring genomic deletions of the indicated coding 
exons of Dicer. Experiments were performed in the absence or presence (+122) 
of 30nM transfected miR-122 mimic. Cells were washed at each timepjoint 
measured. Panels A and B present the same WT data for comparison of the 
remaining mutants. Dashed line indicates mean signal from mock-infected cells. 
Error bars, ± SD. 
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Chapter 3 summary and discussion 
 By applying AGO-CLIP to a virus that appears to require a miRNA for its 
replication, we've generated conclusive biochemical evidence of the miR-122 
interaction with HCV RNA that overwhelmingly agrees with the genetic evidence. 
Additional and likely miRNA dependent AGO binding was also observed and may 
reflect additional roles for small RNAs in HCV biology, though by and large, miR-
122 appears to be the most important for this virus. We've also explored multiple 
host and viral contexts for HCV replication. By deleting miR-122, Drosha, or Dicer 
genes, we've begun to probe endogenous small RNA function on HCV at the 
genomic level. Establishing a miR-122 independent virus (U3) in conjunction with 
swapping HCV miRNA tropism to use miR-15, we've also added new viral 
contexts to address HCV small RNA use. Driven by CLIP, these results provide 
answers to many questions that can now be addressed.  
 One major question still to be resolved in HCV biology is how positive 
strand genomes "decide" between multiple fates: to undergo translation, to 
package into virions, serve as templates for negative strand synthesis, or get 
degraded. miR-122 has been proposed as a regulator in these processes, 
specifically favoring RNA synthesis, by competing at the S2 site with PCBP2 
induced RNA circularization, which favors translation (Masaki et al., 2015). Its 
aforementioned roles in stabilizing viral RNA and perhaps promoting translation 
make it seem as though miR-122 indeed plays multiple parts. Thus, our results 
with CLIP likely capture a mixture of RNAs at various stages of the virus lifecycle. 
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We can consider future means of leveraging CLIP to address the central issue: at 
which stage(s) of the viral lifecyle is miR-122 important?  
 One way to frame this question is to consider whether S1 and S2 sites 
possess distinct functions. Pioneering work established that miR-122 
engagement at both S1 and S2 sites was critically required for HCV replication 
(Jopling et al., 2008). CLIP data agrees with this, though both S1 and S2 are too 
close to distinguish individual AGO binding events. One way around this would 
be to use chimeric viruses, where S1 binds miR-122 and S2 binds miR-15, or 
vice versa. Preliminary work with Yingpu Yu and Troels Scheel in the Rice lab 
has shown the viability of such swap mutants. Combined with detailed CIMS 
analysis and recent AGO-CLIP advances to identify miRNA:target ligation events, 
the stage is set to functionally unravel S1 and S2 activities in the future 
(Grosswendt et al., 2014; Helwak et al., 2013)(Moore, et al. Submitted). AGO and 
miR-122 relocalization to lipid droplets upon HCV infection provides yet another 
clue to interpret CLIP maps (Ariumi et al., 2011; Berezhna et al., 2011). It's 
conceivable that an AGO-CLIP experiment can be designed to specifically 
interrogate AGO association in different subcellular compartments. We can draw 
inspiration from the recent development of proximity specific ribosome profiling 
on this front (Jan et al., 2014).  
 Perhaps a more compelling approach with potential inroads to in vivo 
interrogation of miR-122 usage by a virus is to consider the recently discovered 
hepaciviruses of horses, rats, and mice (Drexler et al., 2013; Firth et al., 2014; 
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Kapoor et al., 2013). Non-primate hepacivirus (NPHV), commonly found in horse 
sera, contains at least one miR-122 site in its 5'UTR and is thought to be 
engaged with AGO (Scheel et al., 2015). Rodent hepacivirus (RHV) has also 
been shown to contain a miR-122 site in the 5'UTR (Kapoor et al., 2013). If these 
viruses represent hepatotropic ancestors of HCV, they may help explain how 
HCV acquired the usage of miR-122 as a key determinant in the virus life-cycle. 
Clearly, much work remains to to done in this area.  
 Of course, given the success of AGO-CLIP in HCV studies, one also gets 
the impression that even more compelling applications of these methods lie with 
other RNABPs, in other viruses, and certainly other host contexts per the above 
discussion. One compelling example are arthropod borne (arbo) viruses that 
cycle through insect and mammalian hosts and uniquely face two very different 
immune systems. As mentioned in the introduction, RNAi plays a key role in 
innate anti-viral defense in insects, while the protein based interferon response 
appears to dominate in mammalian hosts. AGO-CLIP is thoroughly poised to give 
an unbiased picture of endogenous small RNA function in both contexts, and 
may uncover host:viral interactions at the RNA level as targets for therapy. 
Arboviruses such as chikungunya virus (CHIKV, of the Togaviridae), yellow fever 
and West Nile viruses (YFV and WNV, both of the Flaviviridae) are good starting 
candidates, and current work in the Rice lab is aimed at elucidating small 
RNaAinteraction maps for these viruses in insect and mammalian hosts. That all 
of the above viruses are emerging threats driven by human induced climate 
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change lends a sense of urgency to the mission (Fischer et al., 2014; Gould and 
Higgs, 2009).  
 The general application of AGO-CLIP as a screening and discovery tool 
warrants some discussion as we consider how viruses may exploit small RNAs to 
their benefit, and how to properly interpret CLIP maps. Obviously, viruses 
encoding their own miRNAs present an intuitive case for AGO-CLIP whereby 
reads perfectly aligning to a 22-23nt stretch are likely to be miRNA genes, as has 
been extensively shown for many herpesviruses (Haecker et al., 2012; Riley et 
al., 2012a; Skalsky et al., 2012). These primarily constitute evidence of AGO 
loading, while AGO association with mRNA, which yields a broader peak, can be 
reasonably assumed to be repressive. Clearly HCV requiring miR-122 is an 
outlier in this regard, and we propose that the differences in the proportional 
amount of AGO binding (its "peakiness") across the viral genome may indicate 
whether a small RNA is required by the virus. HCV, where over 50% of all AGO 
binding events map to the first 50nt of the viral genome would largely bear this 
out. AGO-CLIP work in Pestiviruses by Troels Scheel has identified miRNA 
dependence among certain members of this virus family, where again, a single 
peak predominates (unpublished observations). In the case of requiring a small 
RNA, we would expect the amount of AGO binding to be both peak-like and to 
positively correlate with RNA abundance, an observation we were able to confirm 
with HCV comparing WT and GNN timecourses (Figure 3.6).  
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 Repressive events are somewhat harder to interpret on the basis of AGO-
CLIP results alone. Given that AGO binding typically results in RNA degradation, 
CLIP results that "catch" these moments should at steady-state be an 
underestimation of the amount of AGO binding at these loci. As a result, AGO-
CLIP alone is not sufficient to conclude which binding events on viral genomes 
are repressive and which may be informatics noise. This is especially true in light 
of CLIP results on viruses that do not yield peaks, but instead are broadly 
"coated" with AGO binding (not shown). However, by pairing AGO-CLIP with 
RNAseq (or for a single virus, qPCR), and then manipulating small RNA levels 
with inhibitors or as genomic deletions, one can overcome this limitation and 
focus on the change in AGO association in these contexts. This is essentially 
what was done with the U3 virus in ΔmiR-122 and ΔDrosha cells. Establishing 
what a true AGO-CLIP signature of viral RNA repression can also be done by 
miRNA overexpression or by forcing an RNAi response (with siRNA) and 
watching how AGO binding changes. These experiments have not yet been 
systematically performed and no doubt provide a compelling jumping off point for 
future studies.  
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Chapter 4: Argonaute HiTS-CLIP studies of HCV infected host cells 
 In the previous chapter, we focused on the insights from AGO-CLIP on the 
HCV genome in a variety of infection contexts. This arguably constitutes the main 
goal of AGO-CLIP in HCV infected cells. But part of the utility of CLIP is that it 
provides a wealth of data on the host transcriptome in addition to the virus. With 
this data, we can begin to piece together the cellular miRNA regulatory response 
to a viral infection in an unbiased manner. To do this, we’ll begin by analyzing the 
small RNA populations within AGO and how they are similar and different from 
total RNA based measurements. We’ll then move on to a novel and globally 
observed phenomena of miR-122 sponging by HCV RNA. This sponge effect will 
be used to establish the miR-122 regulated target network in Huh-7.5 cells and 
will be the subject of rigorous experimental examination and validation. It is 
remarkable, but to some degree unsurprising in hindsight, that the critical miR-
122:HCV interaction could have a specific and de-repressive effect on the host 
miR-122 targetome. The results to be presented here simultaneously offer a 
global yet transcript specific view of miR-122 sponging by HCV, for which many 
possible functions and consequences will be discussed. 
 
AGO-CLIP miRNA abundance measurements - correcting ligation bias 
 Perhaps the most basic analysis to perform with AGO-CLIP data is the 
determination of the AGO associated miRNA profile. This can either be done by 
aligning groomed reads to a database of mature miRNA sequences (such as 
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miRbase) or by aligning to the genome and counting reads overlapping with 
annotated miRNA coordinates. The former approach Is the easiest to carry out 
but is constrained by exact sequence; the latter is constrained mainly by mapping 
coordinates and has the potential to pick up novel miRNAs.  
 Applying either approach we noted significant differences between 
previous data on miRNA abundance in Huh-7.5 cells and results with AGO-CLIP. 
In previous small RNA cloning measurements from the lab, miR-122 was 
measured to be the most abundant miRNA in Huh-7.5 cells, at around 20% of 
total miRNA (Randall et al., 2007). In contrast, AGO-CLIP miRNA abundance 
measurement placed miR-122 as the 65th most abundant miRNA, closer to 0.16% 
of the total (Figure 4.1A). Combined with miRNAs that displayed enrichment in 
AGO-CLIP, very little correlation was observed with previous small RNA cloning 
results (Figure 4.1A).  
 We can extend this analysis further by inferring the miRNA profile based 
on mRNA clusters. This was based on the intuitive idea, first brought up by (Chi 
et al., 2009), that counting miRNA seeds within mRNA clusters, and weighting by 
cluster read density could be used to infer the underlying miRNA profile. In other 
words, the AGO abundance on mRNA targets likely reflects which miRNAs are 
actually used. The resulting target normalized total frequency showed that miR-
122 was among the top ten most frequent seeds within mRNA clusters, indicating 
its functional abundance on AGO. And yet, CLIP derived miRNA abundance 
measurements displayed no correlation with the inferred profile (Figure 4.1B). 
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Figure 4.1. miRNA bias in linker- ligation dependent AGO-CLIP. (A) Scatterplot 
comparing published miRNA percent abundance measurements from total RNA 
(Randall et al., 2007) to linker ligation CLIP. Squared correlation coefficient of the 
linear regression best-fit line is shown. miR-122, miR-15/16 and miR-21 families 
are highlighted. (B) Scatterplot comparing linker ligation CLIP miRNA percent 
abundance to the normalized abundance of miRNA seeds on mRNA clusters, 
from linker ligation CLIP, as in (Chi et al., 2009). Squared correlation coefficient of 
the best-fit line is shown.  
 
There are a few possible reasons for this discrepancy, at least one 
biological and two technical. As most miRNA measurements are made from 
biochemically purified total RNA where levels are assumed to be functional (that 
is, AGO associated), one possibility is that the assumption of functionality does 
not hold. Conceivably, the miRNA profile from total RNA could be categorically 
different from the miRNA profile that is actually AGO associated. Such a bold 
biologic hypothesis would challenge most miRNA measurements made form total 
RNA as they are devoid of cellular context and RNABP interactions key to their 
function. Perhaps AGO-CLIP provides the real answer?  
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 As attractive as the above hypothesis may be at first, there are two 
technical concerns related to cloning bias that warrant attention: the effect of UV 
crosslinking and linker ligation. As UV crosslinking is thought to work on the order 
of ångstroms, perhaps different miRNAs sit in the AGO binding pocket each in 
their own way and as a result are not uniformly cross-linked. Added to this is the 
concern that crosslinking, while amenable to stringent purification, may 
differentially impact a miRNA's ability to be be reverse transcribed into cDNA due 
to the crosslinked amino-acid:RNA adduct that may interfere with RT. We can 
use this last point by considering CIMS deletions on miRNAs to see if the pattern 
and amount of CIMS deletions varies as a function of miRNA abundance. Shown 
in Figure 4.2, we can appreciate the uniqueness of CIMS deletions per miRNA in 
line with previous analyses in brain (Zhang and Darnell, 2011). Notably, CIMS to 
miRNA seeds is largely absent, which agrees with structural studies of miRNA 
occupancy in AGO (Schirle et al., 2014). The most crosslinked nucleotides are 
between positions 8-12, in regions not generally observed to base pair with 
targets. Additionally, among this representative cohort of miRNA examined, all 
four RNA bases are somewhat equally crosslinked (7U, 3G, 6A, 5C). Perhaps the 
most striking feature is the percent deletions across miRNAs. The most abundant 
miRNA measured by CLIP is miR-21 (19% of total reads), less than 0.5% of 
these reads harbored CIMS deletions. In contrast, over 6% of miR-122 reads 
(0.16% of total) exhibited CIMS. By and large, it appears as if the most abundant 
miRNAs in CLIP are among the least cross-linked. However, whether this is a 
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cause or a symptom of the altered miRNA profile on AGO compared to total RNA 
is unclear. Cloning miRNAs from non-crosslinked AGO IPs revealed a similar 
miRNA profile to CLIP in these cells, with drastically lower depth (not shown). 
Taken together, these results imply, but as yet do not confirm, a cross-link bias in 
miRNA abundance measurements with AGO-CLIP.  
 
 
Figure 4.2. CIMS analysis of select miRNAs from AGO-CLIP. The percent of 
reads mapping to each respective miRNA with CIMS deletions is plotted by 5' to 
3' position. miRNAs are ordered by decreasing CLIP abundance. miRNA 
sequences are shown below with significant CIMS nucleotides highlighted in red.  
 
 The second technical concern, and one that compounds the potential 
cross-link bias raised above, is that of cloning bias. Stemming from sometimes 
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conflicting results across labs, over the past decade it has been increasingly 
clear that the dual RNA linker ligation steps using T4 RNA ligase to clone small 
RNAs can dramatically influence the resulting miRNA profile, and must be taken 
into account. The key enzyme involved, RNA ligase 1 (Rnl1) from T4 DNA 
bacteriophage, evolved primarily to counter a host-mediated defense mechanism 
whereby the anti-codon loop of lysine charged tRNAs is cleaved in phage 
infected cells (Amitsur et al., 1987; Silber et al., 1972). By repairing cleaved tRNA 
with Rnl1 and T4 poly-nucleotide kinase (T4 PNK), T4 DNA phage is able to 
ensure availability of tRNA-Lys (Amitsur et al., 1987). Not surprisingly, more 
recent work has found that RNA ligation of adapters to miRNAs using Rnl1 
prefers structural features that most closely mimic anti-codon loops, and as a 
result introduce cloning bias (Zhuang et al., 2012). Solutions to this problem 
range from using RNA ligase mutants with altered ligation efficiencies to 
modifying RNA adapters to a random pool (Brown et al., 2013; Hafner et al., 
2012; Zhuang et al., 2012).  
 As an alternative, we opted to try an RNA ligation independent approach 
(Figure 4.3A). Inspired by ribosomal profiling cloning methods (Ingolia et al., 
2009), we pursued an approach where miRNAs are tailed with G nucleotides 
(see methods). This tail then serves as a handle for reverse transcription using a 
primer containing linker sequences separated with an APE1 ssDNA digestion 
site. Following RT, the cDNA is circularized with an ssDNA ligase, and cleaved 
with APE1 to generate a cDNA product amenable to PCR. This cloning 
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technique, called polyG-CLIP, thus provides an RNA ligation independent means 
to quantify miRNAs from crosslinked AGO IPs. Note however, that polyG-CLIP 
isn't totally ligation free: an ssDNA ligase, modified from an RNA ligase is used.  
 
 
Figure 4.3. miRNA bias correction with polyG-CLIP. (A) . A 3' adapter ligation 
independent miRNA cloning strategy consists of poly-G tailing small RNA (in 
black) followed by reverse transcript (RT) using an anchored oligo (in gray) 
containing an APE1 cut site. Resulting cDNA products are circularized and re-
linearized with APE1 nuclease, prior to PCR. (B) Absolute miRNA quantification 
of select miRNAs measured by qPCR, ordered by decreasing abundance. The 
table highlights the abundance of these miRNAs via linker ligation or poly-G 
CLIP. (C) Scatterplot comparing published miRNA percent abundance 
measurements from total RNA (Randall et al., 2007) to polyG CLIP. Squared 
correlation coefficient of the linear regression best-fit line is shown. miR-122, 
miR-15/16 and miR-21 families are highlighted. (D) Scatterplot comparing polyG 
CLIP miRNA percent abundance to the normalized abundance of miRNA seeds 
on mRNA clusters, from linker ligation CLIP, as in (Chi et al., 2009). Squared 
correlation coefficient of the best-fit line is shown.  
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 Applying polyG-CLIP and comparing to qPCR results of select miRNAs, 
we noted that polyG-CLIP agreed with qPCR abundance order, unlike standard 
ligation based CLIP (Figure 4.3B). Moreover, comparisons to previous miRNA 
data yielded a much higher correlation (Figure 4.3C). Poly-CLIP miRNA 
measurements were also well correlated to the inferred miRNA profile from 
standard ligation based CLIP (Figure 4.3D). Taken together, these results 
strongly suggest a miRNA cloning bias as a result RNA ligation that can be 
corrected with alternate approaches.  
 And yet one question lingers regarding the standard RNA ligation 
approach: why would bias be observed on the miRNA profile, but not on mRNA 
targets? I reason that this is due to the nature of the RNA cloned: unlike an 
individual miRNA with a fixed nucleotide sequence (and not thought to be 
accessible by RNAse), mRNA targets undergo a partial RNAse digestion such 
that a variety of 5' and 3' ends are generated for each target. As a consequence, 
the "cloneability" of an mRNA target is likely to be much more uniform than a 
miRNA, and thus mRNAs should not exhibit such a drastic bias. This would 
explain why the inferred miRNA from mRNA clusters in standard CLIP agrees 
with polyG-CLIP miRNA measurements (Figure 4.3D). While polyG-CLIP 
appeared to be superior to quantifying miRNAs, the overall read depth for both 
miRNAs and mRNAs was lower compared to standard CLIP (not shown). For 
miRNAs, few in number, short and relatively abundant, the lower depth did not 
present a major hurdle for quantification, as showcased above. The same cannot 
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be said for mRNAs, whose much lower read depth in polyG-CLIP (compared to 
standard CLIP), limited the utility of this technique for studying mRNA targets. 
 As a compromise, polyG-CLIP was used to determine the AGO bound 
miRNA profile, while the standard RNA ligation based approach was used to 
determine mRNA targets. For subsequent analysis on mRNA-CLIP clusters, we 
focused on searching the top 50 seed families derived from poly-G CLIP studies, 
which constituted over 97% of miRNA identified in Huh-7.5 cells.  
 As a last point, it should be noted that addressing the above concerns 
does not preclude the initial biologic interpretation, that the AGO associated 
miRNA profile may be categorically different from the profile measured from total 
RNA. Indeed, despite correcting for cloning bias, the correlation between polyG-
CLIP and either total small RNA cloning or the inferred miRNA profile is not 
perfect (Figure 4.3C-D). It remains plausible, perhaps even likely, that miRNA 
measurements from total RNA can miss the real picture of AGO:miRNA function 
precisely because they fail to capture the functional RNABP complex in action. 
Future work based on AGO-CLIP provides a fantastic means to address this 
largely overlooked and somewhat mysterious assumption (Chen, 2013). 
A tour of AGO binding in Huh-7.5 cells 
 Before we go into global and somewhat abstract bioinformatic analyses of 
AGO-CLIP targeting during HCV infection, it's perhaps useful to get a feel for the 
data by simply looking at it in a genome browser. In this manner, we can observe 
what AGO binding an mRNA transcript looks like "in the wild" so to speak. This 
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provides the most accessible introduction to viewing these data, and it's also 
where I began historically, not knowing what else to do with a 2GB sequencing 
file. Exploring it with a genome browser seemed as good a place to start as any, 
and importantly, was the jumping off point for many hypotheses to be discussed.  
 But before we launch our guided safari, a few particulars. mRNA CLIP 
reads were aligned to the human genome and clustered (defined here as any two 
reads overlapping by at least 1nt). As a quick sanity check, we can perceive the 
important of biologic replicates by considering where reads annotate from any 
one or more independent libraries. The idea here is that the more something is 
independently and repeatedly confirmed, the more likely it is to reflect the true 
global picture of RNABP activity. Such an analysis was first performed with the 
3'UTR binding nElavl protein CLIP in mouse brain, where increasing biologic 
complexity increased the 3'UTR signal (Ince-Dunn et al., 2012). These results 
showed that repetition can dramatically lower spurious clusters from individual 
libraries. Performing a similar analysis on AGO-CLIP data from Huh-7.5 cells, we 
observed something very similar (Figure 4.4). Here, clusters in at least one library 
are great in number (>250K) but mostly map to introns and deep intergenic 
regions, and are thought to represent one-off spurious noise. As we increase the 
stringency for clusters, where constituent reads must come from two, three and 
so on up to six libraries, we can appreciate how the percentage of clusters 
mapping to 3'UTRs and CDS exons, places of well known AGO association, 
increases with BC. Note however, that the total number of clusters decreases 
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with increased BC stringency. This tradeoff introduces a decision point in defining 
a cutoff for what is significant. While the lowest BC contains all true positives by 
definition, it is plagued by a high number of false positives. On the other hand, 
the highest BC is likely too stringent as it selects for highly abundant (or highly 
clonable) mRNAs at the expense of lower abundant, but true, mRNA targets. In 
other words, it suffers from a false negative problem. Thus an arbitrary decision 
must be made. For the purposes of these studies, we split it down the middle: I 
stipulated a minimum BC of the number of libraries divided by two, in the case of 
these six libraries (3 Mock, 3 +HCV), we consider clusters composed of reads 
from any three libraries at a minimum. 
 
 
 
Figure 4.4. Cluster annotation results by increasing biologic complexity. AGO-
CLIP reads from up to six libraries were clustered with a minimum overlap of 2nt. 
Clusters with reads from any one, two, three and so on up to six libraries the 
were annotated. The resulting proportions of clusters overlapping known genic 
elements is plotted above, alongside the total number of clusters with the 
respective biologic complexity (BC).  
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 Now, to begin our tour of AGO bound mRNAs, we'll start by focusing on 
the hepatic nature of Huh-7.5 cells. The parental line for these cells, Huh-7, was 
originally isolated in 1982 from a well differentiated hepatocellular carcinoma in a 
57-year-old Japanese male (Nakabayashi et al., 1982). As such, numerous 
hepatic transcripts are maintained in these cells befitting their liver origin. One 
notable transcript 3'UTR bound by AGO is 3-hydroxy-3-methylglutaryl-CoA 
reductase (HMGCR) (Figure 4.5A), the rate limiting enzyme for cholesterol 
biosynthesis and famously, the main target of cholesterol reducing statin drugs. 
Interestingly, miR-122 inhibition in mice and in chimpanzees reduced serum 
cholesterol, and in mice, reduced HMGCR expression was observed (Elmén et 
al., 2008; Esau et al., 2006; Krützfeldt et al., 2005; Lanford et al., 2010). Given 
the importance of miR-122 to HCV replication and to host lipid biosynthesis, later 
work explored a possible connection between the two and found essentially that 
there was none: miR-122's activity on HCV and on regulating cholesterol 
biosynthesis occurred via separate and distinct mechanisms (Norman and 
Sarnow, 2010). With no miR-122 sites and so far no confirmed miRNA sites on 
HMGCR, the above data point to some role for miR-122 in regulating an inhibitor 
to cholesterol biosynthesis upstream of HMGCR (Norman and Sarnow, 2010). 
This possibility remains to be fully explored. Data presented in Figure 4.5A open 
the possibility of direct miRNA regulation of HMGCR where interestingly, miR-21 
was recently shown to regulate HMGCR mRNA in a cellular model nonalcoholic 
fatty liver disease (NAFLD) (Sun et al., 2015).  
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Figure 4.5. Genome browser examples of AGO-CLIP binding to notable hepatic 
transcripts. AGO binding in the presence of WT HCV or uninfected cells in the 
upper red and gray tracks respectively, from triplicate experiments. Reads are 
plotted as normalized densities to enable cross track comparison. miR-122 family 
seeds noted by red boxes, peaks changing between conditions denoted by 
asterisks. PhyloP conservation track shown at the bottom. Genes: (A) 3-hydroxy-
3-methylglutaryl-CoA reductase (HMGCR), (B) apolipoprotein B (APOB) CAA to 
UAA editing site indicated, (C) claudin-1 (CLDN1), and the (D) albumin and 
alpha-fetoprotein (ALB and AFP) locus.  
 
 Consistent with a hepatic origin of Huh-7.5 cells is robust expression (and 
surprising AGO targeting) of apolipoprotein B (APOB) (Figure 4.5B). Long known 
to be a key player in very low density lipoprotein (VLDL) secretion, APOB is also 
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associated with HCV lipoviroparticles (LVPs) (Felmlee et al., 2013). The APOB 
transcript features an unusually long coding exon that in the liver results in a 
100kDa protein (ApoB100), whereas in the small intestine this exon is edited by 
APOBEC1 to produce an in-frame stop codon, resulting in a truncated 48kDa 
protein (ApoB48) critical for chylomicron function. The long APOB exon is coated 
with AGO binding, much of it downstream of the editing site (Figure 4.5B). Could 
this be a surveillance mechanism to ensure that any errantly edited APOB 
transcript does not result in production of the 48kDa protein in liver? This 
hypothesis remains to be tested.  
 Claudin-1 (CLDN1) mRNA, encoding a tight junction protein and co-
receptor for HCV, is also bound by AGO via putative miR-155 sites (Evans et al., 
2007; Qin et al., 2013) (Figure 4.5C). Interestingly, Claudin-1 is upregulated in 
cirrhosis and HCC, suggesting a tumor suppressive role for miR-155 (Holczbauer 
et al., 2014). This parallels observations with occludin (OCLN) another HCV entry 
factor and tight junction protein, whose transcript contains miR-122 sites (Ploss 
et al., 2009; Sendi et al., 2014). Recent work has shown that miR-122 expression 
reduces OCLN mRNA in hepatocytes, and in this manner prevents HCV entry 
(Sendi et al., 2014). Whether this represents a bonafide super-infection exclusion 
mechanism remains to be determined.  
 As a fulcrum that captures both the hepatocyte and HCC derived nature of 
Huh-7.5 cells, it is notable that both albumin (ALB) and alpha-fetoprotein (AFP) 
are robustly expressed and bound by AGO (Figure 4.5D). The former protein is 
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the quintessential liver product and is the most abundant blood protein in 
mammals, where it's required to maintain osmotic pressure of body fluids 
(Theodore Peters, 1995). AFP is thought to be the fetal form of serum albumin 
and is normally not present in the adult liver, but is a common marker for tumors, 
especially HCC (Bialecki and Di Bisceglie, 2005). Whether AGO binding to the 
coding exons of these genes plays any role in their regulation is completely 
unknown.  
 Of course, AFP is not the only indicator of the HCC origin of these cells. 
Both MYC and MYCN oncogenes are expressed, the latter while particularly 
associated with poor progression in neuroblastoma, is highly bound by AGO in 
Huh-7.5 cells (Figure 4.6A). The myc family of transcription factors are well 
known drivers of HCC and recent work has implicated tumor suppressive 
miRNAs (including miR-122) participating in feedback loops to inhibit myc 
expression (Han et al., 2013; Wang et al., 2013a). PEG10, also highly bound by 
AGO, is a paternally expressed imprinted gene that, like myc, is upregulated in 
many HCC cases and uniquely in the regenerating liver (Okabe et al., 2003; Tsou 
et al., 2003) (Figure 4.6B). At least two non-coding RNAs involved in cancer are 
also bound by AGO, one aptly named highly upregulated in liver cancer (HULC) 
(Matouk et al., 2009) (Figure 4.6C-D). The other XIST, the key non-coding 
effector of X-inactivation, is not normally expressed in males but is known to be 
deregulated human cancers, regardless of gender (Weakley et al., 2011). As the 
function of a miRNA is typically cast as a repressor of protein expression, finding 
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non-coding RNAs bound by AGO presents a bit of a conundrum. What is AGO 
doing? Long noncoding RNA biology is at an interesting frontier in exploring this, 
and perhaps other RNABP interactions in various disease states (Shi et al., 
2013).  
 
 
Figure 4.6. Genome browser examples of AGO-CLIP binding to notable coding 
and non-coding transcripts associated with HCC. AGO binding in the presence of 
WT HCV or uninfected cells in the upper red and gray tracks respectively, from 
triplicate experiments. Reads are plotted as normalized densities to enable cross 
track comparison. miR-122 family seeds noted by red boxes, peaks changing 
between conditions denoted by asterisks. PhyloP conservation track shown at the 
bottom. Genes: (A) v-myc avian myelocytomatosis viral oncogene neuroblastoma 
derived homolog (MYCN), (B) paternally expressed 10 (PEG10), (C) 
hepatocellular carcinoma up-regulated long non-coding RNA (HULC), and (D) X 
inactive specific transcript (non-protein coding).  
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 As the above examples indicate, far more questions and testable 
hypotheses than answers are raised by observing AGO-CLIP data with "boots on 
the ground" level views. The descriptive nature of these data imply a role for 
miRNAs in regulating a variety of liver and cancer specific pathways, some not 
having anything to do with HCV. Indeed, all of the above examples, with the 
exception of PEG10, did not show appreciable change upon HCV infection 
compared to mock controls. While certainly a rich dataset for understanding liver 
or cancer biology, more comprehensive and miRNA focused means of analysis 
are clearly needed to make sense of these miRNA:mRNA interaction maps and 
their shifting role during HCV infection.  
 As the molecular link between AGO and HCV RNA, this is where miR-122 
becomes important. Consider three known miR-122 targets (Figure 4.7). The 
first, initially called cationic amino acid transporter 1 (CAT-1) was historically the 
first miR-122 target validated (Chang et al., 2004). This transcript contains three 
7mer sites of which AGO binding is detected in two of them and interestingly, 
appears reduced upon HCV infection (Figure 4.7A). A similar observation was 
made on citrate synthase (CS) and pyruvate kinase muscle isoform 2 (PKM2) 
mRNAs, both confirmed miR-122 targets (Jung et al., 2011; Krützfeldt et al., 
2005) (Figure 4.7B-C). Searching within AGO mRNA peaks for miR-122 seeds to 
putatively define novel miR-122 targets, we observed a similar pattern. For miR-
122 seeds in the 3'UTRs of SLC1A5, SFT2D1 and CANX mRNAs, AGO binding 
was again reduced upon virus infection (Figure 4.8). Taken together, these 
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observations suggest a link between the HCV dependence on miR-122, and de-
repression of endogenous miR-122 targets. To fully explore this, we must 
consider miR-122 targets as a group and compare how targets of other miRNAs 
as a group respond to HCV infection.  
 
 
 
Figure 4.7. Genome browser examples of AGO-CLIP binding to previously known 
miR-122 targets. AGO binding in the presence of WT HCV or uninfected cells in 
the upper red and gray tracks respectively, from triplicate experiments. Reads are 
plotted as normalized densities to enable cross track comparison. 7mer miR-122 
family seeds noted by red boxes (6mers in gray), peaks changing between 
conditions denoted by asterisks. PhyloP conservation track shown at the bottom. 
Genes: (A) solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 1 (SLC7A1, aka CAT-1), (B) citrate synthase (CS), (C) pyruvate kinase 
muscle isoform 2 (PKM2).  
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Figure 4.8. Genome browser examples of novel AGO-CLIP identified miR-122 
targets. AGO binding in the presence of WT HCV or uninfected cells in the upper 
red and gray tracks respectively, from triplicate experiments. Reads are plotted 
as normalized densities to enable cross track comparison. miR-122 family seeds 
noted by red boxes, peaks changing between conditions denoted by asterisks. 
PhyloP conservation track shown at the bottom. Genes: (A) solute carrier family 1 
(neutral amino acid transporter), member 5 (SLC1A5), (B) vesicle transport 
protein SFT2A (SFT2D1), (C) calnexin (CANX).  
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Figure 4.9. An common assay to detect miRNA and HCV RNA levels. (A) Non 
poly-adenylate RNAs (such as HCV RNA or miRNAs) are poly-adenylated and 
reverse transcribed with a tagged oligo-dT primer capable of recognizing the 
junction with non-polyA. The resulting cDNA uses an HCV 3'UTR primer or a 
sense miRNA primer and the common tag primer for qPCR. (B) Absolute qPCR 
measurements of miR-122 and HCV RNA levels at indicated time points post 
electroporation (n=3). Replication-deficient J6/JFH1-GNN and mock controls are 
shown. Dashed line indicates lower limit of quantitation. Error bars, ±SD. 
 
 
HCV infection functionally reduces AGO binding on host miR-122 targets 
 Given the crucial requirement of miR-122 for HCV replication, and in light 
of the result that HCV RNA levels accumulate to within one log of miR-122 levels 
(Figure 4.9), we hypothesized that the HCV genome may act as a "sponge" for 
cellular miR-122, where viral replication may exert a broadly de-repressive effect 
on host miR-122 targets. This would be consistent with CLIP results on miR-122 
targets presented thus far. Two key predictions of the data can be made based 
on this hypothesis: (1) AGO binding to miR-122 targets as a population should be 
reduced upon HCV infection, and consequently, (2) the aggregate expression of 
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this population should increase. We can globally explore this bioinformatically by 
assigning a miRNA to all CLIP derived mRNA clusters with a miRNA seed, 
computing the fold change at a given cluster between HCV and mock infected 
cells, and plotting these values as a cumulative distribution. I assigned a miRNA 
family to clusters bearing seeds based on polyG-CLIP abundance of the top 50 
expressed miRNA families. In cases where a cluster could be bound by more 
than one miRNA family due to the presence of multiple seeds, both miRNA 
families were assigned to that cluster. The median number of miRNA seeds per 
cluster in these data was 1.4, in line with previous estimates (Farh et al., 2005). A 
log2 fold-change between HCV or mock infected cells score was calculated per 
miRNA-assigned cluster, and the cumulative distribution of these score was 
plotted, binned by miRNA family. In these plots, if there was no difference in AGO 
binding between HCV and mock infected cells, the score for that cluster was near 
0. Changes showing a decrease of AGO binding upon virus infection would be 
<0, while increases in AGO binding would be >0 (Figure 4.10A).  
 Viewing the entirety of the data in this manner and focusing on 7-8mer 
seeds, we found that miR-122 3'UTR targets as a population exhibited reduced 
AGO binding upon virus infection (Figure 4.10B). This was highly specific to miR-
122 targets, as the targets of the miR-15 family, or the top ten miRNA families 
exclusive of miR-122, exhibited no such change. Significant changes in miR-122 
binding were observed for all canonical seed types (as defined in (Bartel, 2009)).  
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Figure 4.10. HCV infection de-represses endogenous miR-122 targets. (A) miR-
122 dependence definition by Ago binding profiles. (B) Cumulative density 
function (CDF) of the log2 fold change in CLIP binding between infected and 
uninfected cells for all 3'UTR clusters containing indicated 7-8mer seeds by 
family, from triplicate experiments. "Top" refers to the top 10 miRNA families, 
exclusive of miR-122. "All" refers to the top 50 miRNA families, inclusive of miR-
122. Two-sided K-S test p-value between miR-122 and all targets shown. (C) The 
mean log2 fold change (± ranges) in CLIP binding on miR-122 3'UTR targets 
versus all targets during HCV infection broken down by seed type. (D) A CDF plot 
during HCV infection as in (B) but measuring target mRNA expression via RNA-
Seq, from duplicate experiments at 72hrs post-infection. Targets with more than 
one miRNA binding site were collapsed such that no gene is represented more 
than once per category. (E) The mean log2 fold change (± ranges) in mRNA 
expression of miR-122 3'UTR targets versus all targets during HCV infection 
broken down by seed type. 
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However the greatest change was observed with 7-8mers likely reflecting 
the higher intrinsic false-positivity associated with 6mers (Figure 4.10C). Through 
RNA-seq measurements we observed functional de-repression of CLIP derived 
miR-122 3'UTR targets after virus infection such that greater RNA abundance 
was evident when compared to all miRNA targets (Figure 4.10D). Likewise, 
significant expression changes for all miR-122 target seed types were observed 
in the reciprocal direction as CLIP (Figure 4.10E). Taken together, these results 
establish a correlative role for HCV replication in functionally reducing miR-122 
activity, both at the level of decreased AGO binding and subsequentlyincreased 
mRNA levels.  
While emphasis of miRNA activity largely centers on 3'UTRs, we can peer 
objectively into CLIP data to look for any effects on other genic elements: 
5'UTRs, coding exons and introns. If miR-122 inhibition by HCV is truly general, 
we would expect to see AGO CLIP changes similar to 3'UTRs on other genic 
regions, where these changes should likely not have much of an effect on mRNA 
levels. miRNA activity is well known to be weaker if AGO binding occurs on 
coding regions, presumably due to competition with ribosomes (Bartel, 2009). 
Moreover, there is very little general evidence that miRNA binding to 5'UTRs or 
introns influences mRNA levels, however there are exceptions. 
Unlike HCV, AGO rarely binds cellular 5'UTR elements, of those that 
appear to be bound, there is no miR-122 specific difference in AGO binding due 
to HCV infection, nor is there a a significant change in mRNA abundance (Figure 
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4.11A). The low number of 5'UTRs bound is likely the reason for this, as the 
results are quite noisy. The story is different with miR-122 targeted coding exons, 
 
 
Figure 4.11. HCV infection effects on non-3'UTR miR-122 targets. CDF plots of 
the log2 fold change in CLIP target binding (left) and mRNA expression (right) 
between infected and uninfected cells for 5'UTR (A), CDS (B), and intronic (C) 
targets containing indicated 7-8mer seeds by family, from three experiments. 
"Top" refers to the top 10 miRNA families, exclusive of miR-122. "All" refers to the 
top 50 miRNA families, inclusive of miR-122. Two-sided K-S test p-value between 
miR-122 and all targets shown. For mRNA-seq, targets with more than one 
miRNA binding site were collapsed such that no gene is represented more than 
once per category. 
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 there is a slight reduction of AGO binding on exons upon HCV infection, however 
this difference does not result in a significant increase in mRNA (Figure 4.11B). 
This is consistent with previous observations on exonic miRNA targeting as 
expected.  
 miR-122 binding to introns presents an interesting observation as there is 
a slight decrease in intronic binding upon HCV infection, and also a very slight 
increase in mRNA expression (Figure 4.11D). Whether this points to a role in 
miRNA regulation of transcript levels by binding exons is highly speculative. 
Recall that the population sizes between 3'UTRs, exons, introns and 5'UTRs are 
uneven at any biologic complexity (Figure 4.4). Thus any significance 
calculations are likely to be spuriously magnified with a high enough sample size 
as is very common in genomics and other data science research. This problem, 
known as the "p-value problem", makes it very difficult to interpret if the slight 
mRNA change due to miR-122 intronic binding is meaningful (Lin et al., 2013). 
It's perhaps more intuitive to consider that the effect of mRNA abundance is very 
marginal on introns and coding exons (in Figure 4.11, the red curves are only 
slightly difference than the black curves), while for 3'UTRs there is a drastic 
difference (Figure 4.10). The most conservative interpretation is that AGO 
binding changes on miR-122 targets due to HCV can be observed throughout 
genic elements targeted by miR-122, but they are functionally most pronounced 
on 3'UTRs.  
 182 
 As, mentioned in chapter 3, numerous miRNAs beyond miR-122 have 
been proposed to bind HCV RNA, even in Huh-7 cell derivatives (reviewed in 
(Gupta et al., 2014)). Of these miRNA families, only the let-7 and miR-196 
families were identified as AGO associated in polyG-CLIP. Conceivably, binding 
of these miRNAs to HCV could reduce their functional activity for host targets in a 
similar stoichiometric sponge manner as miR-122. We did not observe this Figure 
4.12. AGO binding and mRNA expression of let-7 and miR-196 targets was not 
altered by HCV infection. This agrees with the CLIP map on HCV, as neither of 
these miRNA seeds were observed in AGO peaks on the viral genome. Overall, 
this points to miR-122 as being very unique among miRNAs in that its criticality 
for HCV replication results in specific and observable changes to host miR-122 
targets.  
 
 
Figure 4.12. HCV infection effects on miRNA targets for miRNAs that putatively 
bind HCV RNA. CDF plots of the log2 fold change in CLIP target binding (A) and 
mRNA expression (B) between infected and uninfected cells highlighting let-7 
and miR-196 family 3'UTR targets. Two-sided K-S test p-value between let-7 
(green), miR-196 (purple), or miR-122 (red) and all targets shown.  
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 As CLIP permits the biochemical identification of miRNA targets, it is 
worthwhile to consider how it compares to bioinformatic prediction. Compared to 
Targetscan6.2 (TS) (Lewis et al., 2005), we found that CLIP largely 
complemented and expanded upon predicted miR-122 targets (Figure 4.13). 
3'UTR targets identified via CLIP and predicted by TS exhibited the greatest 
change in Ago binding (Figure 4.13A) and mRNA de-repression (Figure 4.13B-C) 
compared to expressed targets unique to either search modality. Of the 
expressed 731 miR-122 CLIP targets of all seed types identified via CLIP, 48% 
and 9% overlapped with non-conserved and conserved TS predictions, 
respectively (Figure 4.13D). Focusing on a more stringent set of 7mer and 8mer 
seeds for CLIP data yielded even greater overlap, such that only 5% of CLIP 
derived targets were not represented in either TS conservation category (Figure 
4.13E). These results highlight a broad convergence between CLIP and 
bioinformatic prediction to outline a set of miR-122 targets specifically 
derepressed upon virus infection. Given the bias of bioinformatic prediction to 
favor 3'UTRs and conserved sites, in addition to being unable factor in the 
expressed transcriptome, the empirical nature of CLIP methods make it uniquely 
poised to given an unbiased account of AGO binding, as the above results 
suggest.  
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Figure 4.13. CLIP comparison to the miRNA prediction tool Targetscan6.2. (A) 
CDF plot of Ago binding comparing 3'UTR miR-122 targets unique to CLIP ("CLIP 
Only"), CLIP targets predicted to be conserved ("CLIP, Conserved") and non-
conserved ("CLIP, Nonconserved") according to Targetscan (TS) bioinformatic 
prediction. (B) CDF plot of RNAseq data comparing TS conserved miR-122 
targets confirmed in CLIP data ("CLIP + TS"), expressed miR-122 targets without 
CLIP evidence ("TS Only"), or CLIP targets lacking TS prediction ("CLIP only"). 
Conservation for CLIP only targets was defined by an averaged PhyloP score 
across the miR-122 seed greater than 0.5. (C) CDF plot of RNAseq data as in (B) 
comparing non-conserved TS targets. Conservation for CLIP only targets was 
defined as in (B) (D-E) Proportional Venn diagram showing the overlap of 
conserved and non-conserved TS predictions to CLIP derived miR-122 targets of 
all seed types (D) or 7mer and 8mer seeds only (E). Asterisks: ****P<0.0001, 
***P<0.001, **P<0.01, *P<0.05, two-sided K-S test. 
 
Thus far, our results suggest that HCV functionally reduces miR-122 
levels. If so, then CLIP results obtained from artificially inhibiting or deleting miR-
122 in the absence of virus should be similar. We decided to corroborate our 
observations with HCV by performing CLIP after pharmacologic inhibition of miR-
122 and in ΔmiR-122 Huh-7.5 cells. The reduced Ago binding on miR-122 3'UTR 
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targets during HCV infection was similar to 30nM LNA122 or miravirsen 
treatment (Figure 4.14A-B) and to ΔmiR-122 cells compared to unedited controls 
(Figure 4.14C). 
 
 
 
Figure 4.14. MiR-122 target de-repression in LNA, miravirsen and ΔmiR-122 
cells. Cumulative density function (CDF) of the log2 fold change in CLIP binding 
between treatment over control cells with LNA122 (A) or miravirsen (B) at 30nM 
or genetic deletion of miR-122 (ΔmiR-122) (C), for all 3'UTR clusters containing 
indicated 7-8mer seeds by family, from triplicate experiments. "Top" refers to the 
top 10 miRNA families, exclusive of miR-122. "All" refers to the top 50 miRNA 
families, inclusive of miR-122. Two-sided K-S test p-value between miR-122 and 
all targets shown. (D) Proportional Venn diagram showing the overlap of miR-122 
targets with reduced (<0) CLIP binding across ΔmiR-122, LNA or miravirsen 
treatment, and HCV infection conditions. Hypergeometic p-value of overlap 
shown. (E) Proportional Venn diagram showing the overlap of miR-122 targets 
with greater (>0) CLIP binding across ΔmiR-122, LNA or miravirsen treatment, 
and HCV infection conditions. Hypergeometic p-value of overlap shown. 
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 Interrogating the list of 3'UTR targets exhibiting reduced Ago binding 
across these three conditions revealed highly significant overlap (Figure 4.14D) 
suggesting that the effect of HCV replication on lowering functional miR-122 
levels is as general as antagonizing miR-122. Interestingly, we can also observe 
the noise in this system, by looking the overlap of miR-122 targets that exhibited 
enhanced AGO binding in the presence of virus, LNA or miR-122 deletion. 
Indeed, there is no significant overlap (Figure 4.14E).  
 Overall, while the above results compellingly suggest that HCV 
functionally de-represses miR-122 targets, it is still only correlative. Establishing 
a causative role was in truth the main motivation to construct the miR-15 
dependent virus: by swapping the miRNA tropism of HCV, we should expect de-
repression of miR-122 targets to be relieved and redirected to miR-15 targets. 
Parsing RNAseq from m15 versus mock infected cells, we indeed observed that 
miR-122 targets were no longer de-repressed, and that miR-15 family targets 
were (Figure 4.15A). These results highlight the causal nature of an HCV induced 
miRNA sponge as both functional and somewhat modular. We note that the m15 
virus sponge effect was generally weaker than for the WT virus, likely due to the 
lower replication level observed and possibly to binding of the miR-15 family 
member, miR-16, which shares the seed site but may not be able to engage the 
m15 genome due to lack of auxiliary pairing (see previous chapter). On a 
transcript level, we could also observe via CLIP that binding to miR-15 targets 
was reduced in m15 virus but not WT virus infected cells; likewise, miR-122 
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targets with reduced binding in WT virus infection showed no reduction in m15 
infected cells (Figure 4.15B-C). Thus at the level of AGO binding and mRNA 
expression, we can observe HCV RNA as a causal miRNA sponge in action.  
 
 
Figure 4.15. Exchanging HCV miRNA tropism redirects functional miRNA 
sequestration. (A) CDF plot of the log2 fold change in mRNA expression between 
HCV m15 infected and uninfected cells for all 3'UTR clusters containing indicated 
7-8mer seeds by family, from duplicate experiments at 96hrs post infection. "Top" 
refers to the top 10 miRNA families, exclusive of miR-122 and miR-15. "All" refers 
to the top 50 miRNA families, inclusive of miR-122 and miR-15. Two-sided K-S 
test P-value comparing miR-15 (blue) or miR-122 (red) clusters to "All" is shown. 
(B) Genome browser tracks of two known miR-15 family targets, CCNE1 and 
CDC25A. AGO binding in the presence of WT HCV (3 libraries) or m15 HCV (4 
libraries) in the upper red and blue tracks, respectively. Reads are plotted as 
normalized densities to enable cross track comparison. miR-15/16 family seeds 
noted by gray bar. PhyloP conservation track shown at the bottom. (C) Genome 
browser tracks as in (B) of two known miR-122 family targets, ALDOA and 
P4HA1. MiR-122 family seeds noted by gray bar. 
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Validation of HCV induced miR-122 sequestration in bulk and single cells 
 Based on the results so far, it's arguable that HCV RNA can be said to 
"validate" miR-122 targets, given the effect of WT virus on host transcripts 
containing miR-122 seeds. The same can apply to the m15 virus and miR-15 
family targets. It bears stressing that all of the above HCV work was done by 
observing the effects of virus on the endogenous transcriptome, without 
manipulating miRNA levels. Thus, any further attempts to validate the sponge 
effect are likely to yield fruit and may provide additional mechanistic insight on 
how HCV usage of miR-122 impacts host targets.  
 As a first attempt, we decided to observe in practical terms, what mRNA 
de-repression due to sponging of a miRNA looks like via qPCR to validate 
changes observed via RNAseq, and luciferase reporter assays, to measure the 
magnitude and seed dependence of HCV induced miR-122 sponging. In general, 
qPCR of 3'UTR miR-122 targets were increased between 1.1 and 1.8 fold in the 
presence of virus, in line with the median RNA-seq measurement of a 50% 
change, and in line with estimates of miRNA function (Mukherji et al., 2011) 
(Figure 4.16). As expected, only 3'UTR targets appeared de-repressed (8 of 12) 
and not coding exon targets (0 of 3) Figure 4.16. These results provide an 
independent validation of CLIP and RNAseq measurements. 
 Next, we used luciferase reporters of miRNA activity to validate the HCV 
miR-122 sponge on individual 3'UTRs. Using miRNA mimics or LNAs as positive 
controls for repression and de-repression respectively, we observed that HCV 
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infection broadly resembled LNA inhibition with reporters bearing miR-122 seeds, 
or with cloned full length miR-122 target 3'UTRs (Figure 4.17). As expected, this 
effect was specific to miR-122 containing seeds, as no de-repression by HCV 
was observed on a miR-17 reporter. 
 
 
Figure 4.16. QPCR of AGO-CLIP derived miR-122 targets after HCV infection, 
from triplicate experiments. Two previously known miR-122 targets (SLC7A1 and 
SCD) served as positive controls. 3'UTR and CDS miR-122 targets tested are 
indicated. A miR-33 target (ABCA1) served as a negative control. Error bars, 
±SD.  
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Figure 4.17. Validation of HCV induced de-repression of miR-122 targets with 
luciferase reporters. Luciferase reporter measurements for synthetic miR-122, 
miR-17, or cellular 3'UTR target constructs. Data were normalized to "no oligo" 
p3,4 mutant conditions. Significance testing was performed relative to 
endogenous "no oligo" repression for each tested construct. Asterisks: *** 
P<0.001, ** P<0.01, * P<0.05, ANOVA with bonferroni correction. 
 
 
 Perhaps an under appreciated but salient point of the results presented 
thus far is that they stem from measurements on populations of cells. As cellular 
mRNA and HCV RNA expression levels are known to vary widely between 
individual cells (Kandathil et al., 2013; Sheahan et al., 2014), we sought to 
achieve a more thorough understanding of the HCV miRNA sponge on host 
miRNA targets at a quantitative single-cell level. Previous work by Mukherji, van 
Oudenaarden, Sharp, and colleagues demonstrated that miRNAs generate 
thresholds of gene expression such that miRNA repression can be highest on low 
abundance targets, and can be virtually non-existent on high abundance targets 
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(Mukherji et al., 2011). Furthermore, these thresholds can be altered upon 
manipulating miRNA levels. Perhaps the most intriguing feature of this work is 
that it provides a testable mathematical model of miRNA function across a range 
of mRNA expression patterns. How might the HCV:miR-122 sponge work in this 
context?  
 To test this, we adapted the strategy used by Mukherji et al. to construct 
two-color tet-inducible fluorescent reporters of miRNA activity amenable to flow 
cytometry (Figure 4.18) (Mukherji et al., 2011). In this assay, a bidirectional Tet 
promoter drives expression of blue and red fluorescent proteins (TagBFP and 
TagRFP). Each fluorescent protein is tagged with a nuclear localization sequence 
(NLS) to aid in flow cytometric analysis. The 3'UTR of TagRFP is engineered to 
contain N binding sites for miR-122, or full 3'UTRs of selected miR-122 targets, 
while TagBFP serves as an expression control. When expressed in Huh-7.5 
TetON cells (see methods), a TagRFP with no miR-122 sites will be expressed at 
equal per-cell levels as TagBFP. However, upon introducing miR-122 sites to the 
3'UTR of TagRFP, its expression will be repressed by endogenous miR-122 
(Figure 4.18A). In this manner, manipulation of miRNA levels with mimic, LNA or 
virus can be used to determine miRNA activity on TagRFP across a range of 
TagBFP expression values.  
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Figure 4.18. A single-cell assay for miRNA activity. (A) Two-color fluorescent 
reporter containing a bidirectional Tet promoter that drives expression of blue and 
red fluorescent proteins (TagBFP and TagRFP). Each fluorescent protein is 
tagged with a nuclear localization sequence (NLS) to aid in flow cytometric 
analysis. The 3'UTR of TagRFP is engineered to contain N binding sites for miR-
122, or full 3'UTRs of miR-122 targets. (B) Sample processing starts by 
calculating the mean cellular BFP and RFP auto-fluorescence from untransfected 
cells (mean denoted by lines). The auto-fluoresence of each channel plus two 
standard deviations is subtracted from every point. The resulting distribution is 
binned across the BFP signal, and the RFP mean calculated for each bin and 
plotted. In this example, a construct with four miR-122 sites was transfected 
alone or in the presence of 30nM miR-122 mimic. Contour lines for each FACS 
plot denote 10% increments of the total density.  
 
 Testing reporters with N = 1 and 6 miR-122 binding sites in the presence 
of miR-122 mimic, we observed dose dependent miR-122 repression that 
increased with N, as expected, whereas adding LNA122 decreased repression 
(Figure 4.19A-D). HCV infection, using a Ypet expressing clone2 reporter virus, 
in both contexts resembled LNA inhibition where de-repression was notably more 
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pronounced in cells expressing low amounts of reporter, extending previously 
reported miRNA thresholding effects for miR-20 to miR-122 (Mukherji et al., 
2011)(Figure 4.19A and C). Importantly, no such changes were observed for a 
reporter with a p3,4 miR-122 seed ("N1m") (Figure 4.19E-F). Additionally, we 
tested a reporter with a perfectly complementary miR-122 site, thus making the 
miRNA behave as a siRNA. As highlighted in the introduction, this distinction is 
useful to separate the modes of action of small RNAs on AGO: miRNAs appear 
to work stoichiometrically to suppress gene expression, and a as consequence, 
their repressive activity can be diluted out by expressing more target mRNA. This 
is why miRNA repression appears to fail at high target expression levels. In 
contrast, siRNAs work catalytically as AGO:siRNA complexes can move on to a 
new target after mRNA cleavage. By using miR-122 as an siRNA, we expect that 
no such "threshold" should be observed as it would for miRNAs. Indeed, miR-122 
as siRNA reporter exhibited no thresholding such that mimic repression, or LNA 
and HCV de-repression was observed at all expression levels (Figure 4.19G-H). 
Taken together, these data suggest that HCV infection modulates functional miR-
122 levels to relieve endogenous repression on host targets in a stoichiometric 
manner, and is governed by target expression level and the number of miRNA 
binding sites.  
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Figure 4.19. Single cell fluorescent reporters of miRNA activity measurements 
after modulating miR-122 levels. (A) Log-log transfer functions for N=1 miR-122 
site in the presence of increasing concentrations of miR-122 mimic or HCV 
infection. (B) Transfer functions for N = 1 miR-122 site in the presence of 
increasing concentrations of LNA inhibitors to miR-122. (C-H) Transfer functions 
as in (A) and (B) for N=6 (C-D), a mutated miR-122 seed ("1m") (E-F), and N = 1 
perfectly complementary ("1pf") miR-122 sites (G-H).  
 
 
 We extended this analysis to measure actual cellular miR-122 target 
3'UTRs using this system. We observed modest de-repression upon HCV 
infection for previously known targets with one miR-122 site, AldoA, PKM2, and 
P4HA1, but not for CS 3'UTRs (Figure 4.20A-D). We also tested novel CLIP-
identified targets CTDNEP1, SFT2D1, MASP1 and MAL2 and obtained similar 
results, with all four tested being reduced upon miR-122 mimic addition and all 
except MAL2 de-repressed upon adding virus (Figure 4.20A-D).  
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Figure 4.20. Fluorescent reporter measurements for select cellular 3'UTRs. Log-
log transfer functions of full-length cellular 3'UTRs in the presence of miR-122 
mimic, LNA inhibitor, or HCV infection. The effective number of miR-122 sites (N) 
is indicated for each construct. (A-D): previously reported miR-122 targets 
confirmed via CLIP. (E-H): Novel CLIP derived miR-122 target 3'UTRs.  
 
 In broad terms, HCV infection resembled LNA inhibition of miR-122 for 
these reporter measurements. One caveat that must be addressed is the 
apparent discrepancy between miR-122 levels in liver versus those in Huh-7.5 
cells. As miR-122 levels in Huh7 derived cells are estimated to be 10-fold lower 
than primary adult liver tissue (Chang et al., 2004), we next explored the HCV 
sponge effect in the presence of excess miR-122. Exogenous miR-122 addition 
increased intracellular miR-122 in a dose dependent manner by up to 10-fold in 
Huh-7.5 cells, within the range of miR-122 levels measured from patient liver 
biopsies (Figure 4.21A-B). As no changes in HCV RNA levels were observed 
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upon adding miR-122, the resulting miR-122:HCV ratio went from ~15:1 fold at 
the lowest, to over 100:1 with 30nM of miR-122 mimic added (Figure 4.21C). 
Testing N = 1 or AldoA 3'UTR reporter constructs in this in vivo-like context, we 
observed that HCV infection was able to relieve 30nM of mimic repression to 
untreated levels for low but not high abundance targets (Figure 4.22A-B). The 
ability for HCV to rescue excess miR-122 repression was not as pronounced for 
the N = 6 construct (Figure 4.22C) whereas a reporter containing a perfectly 
complementary miR-122 site was particularly sensitive to rescue by HCV 
replication (Figure 4.22D). Similar, dose-dependent results were obtained under 
0.3 or 3nM mimic treatment for all constructs (Figure 4.23). Taken together, these 
results suggest that miR-122 sponging by HCV RNA can exist in more 
physiologic miR-122 concentration settings.  
 
 197 
 
 
Figure 4.21. Boosting miR-122 levels in Huh-7.5 cells to mimic human liver. (A) 
qPCR measurements of miR-122 and HCV RNA copy numbers per cell in 
infected Huh-7.5 cells after addition of increasing amount of miR-122 mimic. miR-
122 copy number from human liver biopsy specimens is also shown. n.d.: not 
done. (B) The relative miR-122 abundance over mock Huh-7.5 cells, from data in 
(A). Significance testing was performed via Student's two-tailed t-test. (C) The 
miR-122:HCV ratio from data in (A). 
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Figure 4.22. Validation of miR-122 sponging by HCV under in-vivo-like levels of 
miR-122. Log-log transfer functions for N = 1 (A), ALDOA 3'UTR (B), N = 4 (C) or 
one perfectly complementary (D) miR-122 site single cell fluorescent reporter 
constructs in the presence or absence of 30nM miRNA mimic and/or HCV 
infection. 
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Figure 4.23. Validation of miR-122 sponging by HCV in 0.3nM or 3nM of miR-
122. Log-log transfer functions for N = 1 (A), ALDOA 3'UTR (B), N = 4 (C) or one 
perfectly complementary (D) miR-122 site single cell fluorescent reporter 
constructs in the presence or absence of 0.3nM or 3nM miRNA mimic and/or 
HCV infection. 
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A quantitative model of miR-122 sponging by HCV RNA 
 Based on these dose-dependent mimic and LNA reporter system 
measurements, we expanded the miRNA model of gene regulation presented by 
Mukherji et al. to incorporate a competing self-replicating viral target (Figure 
4.24A). Here, if HCV RNA is present at sufficiently high numbers or has relatively 
high binding strengths compared to other miR-122 targets, it acts to reduce the 
available miR-122 pool, and de-represses miR-122 targets (r, measured as 
TagRFP fluorescence) relative to non-targets (r0, measured as TagBFP 
fluorescence) (Figure 4.24B). We developed a quantitative model for HCV 
induced reduction of the miR-122 pool in this scenario (see methods). This model 
describes the concentrations of a target mRNA species (r), an HCV mRNA 
species (h), and binding of miRNA (m) to form complexes with target or HCV 
mRNA species, respectively (r*, h*). Production of a target mRNA comes from 
transcription of a gene at a rate (kr) with a corresponding degradation rate (γr). 
We assume the miRNA-mRNA complex (r*) does not undergo translation and 
degrades at a rate allowing for recycling of the miRNA species into the pool. The 
total amount of miRNA is assumed to be constant and can bind to either target 
mRNA (r) or HCV mRNA (h). HCV RNA also decays at a particular rate (γh). As 
previously demonstrated, HCV RNA degradation is slower when bound to miR-
122 (Li et al., 2013d; Shimakami et al., 2012), and we therefore assumed a 
model of HCV degradation primarily from its unbound form. Assuming steady 
state levels of HCV RNA at the time of measurements resulted in a decrease of 
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the model parameter theta, which governs the amount of free miRNA in the 
system. The number of miR-122 sites is estimated by the model parameter 
lambda that is related to the total binding strength of miR-122 to a particular site. 
By tuning these parameters, we accurately fitted experimental data of 
endogenous miR-122 repression of reporters with increasing numbers of miR-
122 sites (Figure 4.24C).  
 To explore the effect of HCV on the miR-122 pool, we fitted the model to 
experimental data with four miR-122 sites during infection (Figure 4.24D), and 
estimated the change to parameter theta to correspond to an approximate 50% 
reduction in available miR-122. A similar result was obtained for the N = 4 
construct in the presence of HCV and 30nM miR-122 mimic (Figure 4.24E). The 
model estimated that the highest theoretical HCV levels reducing the miR-122 
pool by 90% could de-repress mRNA targets by up to 4.5-fold for low-expressed 
mRNAs (Figure 4.24F). Synthetic reporter and cellular measurements agreed 
with model predictions for 50% reductions in miR-122 levels, where de-
repression was most drastic for low expressed targets harboring multiple miR-
122 sites or an siRNA-like context (Figure 4.24G-H). Taken as a whole, the 
quantitative model outlines several factors controlling HCV induced de-repression 
of host mRNA targets given steady-state levels of HCV RNA: the expression 
level of the target mRNA, mRNA-miR-122 binding strength, and the number of 
sites on the target mRNA.  
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Figure 4.24. Quantitative modeling of miR-122 sequestration by HCV. (A) 
Illustration of model reactions for miR-122 dynamics, including transcription and 
translation of a target mRNA, binding to miR-122 and decay of mRNA species. 
HCV RNA can replicate, be degraded, or bind miR-122, functionally sequestering 
miR-122 and leading to de-repression of mRNA targets. (B) Increasing amounts 
of HCV (or a relative increase in binding strength at miR-122 sites) leads to 
changes in single-cell gene expression as compared to unregulated targets, with 
stronger effects at the low mRNA expression levels. Parameters used are fitted 
from data in (C). Each curve, from top to bottom, represents a reduction in the 
miRNA pool by 20%. Inset displays model on a linear scale. (C) Model fitting of 
the steady state approximation to experimental data while increasing the number 
of binding sites corresponding to changes in total binding strength. (D) Model 
fitting for the N = 4 case showing a 50% reduction in the miRNA pool by HCV 
modeled by a proportional change in the theta parameter. (E) Model fitting for the 
N = 4 construct under 30nM miR-122 mimic addition ± HCV infection. (F) 
Increasing HCV:miR-122 binding strength or HCV RNA abundance results in 
functional de-repression of miR-122 targets. The curves (top to bottom) represent 
10 percentage-points increases in the available miR-122 pool (10% to 100% 
availability). (G-H) Experimental HCV induced derepression of synthetic miR-122 
binding site constructs (G) or endogenous 3' UTRs with miR-122 binding sites 
(H). Modeling done with Tal Danino.  
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As the model largely agrees with previous work, applying this framework to other 
more robust miRNA sponge systems (viral or otherwise) or testing other HCVs 
with different replication capacities than the robust clone 2 virus, will be useful to 
refine our understanding of miRNA function in the cell.  
Chapter 4 summary and discussion 
 In this chapter, we've explored the converse side of AGO-CLIP data in 
HCV infected cells by focusing on the host. Starting from genome browser 
gazing, continuing with sponge hypothesis formation, global validation using 
RNAseq, and further characterization in bulk and single cells, our results chiefly 
establish that HCV RNA may act as a competitive inhibitor of miR-122 activity. 
Natural viral derived miRNA sponges have been described previously (Cazalla et 
al., 2010; Lee et al., 2013) though no examples are currently known from RNA 
viruses. Whether this systems-level phenomenon occurs with other, more robust 
RNA virus infections remains to be explored, and presents a novel frontier worthy 
of followup. For HCV biology, our elucidation of a miR-122 sponge raises a 
number of questions that revolve around two key issues, namely, whether the 
HCV:miR-122 sponge exists in vivo and whether such a miRNA sponge has a 
functional or pathogenic role in HCV disease biology.  
On the likelihood of an HCV:miR-122 sponge in liver 
 The idea that HCV RNA may act as a competitive inhibitor of miR-122 is 
closely aligned with proposed roles for competing endogenous RNAs (ceRNAs) 
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(Salmena et al., 2011). While both HCV RNA and ceRNAs share the theme of 
de-repressing a miRNA regulated network by increasing the pool of available 
targets through RNA expression, they importantly differ in their mode of 
interaction with miRNAs. HCV genomic RNA critically requires miR-122 
interaction to stabilize the viral genome and stimulate translation and replication, 
while most cellular transcripts are repressed upon encountering a miRNA. 
Moreover, unlike cellular mRNA targets, HCV genomic RNA is its own substrate 
for replication, and thus constitutes a direct and positive feedback loop to 
sequester additional miR-122. These distinguishing features suggest different 
parameters for HCV versus cellular ceRNA based sponge effects on a miRNA 
target network.  
 This is particularly relevant in light of recent findings showing that 
endogenous miR-122 repression is only relieved when ceRNAs are forcibly 
expressed at super-physiological levels in mouse liver (Denzler et al., 2014). In 
this work, the authors over-expressed the AldoA 3'UTR to constitute up to 40% of 
RNA in the cell; only at these extremes was de-repression of endogenous miR-
122 targets observed. Notwithstanding the fact that no attempt was made to 
confirm that the over-expressed miR-122 target was at all regulated by 
endogenous miR-122, the authors generally concluded that ceRNA effects are 
unlikely under the normal paradigm whereby an individual ceRNA is induced, 
even if highly so. While perhaps over-generalized, this work raises some key 
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issues that are worth exploring as we consider HCV RNA as a functional miR-
122 inhibitor.  
 The first key issue relates to cellular infection frequency and per cell HCV 
RNA abundance. Unlike the >90% infection frequencies in Huh-7.5 cells, the 
percentage of infected hepatocytes in chronically infected patients based on in 
situ hybridization of liver biopsy tissue, ranges from as low as 0.07% to as high 
as 100%, with medians in the 20-40% range (Liang et al., 2009; Pal et al., 2006). 
Combined with HCV genotype, dynamic replication variation within the liver, 
circadian miR-122 expression and regulation, and host variability in innate 
immune responses (Sheahan et al., 2014), a complex picture of HCV infection 
emerges that would largely mask observations of HCV sponge effects in bulk cell 
or tissue Ago-CLIP or RNAseq measurements. HCV levels per cell are estimated 
to range from 1 to 102 copies per hepatocyte in contrast to Huh-7 derivatives with 
in excess of 103 copies per cell (Kandathil et al., 2013) (Figure 4.21A). However, 
extrapolating from liver biopsies or back-calculations of the number of cells 
required to account for HCV levels in serum are all confounded such that it is 
very unclear what the HCV RNA level truly is in a "highly infected" human 
hepatocyte. So, on this point, we can only ask a speculative question: assuming 
a distribution centered on a few hundred RNA copies per cell, how likely are 
these viral RNAs capable of inducing a sponge effect? 
 This leads to the second main concern: miR-122 abundance. Our bulk cell 
measurements estimate ten-fold higher miR-122 levels in primary liver tissue 
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versus hepatoma cell line derivatives (105 vs 104 estimate ranges per cell, Figure 
4.21A) and are in line with previous estimates (Chang et al., 2004; Denzler et al., 
2014). Taken at face value, this suggests that the HCV:miR-122 sponge might be 
a feature of replication unique to Huh-7.5 cells and likely plays little if any role in 
the liver, where viral RNAs are drastically outnumbered by miR-122.  
 However, there are a number of assumptions with this interpretation that 
we must consider. Chief among them is the assumption that miR-122 binding to 
HCV RNA is functionally and mechanistically the same as binding to a cellular 
3'UTR. Considering the basic premise of miRNA function, this is demonstrably 
false: while miRNAs function to repress mRNAs, no target transcript "needs" to 
encounter miRNA for its function to undergo translation. HCV RNA on the other 
hand, critically requires a miRNA for its function to make viral protein (by 
stabilizing the viral RNA and/or directly aiding in translation). In the context of 
these opposing outcomes of miRNA binding, ceRNAs are argued to behave as 
ordinary mRNA targets (Salmena et al., 2011), as they are neither stabilized by 
miRNA binding nor is there as direct a mechanism of propagating ceRNA activity 
as cytoplasmic viral RNA replication. Our results that HCV can exert sponge 
effects in the presence of excess miR-122 would support the view that HCV RNA 
as a miRNA sponge does not abide by simple miRNA stoichiometry assumptions 
made for ceRNAs or mRNA targets (Figure 4.22).  
 But why might this be? This idea of "needing" to encounter a miRNA might 
imply a more active mechanism of miR-122:HCV RNA binding, that goes beyond 
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passive miR-122 abundance. Conceivably, the virus could have evolved a 
specific means to recruit miR-122 as an essential host factor to sites of viral 
replication or assembly. Indeed, mounting evidence supports such a hypothesis. 
HCV replication is known to disperse and prevent formation of processing bodies 
(P-bodies), the sites of miRNA silencing (Ariumi et al., 2011; Berezhna et al., 
2011; Pager et al., 2013). Additionally, AGO2, miR-122 and Dicer, but not RISC 
components GW182 and DCP2, selectively partition to sites of HCV replication / 
assembly at lipid droplets (Ariumi et al., 2011; Berezhna et al., 2011). These cell 
biological findings highlight the possibility that HCV RNA coercion of miR-122 
might engender a sponge effect, even when miR-122 is highly abundant.  
 As mentioned in the introduction but refined here in full, the mouse liver 
provides additional evidence that total miR-122 levels aren't the whole story. 
Despite invariantly high levels of mature miR-122 in the liver, miR-122 
transcription is under circadian control and a number of targets oscillate in a 
circadian manner corresponding to repression by miR-122 (Gatfield et al., 2009). 
This puzzling finding could be explained in at least two ways (Figure 4.25A-B). 
MiR-122 could function to amplify target protein oscillation by repressing basal 
translation at an expression trough; thus miRNA function cycles between switch-
like and neutral modes (recall Figure 1.7B)(Figure 4.25A).  
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Figure 4.25. Potential mechanisms of miR-122 activity despite invariant mature 
levels. (A) Constant miR-122 (dark gray) may shape circadian rhythm of targets 
(light gray) by repressing basal levels of translation. In this case, only targets 
represented by the dotted area is available for translation. This context would 
impart higher protein amplitudes throughout the circadian cycle. (B) Conceivably, 
a newly synthesized or a chemically distinct miR-122 sub-population may exist. If 
this circadian expressed population was functionally distinct from bulk miR-122, 
target mRNAs could be subject to circadian oscillation (dotted area again depicts 
fraction of mRNA available for translation). (C) In one model of how HCV RNA 
might depress miR-122 targets, we can consider miR-122 bound to HCV as 
effectively reducing the total miR-122 pool, thus enabling more target to be 
translated (dotted area). (D) In another model, HCV RNA may hijack the more 
"active" newly synthesized or precursor that is perhaps a limiting miR-122 
subpopulation, such that mature levels are reduced through this upstream 
targeting. Panels A and B modified from (Gatfield et al., 2009).  
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Should a sub-population of miR-122 exist that is either chemically altered and/or 
newly synthesized, and assuming this sub-population is functionally distinct from 
total levels, then it's possible that circadian expression of this sub-population 
influences target mRNA translational ability to oscillate (Figure 4.25B). These in 
fact are the main mechanisms proposed by Gatfield, et al. and are bolstered by 
observations of cytoplasmic modifications to miR-122, particularly adenylation 
and uridylation (Burns et al., 2011; Katoh et al., 2009). Relating changing miR-
122 activity due to HCV RNA can be similarly considered, whereby viral RNA 
replication has a direct and negative impact on miR-122 levels available to 
repress targets (Figure 4.25C). Along the lines of newly synthesized miR-122, 
perhaps HCV actually targets this lower abundance and limiting precursor of 
mature miR-122, and in so doing reduces mature miRNA by preventing 
biogenesis (Figure 4.25D).  
 All of the above suggests additional nuanced factors and raises questions 
that are largely obscured from bulk miRNA abundance measurements of high 
miR-122 levels in liver, and the assumption that all this miRNA is functional. Are 
distinct AGO:miR-122 complexes recruited to HCV RNA in special 
compartments? Are these complexes limiting? Might coercion of newly 
synthesized or chemically distinct miR-122 be the mechanism of miRNA 
subversion? What happens to miR-122 after it engages the viral genome?  
 Numerous experimental paths forward spring to mind to explore these 
ideas, a few of which are summarized here. The miR-15 dependent virus 
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presents an excellent test case to see if miR-15 family members can be 
redirected to sites of HCV replication and assembly in place of miR-122. A 
detailed analysis of S1 an S2 swap mutants where one site is miR-122 and the 
other site miR-15 could be used to test if the 2x stoichiometry of binding sites is 
needed to render an effective sponge. Deletion of a cytoplasmic polymerase 
GLD2, that is known to stabilize miR-122 could be used to evaluate the possibility 
of mature but largely non-functional "old" miR-122 that is distinct from newly 
synthesized miR-122 (D'Ambrogio et al., 2012; Katoh et al., 2009). Combined 
with the development of cell compartment specific AGO-CLIP, these experiments 
may continue to unravel the unique interplay between HCV RNA and miR-122.  
On the functional role of the HCV:miR-122 sponge 
 The establishment of a miR-15 dependent HCV suggests that the miR-122 
sponge effect is largely dispensable for the virus in the Huh-7.5 cell context. 
From the previous chapter, recall that LNA-122 slightly reduced m15 virus titers 
and that restoring miR-122 in ΔmiR-122 cells increased titers, suggesting that the 
miR-122 sponge may reflect a trade-off for the large, positive and direct impact of 
miR-122 on WT HCV replication. Conceivably, HCV replication may exert enough 
pressure on miR-122 levels to de-repress targets such that the cellular 
environment is passively altered to negatively impact viral replication. Or more 
actively, some targets may act as sensors for low miR-122 levels, and by 
extension, the health of the hepatocyte. While future work will be needed to shed 
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light on specific players involved in this process, our data suggest that viral 
replication faces a ceiling by reducing levels of an otherwise pro-viral miRNA.  
 Note that throughout this chapter I have avoided discussing specific 
targets that are de-repressed upon miR-122 sponging, even those targets 
extensively tested in reporter assays. This has been deliberate. Due to the 
hepatoma nature of Huh-7.5 cells, extreme caution is needed when attempting to 
extrapolate results to liver biology, no matter how compelling. The transcriptomes 
between these cell types, not withstanding hepatic examples above, are so 
drastically different so as to be nearly incomparable (not shown, but median 
correlation was ~0.2-0.5). So we're likely to suffer from both a false-positive and 
false negative problem if we start to seriously parse Huh-7.5 cell data without 
informed knowledge of actual miRNA targeting in the liver. This will be the stated 
goal of the next chapter.  
 But we can begin consideration of an important question: how might the 
HCV miR-122 sponge impact a hepatocyte? Work with miR-122 knockout mice, 
which develop progressive liver disease that spontaneously results in HCC, 
suggests that miR-122 tumor suppressor activity is essential for long-term liver 
homeostasis (Hsu et al., 2012; Tsai et al., 2012). It is tantalizing to speculate that 
miR-122 sequestration in a chronic HCV infection may be a molecular link to the 
heterogeneous liver dysfunction that characterizes HCV induced disease(s). 
Many miR-122 targets found in Huh-7.5 cells would corroborate this with no 
shortage of potential mechanisms. For instance, miR-122 targets that we confirm 
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or establish via CLIP and reporter measurements, such as P4HA1, PKM2, and 
MASP1 are known to be upregulated in fibrosis or HCC (Jung et al., 2011; Li et 
al., 2013b; Liu et al., 2014a), with MASP1 notable for being specifically linked 
with HCV-associated HCC (Saeed et al., 2013). P4HA1, or prolyl 4-hdroxylase, is 
a key enzyme in collagen maturation; miR-122 suppression of this enzyme is 
hypothesized as a mechanism to control fibrogenic responses in the liver and the 
associated action of hepatic stellate cells (Li et al., 2013b). Pyruvate kinase 
muscle isoform 2, a key enzyme in glycolysis, is thought to be a primary driver in 
cancer metabolism. That miR-122 targets PKM2 provides an intuitive hypothesis: 
loss of miR-122 promotes PKM2 expression, and alters cellular metabolism to 
rely on glycolysis instead of oxidative phoshorylation based cellular energetics. 
The enzyme, as a miR-122 target specifically, has been linked to poor 
progression of HCC and in breast cancer (Fong et al., 2015; Liu et al., 2014a). 
Lastly, mannan binding lectin-associated serine protease 1 (MASP1), known to 
be unregulated by HCV via unknown mechanisms (Saeed et al., 2013), 
according to our data appears to be a miR-122 target. This secreted protease is 
thought to promote the proliferation of hepatic stellate cells which in turn adopt a 
pro-fibrotic course. In this manner, levels of this protein are thought to be a 
specific indicator of HCV induced liver disease, though the putative role of 
MASP1 in the virus lifecycle is unknown. The above examples are but the tip of 
the iceberg. As we begin to consider miR-122 targets in the liver, the stage is set 
for HCV induced sponging to play a role in defining virus specific pathology. 
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 Overall, as it remains possible that functional effects of such a sponge 
may primarily impact highly infected cells, our data highlight the possibility of 
searching for transcriptome level changes to the miR-122 target network in 
response to HCV infection in individual hepatocytes. The extension of CLIP and 
RNA-seq in single-cell and primary contexts provides a compelling platform to 
address these and other long-term disease driven changes to a miRNA target 
network.  
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Chapter 5: AGO-CLIP studies of mouse and human liver 
 Thus far, we have focused on a so called HCV driven "sponge effect" 
whereby viral RNA uses miR-122 to an extent that host miR-122 targets are 
deprepressed. What we haven't delved into very much are the identities and 
functions of these actual targets and their roles in HCV or liver biology. Due to the 
Huh-7.5 context, this has been appropriate, given that we cannot assume a 
similar transcriptome in these cells compared to hepatocytes. The work 
presented in this chapter aims to overcome this limitation by exploring miR-122 
targeting in its native in vivo setting in both mouse and human liver. The 
availability of a miR-122 knockout mouse, and its associated cancer related 
phenotype, offers an excellent platform to unambiguously map the entire miR-
122 regulated network in situ and begin to define the molecular consequences of 
miR-122 disregulation. Combined with RNAseq, we are further likely able to 
distinguish between primary effects due to loss of direct miR-122 binding, and 
secondary effects of altered signaling. In addition, AGO-CLIP studies of human 
liver add direct and clinically relevant depth to results obtained in mice, by 
providing points of comparison across species and across tissue types (liver 
versus Huh-7.5 for instance) in the hunt for targets most likely to impact HCV or 
liver disease biology.  
 Throughout, while this work was conducted squarely with HCV in mind, it 
must be noted that no virus will be present in the ensuing work. As we'll see, 
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miR-122 use by HCV is but one of the many surprises to be gleaned from this 
miRNA.  
Experimental setup for AGO-CLIP in miR-122 KO mice 
 This work was initiated jointly with Kalpana Ghoshal at the Ohio State 
University. Shortly after publishing the initial description of a miR-122 knockout 
mouse in 2012 (discussed below), Kalpana contacted us about performing AGO-
CLIP in these mice. Sensing an overlap with the HCV story then forming, I was 
brought in to lead the effort. Or more accurately, I enthusiastically volunteered to 
do AGO-CLIP in this in vivo context. 
 My enthusiasm was multi-fold. At this stage, I was convinced that the miR-
122 sponge effect was probably real, but validating targets became an issue in 
Huh-7.5 cells given the high false positive (transcripts expressed in Huh-7.5 but 
not in liver) and false negative (liver transcripts lost in Huh-7.5 cells) likelihoods of 
RNA expression compared to liver. The literature comparing Huh-7.5 and liver 
transcriptomes is thin, but analyzing RNAseq data generated by William 
Schneider of human fetal liver cultures (HFLCs), a presumed closer substitute for 
liver, the transcriptome correlation of these data with Huh-7.5 was ~0.4 (not 
shown). This low correlation for ostensibly the same tissue type did not bode well 
for direct extrapolation of relevant liver targets in Huh-7.5 cells.  
 The miR-122 knockout mouse is the ideal context to solve this problem 
and possess an unusual phenotype. While miR-122 has been proposed to 
influence liver development (Laudadio et al., 2012; Xu et al., 2010), the first main 
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surprise of the knockout mouse is that livers develop normally, with no 
observable defects in anatomy and physiology (Hsu et al., 2012). A liver 
phenotype does emerge at 10 weeks of age when microsteatosis and liver 
inflammation begin to occur. Hepatic triglyceride synthesis increases at this 
stage, and yet serum cholesterol, LDL and HDL, all decrease. The result is an 
accumulation of fat in hepatocytes (steatosis) that progressively gets worse as 
the animals age. Combined with an infiltration of IL-6 producing immune cells, 
this steatosis progresses to a well defined fibrosis and hepatitis by six months of 
age. Between 12-17 months of age, miR-122 knockout mice then spontaneously 
develop HCC where interestingly, the penetrance differs by sex: 50% of males 
develop HCC whereas only 10% of females are affected (Hsu et al., 2012). This 
difference phenocopies the known male skew of HCC in humans el (El-Serag, 
2011).  
 The the slowly unfolding HCC observed by Hsu, Ghoshal and colleagues 
in miR-122 knockout mice appears consistent with the human trajectory of 
disease as correlating with age, sex and hepatic injury. It also points to a role for 
miR-122 as a key factor in maintaining long-term liver homeostasis,as a putative 
tumor suppressor. This last point was addressed in the initial report, as miR-122 
overexpression was able to rescue liver tumorigenesis in a model driven by 
overexpressed c-MYC, drastically reducing tumor burden (Hsu et al., 2012).  
 Along the lines of the main hypothesis of the HCV sponge, that chronic 
repression of miR-122 may influence HCV associated disease progression, the 
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miR-122 knockout mouse permits a refinement of this hypothesis by providing 
the extreme case. Since long-term deletion of miR-122 results in spontaneous 
HCC, perhaps by investigating the miR-122 targets network in these mice, we 
might gain insight as to how HCV may do the same in humans. This was the 
main motivation to pursue AGO-CLIP in these mice.  
 The second point of enthusiasm involves using miRNA knockout systems 
for AGO-CLIP studies. Historically, miRNA activity in mammalian cells has 
typically been characterized by miRNA overexpression and monitoring of a target 
reporter, usually in a contrived cell type or in a context where the miRNA is 
usually not expressed. This basic idea was extended in the pioneering AGO-
CLIP study, where miR-124 (a brain specific miRNA) was overexpressed in HeLa 
cells to look for novel miR-124 dependent peaks (Chi et al., 2009). While no 
doubt a useful proof-of-principle for "validating" a miRNA target with CLIP, this 
idea is plagued with problems: from overexpression artifacts that cannot be 
confirmed with knockouts (Vidigal and Ventura, 2015), to the aforementioned 
context problem where the miRNA encounters targets it usually never observes 
in vivo. Performing CLIP in a miRNA knockout context addresses these 
limitations succinctly, and as we've seen with ΔmiR-122 Huh-7.5 cells, allows for 
the unambiguous determination of miRNA target by looking for the specific loss 
of AGO-CLIP peaks. This approach has been validated in vivo with great 
accuracy using miR-155 knockout mice, probing effects of this miRNA on 
immune cell function (Loeb et al., 2012) 
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 To begin, we decided that to avoid any confounding events due to 
emerging liver pathology at 10 weeks, we would perform AGO-CLIP in miR-122 
knockout mouse livers and floxed littermate controls from 6-week old mice, 
before pathology emerges. Both control and knockout mice were on the same 
feeding schedule, and importantly, livers were flash frozen at the same time of 
day (mornings). AGO-CLIP was performed on four knockout livers (1 female, 3 
males) and five floxed controls (2 female, 3 male), for a total of nine mice (Figure 
5.1). The autorads gave clear 110kDa miRNA bands in addition to mRNA smears 
between 130-150kDa. mRNA sized regions were excised and used to make DNA 
libraries compatible with NGS and sequenced.  
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Figure 5.1. Autoradiogram of AGO bound RNA in miR-122 KO mice and flowed 
controls. Autoradiogram of 32P-labelled RNA bound to AGO after IP using the 
pan-AGO 2A8 antibody. AGOs migrate at 97kDa, which shifts by RNA species 
bound by approximately 1kDa/3nt, thus AGO bound to ~22nt miRNA should be 
around 105kDa. IgG used as a non-specific control. Minus crosslink control 
shows the stringency of washes in that only a faint Ago:miRNA complex remains. 
High RNAse and low RNAse conditions indicated. Regions excised 
corresponding to 110, 130 or 150kDa are highlighted. Left panel depicts signal 
from four miR-122 knockout animals, where the gender and the amount of liver 
tissue used per sample is indicated. The right panel depicts the same but for five 
floxed control mice, treated as "WT." 
 
 As a confirmation of miR-122 loss, I first analyzed the miRNA profiles 
between WT and KO mice. While standard CLIP was performed with its 
attendant miRNA cloning bias issues, this analysis focuses only on comparing 
the same miRNA across conditions. Thus, assuming the cloning bias for a 
particular miRNA is constant between conditions, this issue is circumvented. We 
observed that mature miR-122 (-5p) and its passenger strand (-3p) were the 
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most significantly reduced miRNAs in knockout livers, as expected (Figure 5.2). 
An additional miRNA, miR-31-5p was also reduced, while a number of miRNAs 
were upregulated in knockout livers (Figure 5.2). These results suggest additional 
roles for miR-122 in affecting the abundance of other miRNAs.  
 
 
 
Figure 5.2. Volcano plot showing the log 2 fold change between miR-122 
knockout versus wild-type mouse liver tissue of miRNA-CLIP results. Y-axis 
denotes FDR, where p = 0.0001 line is indicated. Notable miRNAs are highlighted 
by color and/or label.  
 
 Next, groomed reads were aligned to the mouse genome (mm9) and 
clustered mapped reads that overlapped by 1nt. Clusters were then grouped by 
BC and plotted as before to get a sense of the distribution of clusters across 
various genomic regions (see Chapter 4). In contrast to data in Huh-7.5 cells, 
where up to 50% of clusters mapped to 3'UTRs, most clusters in mice mapped to 
coding exons (>50%) with at best 30% in 3'UTRs Figure 5.3. For downstream 
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analysis of miRNA seeds, a cutoff of five libraries with a minimum peak height of 
10 reads was used. Unlike Huh-7.5 data where only a BC threshold was used, 
the much higher depth of AGO-CLIP achieved in mouse liver made peak height 
filter appropriate, if only to enable a more "stringent" definition of clusters, though 
in truth, just as specified with Huh-7.5 cells, this call was arbitrary.  
 With these cluster definitions, a more detailed annotation was performed 
comparing all WT clusters to KO clusters, including those commonly shared. We 
observed that clusters in 3'UTRs were only mildly reduced in KO libraries (21.4% 
to 19.3%) (Figure 5.4). Given that a typically miRNA target contains binding sites 
for more than one miRNA, this is perhaps somewhat expected. Less expected 
was the decrease in coding exon clusters in knockout virus WT livers (40.2% to 
31.5%), suggesting that a substantial fraction of unique miR-122 binding occurs 
in coding exons. Other genic regions, such as introns, transposable elements 
(TEs), 5'UTRs, and intergenic regions, were not appreciably different between 
KO and WT livers.  
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Figure 5.3. Cluster annotation results by increasing biologic complexity. AGO-
CLIP reads from up to nine libraries from mouse liver were clustered with a 
minimum overlap of 2nt. Clusters with reads from any one, two, three and so on 
up to nine libraries the were annotated. The resulting proportions of clusters 
overlapping known genic elements is plotted above, alongside the total number of 
clusters with the respective biologic complexity (BC).  
 
 
 
Figure 5.4. Proportion of clusters after robust clustering of overlapping reads from 
miR-122-deficient (KO) or floxed control (WT) libraries mapping to various 
regions of the genome. Clusters unique to each case plus those in common are 
indicated. TE, transposable elements; Other, includes non-coding RNA, satellite 
repeats, low complexity elements, etc.  
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miR-122 dependent peaks in mouse liver: some unexpected findings 
 Having confirmed miR-122 loss in knockout livers with CLIP, and after 
specifying BC and size cutoffs for clusters, we next approached defining miR-122 
peaks. To do so in a less biased fashion that searching for the canonical miR-
122 seed, we opted instead to search for instances where a cluster was 
specifically lost in KO libraries, extract the underlying sequence for the AGO 
footprint (+/- 32nt from the peak position), and search for enriched motifs (Figure 
5.5A-B). For putative miR-122 dependent clusters, this analysis revealed 
significant enrichment for 8mer, 7merM8, 7merA1 and 6mer miR-122 seeds 
(Figure 5.5B). Unexpectedly, it also revealed a non-canonical miR-122 site motif, 
characterized by a G-bulge between the 6th and 7th seed positions (Figure 5.5B 
and D). Such "nucleation" bulges were observed previously with miR-124 
between positions 5 and 6, and were demonstrated to be functional (Chi et al., 
2012). We confirmed the presence of both canonical and G-bulged (hereafter 
also called miR-122-B) seeds by searching for motifs relative to AGO cluster 
peak coordinates. As expected we found significant enrichment for canonical 
miR-122 seeds within 20 nucleotides of AGO peaks (Figure 5.5C). We observed 
a similar enrichment, though fewer target sites, with the bulged motif (Figure 
5.5D). Taken together, these results point to an alternative mode of miR-122 
target recognition that occurs in vivo. 
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Figure 5.5. Identification of a novel G-bulged miR-122 motif. (A) Example of a 
miR-122 dependent peak. Robust WT signal is absent in KO libraries. (B) MEME 
analysis table of top motifs within clusters displaying miR-122 dependence as in 
(A). (C) Canonical miR-122 motif enrichment around Ago peaks. miR-122 KO 
dependent peaks (red) were compared to background clusters (gray). Inset 
shows miR-122 motif binding profiles. (D) Bulged miR-122 motif enrichment 
around Ago peaks. miR-122 KO dependent peaks (pink) were compared to 
background clusters (gray). Inset shows bulged miR-122 motifs binding profiles. 
 
 After assigning miRNAs (the top 100 expressed) to clusters by seed 
presence, we annotated the miR-122 and miR-122-B targetomes in detail (Figure 
5.6). About 8% of CLIP clusters contained no discernable canonical miRNA seed, 
consistent with previous reports for "orphan" clusters (Chi et al., 2009; 2012). 
Roughly 5% of AGO-CLIP clusters contained a miR-122 seed, an additional 1% 
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of clusters contained a miR-122-B seed, for a total of ~4500 miR-122 targets 
spread across a variety of genomic regions (Figure 5.6A). We noted that 3'UTRs 
were targeted in similar proportion between canonical and G-bulged miR-122 
sites, however, coding exon targeting predominated for both, and was 
considerably expanded for miR-122-B targets (Figure 5.6B). Additionally, 
between 20-40% of miR-122 targeting appears to occur in regions beyond 
3'UTRs and coding exons. miR-122 dependent AGO targeting of introns, 
intergenic regions, 5'UTRs and TEs is totally novel and functionally unexplored, 
but clearly expands the AGO:miR-122 bound transcriptome. Combined with a 
binding preference for coding exons, and the identification of a G-bulged miR-122 
seed, the classic assumption by virtue of bioinformatic target prediction that most 
miRNAs regulate a few hundred targets, is perhaps in need of revision.  
 
 
 
Figure 5.6. Annotation of miR-122 dependent clusters. (A) Pie chart highlighting 
miR-122 or bulged miR-122 targets as a proportion of all miRNA targets in 
mouse. Of the ~64,000 miRNA matched clusters roughly 5% are canonical miR-
122 bound targets, and 1% G-bulged sites. Total number of clusters per category 
indicated. (B) Genomic annotation breakdown of canonical or bulged miR-122 
sites.  
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Global analysis of miR-122 AGO peaks in WT versus miR-122 KO mice 
 With an expanded set of RNAs containing miR-122 or miR-122-B seeds, 
we next sought to quantify the fold change between WT and KO libraries. Similar 
to our analysis comparing HCV versus mock infected Huh-7.5 cells, we first 
calculated from read depth normalized data the log2 fold-change between WT 
and KO samples per miRNA-assigned cluster. The cumulative distribution of 
these score was plotted, binned by miRNA family. Again, for these plots, if there 
was no difference in AGO binding at a particular cluster between WT and KO 
libraries, the score for that cluster was near 0. Changes showing a decrease of 
AGO binding upon miR-122 loss would be >0, while increases in AGO binding 
would be <0 (Figure 5.7A).  
 Focusing on 3'UTRs, we observed a highly significant reduction in AGO 
binding in miR-122 seed containing clusters in KO libraries. This was true for 
both canonical and G-bulged seeds (Figure 5.7B). Other miRNA families, such as 
miR-21 and miR-15/16 were not significantly altered in their AGO-CLIP 
distributions. Two examples of canonical and G-bulged miR-122 targeting are 
shown in Figure 5.7D-E. In both cases, a miR-122 seed can clearly be discerned 
as underlying peaks lost in knockout livers.  
 To corroborate our CLIP results with effects on RNA abundance, we 
performed RNAseq in the same livers used for CLIP. Here we expect that loss of 
miR-122 should result in a measurable increase of target mRNA levels 
presumably for both seed types.  
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Figure 5.7. Global AGO binding changes on 3'UTRs affect mRNA abundance 
specifically for miR-122 targets. (A) miR-122 dependence definition by Ago 
binding profiles. (B) Cumulative distribution fraction (CDF) plot of the log2 fold 
change in Ago binding within cluster harboring indicated miRNA seeds. KS Test 
p-values indicated for miR-122 distributions vs all targets. (C) CDF plot of the 
log2 fold change in RNA expression of transcripts harboring indicated miRNA 
seeds, as in (B). Clusters were collapsed by gene so that no gene is represented 
twice. KS Test p-values indicated for miR-122 distributions vs all. (D) Canonical 
3'UTR binding example of the Agpat1 3'UTR. Inset nucleotide conservation 
scores (PhyloP) and multi-alignments. (E) Non-canonical 3'UTR binding example 
of the Neo1 3'UTR. Inset nucleotide conservation scores (PhyloP) and multi-
alignments. 
 228 
While we observed robust de-repression for canonical targets, we noted that 
3'UTR targets with G-bulged seeds were not significantly de-repressed (Figure 
5.7C). Thus it seems that while the non-canonical seed is clearly used in the 
sense that AGO:miR-122 complex binds, it does not appear to confer any 
repression.  
There are a few plausible explanations for this. Unlike the results obtained 
with miR-124, where G-bulges occur at between positions 5 and 6 of the mRNA 
and maintain full Watson-Crick base pairing (Chi et al., 2012), the miR-122 G-
bulge occurs between positions 6 and 7 and induces a G:U base pair at position 
7. Conceivably, this may confer a difference in the ability for miR-122 to nucleate 
on a target where the end result is a less stable seed with a G:U base pair. 
Structural evidence is consistent with this hypothesis, where notably base pairing 
at positions 6 and 7 requires that the target mRNA displace an alpha-helix that 
normally kinks the miRNA at the end of the seed region and permits binding 
beyond position 6 (Schirle et al., 2014). A bulge in the corresponding position in 
the mRNA target may alter the conformational dynamics of AGO, to say nothing 
of potentially modulating repression. For now, the most conservative 
interpretation for the lack of repression for G-bulged miR-122 targets is to take 
them at face value, and posit that G-bulged targets may be competitive inhibitors 
of canonical miR-122 activity, may serve as reservoirs for AGO:miR-122 
complexes, and/or possess additional functions beyond mediating mRNA 
repression.  
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 The same conclusion appears to hold for miR-122 binding in regions 
beyond the 3'UTR. Summarized in Figure 5.8, we noted that for both canonical 
and G-bulged miR-122 targets, significant loss of AGO binding was observed in 
KO samples in coding exons, introns, transposable elements (LTRs, LINEs and 
SINEs), intergenic regions, and 5'UTRs (Figure 5.8A). However, for transcript 
regions that can be measured by RNAseq, only canonical miR-122 seed targets 
in 3'UTRs and to a lesser extent coding exons were de-repressed as a class in 
KO livers (Figure 5.8B). No significant effects in RNA levels were observed for 
intronic and 5'UTR targets ((Figure 5.8B). Taken together, these data provide 
robust confirmation for functional miR-122 regulation of 3'UTR targets as a 
prevailing mechanism for regulating target mRNA levels, while at the same time 
showcasing the limits of miRNA targeting function as strictly impacting mRNA 
levels. What all the extra AGO:miR-122 binding is functionally doing can only be 
guessed at with these data, though on a transcript level some targets are worth 
emphasizing.  
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Figure 5.8. Widespread canonical and non-canonical miR-122 targeting 
throughout the transcriptome. (A) AGO binding profiles for miR-122, bulged miR-
122, and the top 10 miRNA family targets (exclusive of miR-122), broken down 
by annotated region. Gray shading indicate statistical significance (P<10e-10, 
KS-test) for each annotated category compared to the same category among the 
top 10 miRNA families. (B) RNA expression profiles (as in a) for miR-122, bulged 
miR-122, the top 10 miRNA, and all miRNA family targets, by expressed 
annotated region. Asterisks indicate statistical significance (P<10e-10 KS-test) for 
each annotated category comparison. All other comparisons were not significant. 
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A brief survey of miR-122 dependent AGO binding beyond 3'UTRs 
 In the following sections, I will focus primarily on 3'UTR targets de-
repressed in miR-122 KO livers as the key players whose disregulation probably 
contributes most to the cancer phenotype of these mice. Still, some discussion is 
appropriate for non-3'UTR genic targets, especially those for which a 
measureable change in mRNA abundance can be assessed from paired RNAseq 
data. While repressive 3'UTR targeting may be the most straightforward to 
interpret globally across a transcriptome, it is by no means definitive at the 
transcript level, as the case of HCV clearly demonstrates. So we must suspend 
our general concept of "miRNAs as repressors of mRNA at 3'UTRs" when we 
zoom in, and consider alternatives.  
 For instance, perhaps miR-122 binding stabilizes cellular RNA, as in HCV, 
or activates translation, as in AU rich elements in the 3'UTR of TNF mRNA under 
stress (Vasudevan et al., 2007). An enhancement of translation has also been 
shown for AGO binding the 5'UTR of ribosomal protein transcripts with miR-10a 
(Ørom et al., 2008). Intronic targeting has in general been only obliquely 
addressed functionally, but given the plurality of evidence of AGO shutting to the 
nucleus, where localization is often dictated by miRNA isoforms, roles in 
regulating mRNA stability, alternative splicing, mRNA processing, and perhaps 
RNA transcription cannot be ruled out (Hwang et al., 2007; Schraivogel and 
Meister, 2014). Lastly, recent evidence that non-linear splicing of exons to form 
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circular RNAs (circRNAs) may act as miRNA sponges offers yet another 
functional mechanism to consider for non-3'UTR binding (Memczak et al., 2013). 
In all of the above cases, it is not necessary that mRNA levels be impacted, so 
our inability to see a change in RNA abundance does not preclude additional and 
as yet unknown functions. Just the same however, it is important to stress that 
the null hypothesis, that these non-3'UTR AGO binding events "aren't doing 
much" must be taken seriously, particularly when considering the lack of purifying 
selection observed for the majority of non-3'UTR sites (discussed in the next 
section). Still, some outliers appear very interesting.  
 Carboxylesterase1 (Ces1) proteins are a class of enzyme that participate 
in drug, lipid and xenobiotic metabolism of small molecules. Primarily expressed 
in the liver, the Ces1 gene has undergone many duplication events with at least 5 
members clustered in a 0.2Mb stretch of chromosome 8 (Holmes et al., 2010). 
Interestingly, Ces family members 1d, 1e, and 1f all exhibit miR-122 dependent 
binding in coding exons, and all are significantly down-regulated (~2-3 fold) in KO 
livers (Figure 5.9A). Notably, Ces1 expression also goes down in mouse livers 
with age (Fu et al., 2012). Thus, it's possible that miR-122 may act to stabilize or 
stimulate translation of this protein family, and that over time, lower miR-122 
results in lower expression of these detoxifying enzymes. Thinking of miR-122 
KO livers from an aging perspective might be an interesting new frame for 
interrogating the altered liver biology of these mice.  
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Figure 5.9. Two examples of miR-122 regulation on cellular coding exons. (A) 
Ces1 or (B) Drosha genes are shown below WT and KO CLIP tracks after read 
depth normalization. Zoom in view displays nucleotide conservation scores 
(PhyloP) and multi species alignments for indicated regions. miR-122 seeds 
highlighted in gray. In both cases, transcript levels were significantly altered in 
KO livers. See text for details.  
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 Another example of coding exon targeting is Drosha, a key nuclear RNAse 
involved in miRNA biogenesis. The second exon of Drosha has two miR-122 
sites in mice, one of which is reasonably well-conserved (Figure 5.9B). As 
Drosha expression goes up in KO livers, it's likely that miR-122 is normally 
playing a repressive role on Drosha gene expression. This could constitute a 
feedback loop to regulate Drosha expression levels as a means of controlling 
global miRNA biogenesis. In this manner, the cell might be able to "sense" 
altered miR-122 (or other miRNA) abundance and regulate miRNA processing 
accordingly. Along these lines, the Dicer 3'UTR possesses a non-canonical miR-
122 site, found only in mice (not shown), however, little change in RNA levels 
was noted.  
 Additional interesting results can be observed in 5'UTRs that possess 
miR-122 sites. One example is CXC chemokine-ligand-1 (Cxcl1). Previously 
called Gro-alpha, this inflammatory cytokine is produced by a variety of cells and 
binds the Cxcr2 chemokine receptor to promote fibrogenesis and angiogenesis. 
Shown in Figure 5.10A, it possesses clear miR-122 binding sites in its 5'UTR. In 
KO livers, Cxcl1 expression is significantly increased (~3.2 fold), thus it's likely 
that miR-122 normally plays a repressive role in binding the 5'UTR. Cxcl1 
expression has been recognized as an inflammatory hallmark in a number of 
cancers, including HCC (Bandapalli et al., 2012; Tang et al., 2012). Moreover, 
increased Cxcl1 expression has been identified as a predisposition marker for 
HCV and alcohol induced cirrhosis, where interestingly a SNP in the Cxcl1 intron 
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appears to be involved (Nischalke et al., 2012; 2013). In mice, two miR-122 sites 
are present in the 5'UTR, however, and this is a theme which we'll return to, 
neither of them are conserved in humans (Figure 5.10A).  
 Another example of 5'UTR binding is Mavs, a well known anti-viral 
signaling molecule and as discussed in the introduction, a target for the HCV 
NS3/4A protease to blunt the innate immune response. The Mavs 5'UTR robustly 
binds miR-122 and expression is elevated ~2 fold in KO livers, thus pointing to a 
normally repressive role for miR-122 binding (Figure 5.10B). It's certainly 
tempting to hypothesize that Mavs regulation by miRNA at the 5'UTR may act as 
a miR-122 sensor, where in the case of the HCV:miR-122 sponge, an up 
regulation of Mavs may help dampen the effects of NS3. But alas, this makes 
zero sense considering that the miR-122 site is not conserved in humans (Figure 
5.10B). 
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Figure 5.10. Two examples of miR-122 regulation on cellular 5'UTRs. (A) Cxcl1 
or (B) Mavs genes are shown below WT and KO CLIP tracks after read depth 
normalization. Zoom in view displays nucleotide conservation scores (PhyloP) 
and multi species alignments for indicated regions. miR-122 seed highlighted in 
gray. In both cases, transcript levels were significantly upregulated in KO livers.  
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miR-122 3'UTR targets are poorly conserved 
 Despite clear and robust miR-122 binding along with a correlated change 
in expression level, the preceding examples appear in large part to be species 
specific, given that the miR-122 seed sites do not appear conserved in 
mammalian lineages, especially between mouse and human. We can explore 
this in a more general fashion by considering the nucleotide conservation of the 
core 6mer of a miRNA binding site, using PhyloP conservation scores across 
sequenced mammalian genomes (Pollard et al., 2010). Importantly, PhyloP 
scores are calculated per nucleotide and assume a neutral model of evolution. 
Positive scores indicate high conservation, while negative scores indicate rapidly 
diverging sequences; scores near zero are undergoing neutral drift. By plotting 
the mean PhyloP score across a miRNA 6mer, and binning by miRNA and 
genomic region, we can discern how well conserved miR-122 target sites are 
relative to other highly expressed miRNAs. The expectation, largely afforded by 
miRNA target prediction efforts, is that highly conserved miRNAs (such as miR-
122) usually regulate a conserved set of targets.  
 The results are shown in Figure 5.11. As expected exonic regions are 
more conserved (>0) than intronic regions (~0) which are largely undergoing 
neutral drift. For the top ten expressed miRNAs, conservation on 3'UTRs 
approaches that of coding exons. 3'UTR targets for miR-122 however, are 
significantly less conserved compared to the top 10 or all miRNAs (Figure 5.11A). 
Such a pattern is repeated among coding exon miR-122 targets generally, and is 
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magnified by focusing on 3rd codon positions, which are under less selective 
pressure to maintain protein coding sequences at the nucleotide level (Figure 
5.11B). Bulged miR-122 sites generally were not statistically different than the top 
ten miRNA or all miRNAs. These results are somewhat surprising in that they 
imply that most canonical miR-122 targeting in mice is species specific. 
Moreover, it also predicts that only a select subset of targets are shared between 
mouse and human, and that humans likely have a completely different set of 
miR-122 regulated targets. The causes, consequences, and potential 
mechanisms for miR-122 species specificity despite the fact that this miRNA is 
highly conserved down to fish will be addressed in the discussion. For now, it 
suffices to bring this point up as we begin to consider what classes of targets are 
derepressed in KO livers.  
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Figure 5.11. miR-122 CLIP targets are not well conserved in mouse. (A) Mean 
nucleotide conservation scores for mouse miR-122, bulged miR-122, the top 10 
miRNAs and all miRNA targets, denoted by genic region. PhyloP scores from 
placental mammals were averaged across the core miRNA 6mer and plotted. 
Shaded areas indicate statistical significance compared to the top 10 or all 
miRNA targets (P<10e-10, KS-test). (B) Per nucleotide PhyloP scores calculated 
as in (A) were further subdivided by codon position for coding exons. Shaded 
areas indicate statistical significance (P<10e-10, KS-test). 
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miR-122 regulates a diverse set of metabolic proteins 
 Pioneering studies in mice following miR-122 antagonism with anti-sense 
oligonucleotides (ASOs) or locked nucleic acids (LNAs) revealed altered lipid 
profiles characterized by reduced plasma cholesterol levels, increased hepatic 
fatty-acid oxidation, and a decrease in hepatic cholesterol and fatty-acid 
synthesis rates (Elmén et al., 2008; Esau et al., 2006; Krützfeldt et al., 2005). 
These studies identified a number of direct miR-122 targets using microarrays, 
and further defined secondary targets whose expression was altered but did not 
contain predicted miR-122 sites. Indeed several genes with crucial to lipid 
metabolism but lacking miR-122 sites (Acc1, Acly, Scd1, Srebp2 and Hmgcr) 
were down-regulated (Esau et al., 2006; Krützfeldt et al., 2005). Consistent with 
these findings, miR-122 antagonism decreased serum cholesterol levels in 
chimpanzees (Lanford et al., 2010). 
 As the miR-122 KO mouse provides a more detailed identification of all 
miR-122 regulated genes (via RNAseq) and enables subsetting of direct targets 
(via AGO-CLIP), we revisited proposed groupings of miR-122 targets using gene 
ontology (GO) analysis. We first focused on all de-repressed mRNAs in miR-122 
livers using all expressed genes as the background control. We found that 
transcripts encoding small molecule and lipid metabolism were highly enriched 
biologic processes (Figure 5.12A). Significant enrichment for proteins in 
membrane bound organelles and secreted vesicles was also observed (Figure 
5.12B). Focusing on direct miR-122 targets (CDS and 3'UTR), we observed a 
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similar enrichment for biologic process and cellular component (Figure 5.12C-D). 
No qualitative difference was observed between GO results of miR-122 versus 
bulged miR-122 targets. Taken together, these data largely confirm and expand 
upon previous studies with the identification of a non-canonical miR-122 binding 
site as contributing to the overall theme of miR-122 as a key regulator of liver 
metabolism. And yet, as we consider the apparent species specificity of a 
substantial fraction of miR-122 regulation, we must ask: does the same hold for 
humans?  
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Figure 5.12. Gene ontology (GO) analysis of de-repressed miR-122 targets in 
mice. (A) GO term enrichment and FDR significance of the top GO Process terms 
for all miR-122 targets de-repressed in miR-122 KO mice. (B) As in (A), but for 
the top GO Component terms. (C) GO term enrichment and FDR significance of 
the top GO Process terms for all 3'UTR and CDS miR-122 targets de-repressed 
in miR-122 KO mice. (D) As in (C), but for the top GO Component terms. 
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Establishing a miR-122 target network in human liver 
 The results presented thus far with miR-122 knockout mice livers have 
been illuminating to define the complex web of targets directly and indirectly 
regulated by miR-122. Given the high conservation and expression of miR-122 in 
mammalian livers, it has so far been reasonable to assume that miR-122 likely 
plays similar roles in these varied organisms. Surprisingly, the high frequency of 
mouse specific miR-122 targeting suggests otherwise.  
 To address this and to enable a direct comparison between human and 
mouse, we decided to perform AGO-CLIP in human liver samples procured by 
Kalpana Ghoshal at OSU. Specifically, we chose liver resections from HCC 
patients to compare tumor to histologically "normal" adjacent tissue. 
Pathologically, these samples exhibited moderate to poorly differentiated HCC 
with adjacent fibrosis and cirrhosis (Table 5.1). Importantly, we used lower miR-
122 expression in HCC tumors compared to adjacent tissue as an additional 
selection criteria (Figure 5.13).  
We reasoned that the matched nature of these samples (tumor versus 
normal from the same patient) combined with differences in measured miR-122 
abundance would increase our chances in identifying not just static miR-122 
targets (i.e. transcripts with seeds) but also to observe AGO-CLIP binding 
changes analogous to the miR-122 KO mouse. AGO-CLIP was performed on five 
human HCC samples and five matched controls for a total of ten libraries. 
 
 244 
             Table 5.1 HCC subject characteristics 
 
Table 5.1 and Figure 5.13. HCC subject characteristics and concurrent miR-122 
qPCR in human liver samples. (Left) Subject characterstics table for five HCC 
patients. (Right) miR-122 qPCR in arbitrary expression values for paired tumor 
versus normal adjacent tissue for five HCC patient liver samples. Paired t-test p-
value between normal versus tumor samples shown.  
 
 
Figure 5.14. Autoradiogram of AGO bound RNA in human HCC tumors or 
matched normal adjacent tissue. Autoradiogram of 32P-labelled RNA bound to 
AGO after IP using the pan-AGO 2A8 antibody. AGOs migrate at 97kDa, which 
shifts by RNA species bound by approximately 1kDa/3nt, thus AGO bound to 
~22nt miRNA should be around 105kDa. IgG used as a non-specific control. 
Minus crosslink control shows the stringency of washes in that only a faint 
Ago:miRNA complex remains. High RNAse and low RNAse conditions indicated. 
Region excised corresponding to 110-150kDa complexes is highlighted. Left 
panel depicts signal from five patient samples of normal adjacent tissue, where 
the amount of liver tissue used per sample is indicated. The right panel depicts 
five liver tumors matched by number to normal adjacent tissue.  
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The autorads gave clear 110kDa miRNA bands in normal tissue, however 
some differences in signal intensity were apparent in matched tumor samples 
(Figure 5.14). One general reason for this may be the lower tissue volume used 
compared to mouse liver. Nevertheless, library construction after excising mRNA 
sized regions was successful (not shown) and so we moved forward with 
sequencing.  
 As before, the first analysis we performed was on the miRNA profiles 
between tumor and normal samples. We confirmed our qPCR results and 
observed that miR-122 was indeed reduced on AGO in tumor samples, in 
addition to other miRNAs, notably miR-194 and miR-144 Figure 5.15. Loss of 
miR-194 and miR-144 in hepatocytes have been previously implicated in HCC 
progression and liver inflammation (Krützfeldt et al., 2012; Li et al., 2015). A 
number of miRNAs, such as miR-21 and miR-221/222 exhibited increased AGO 
association in tumors, and largely confirms previous and recent observations 
(Dong et al., 2015; Karakatsanis et al., 2013; Ogawa et al., 2012; Sun et al., 
2015). Taken together, these largely congruous results set the stage for exploring 
miRNA target regulation where clearly miR-122 is one of many miRNAs involved 
in cancer progression.  
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Figure 5.15. Volcano plot showing the log 2 fold change between tumor versus 
normal human liver tissue of miRNA-CLIP results. Y-axis denotes FDR, where p 
= 0.01 and 0.05 lines are indicated. Notable miRNAs are highlighted by color 
and/or label.  
 
 Next, groomed reads were aligned to the human genome (hg18) and 
clustered such that mapped reads that overlapped by 1nt. Clusters were then 
grouped by BC and plotted as before to get a sense of the distribution of clusters 
across various genomic regions (see Chapter 4). A greater proportion of coding 
exon targeting was evident across all libraries and this frequency did not appear 
to vary much with increasing BC (Figure 5.16). For downstream analysis of 
miRNA seeds, a cutoff of five libraries was used.  
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Figure 5.16. Cluster annotation results by increasing biologic complexity. AGO-
CLIP reads from up to 10 libraries from human liver were clustered with a 
minimum overlap of 2nt. Clusters with reads from any one, two, three and so on 
up to ten libraries the were annotated. The resulting proportions of clusters 
overlapping known genic elements is plotted above, alongside the total number of 
clusters with the respective biologic complexity (BC).  
 
 With these cluster definitions, a more detailed annotation was performed 
comparing all normal tissue versus tumor clusters, including those commonly 
shared (Figure 5.17). Of the ~19000 clusters at this stringency, close to 20% 
were in 3'UTRs and an even greater proportion (~70%) mapped to coding 
regions than in mice. Other genic regions, such as introns, transposable 
elements (TEs), 5'UTRs, and intergenic regions, were not appreciably different 
between made up the remaining 10%. Comparing the same annotation in mouse 
livers (Figure 5.4), 3'UTR binding was consistent at 20% of all clusters. The 
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marked increase in coding exon binding between human and mouse (or 
conversely, the decrease in intronic and TE binding) is a bit puzzling and 
probably reflects distinct transcriptome differences between human and mouse 
liver. Some amount of bioinformatic noise can also not be ruled out.  
 
 
Figure 5.17. Cluster annotation of normal adjacent liver tissue (Normal) or 
matched tumor (Tumor) CLIP libraries from human liver mapping to various 
regions of the genome. Clusters unique to each case plus those in common are 
indicated. A BC filter of 5 of 10 libraries was specified. TE, transposable 
elements; Other, includes non-coding RNA, satellite repeats, low complexity 
elements, etc.  
 
 Just the same, we went forward with the same analysis performed in 
mouse liver, where clusters were grouped by the presence of miRNA seed and 
genomic region, and the log2 fold change between normal and tumor plotted as a 
CDF. In this plot, as in the mouse, positive values indicate greater AGO binding 
in the normal tissue, while negative values indicate greater binding in tumors 
(Figure 5.18A). For miR-122 3'UTR targets, we observed significant reductions in 
AGO binding in tumor tissue for both canonical and G-bulged targets, consistent 
with miR-122 loss in this context (Figure 5.18B).  
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Figure 5.18. Global reduction of AGO binding miR-122 targets observed in liver 
tumors. (A) miR-122 dependence definition by Ago binding profiles. (B) umulative 
distribution fraction (CDF) plot of the log2 fold change in Ago binding within 
cluster harboring indicated miRNA seeds. KS Test p-values indicated for miR-122 
distributions vs all targets. (C) AGO binding profiles for miR-122, bulged miR-122, 
and all miRNA targets (exclusive of miR-122), broken down by annotated region. 
Gray shading indicate statistical significance (P<10e-5, KS-test) for each 
annotated category compared to the same category among all miRNA targets. 
(D) Pie chart highlighting miR-122 or bulged miR-122 targets as a proportion of 
all miRNA targets in mouse. Total number of clusters per category indicated. (E) 
Genomic annotation breakdown of canonical or bulged miR-122 sites.  
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Intriguingly, we also observed the opposite for some miRNAs, most 
notably miR-21, whose increased expression in tumors also results in increased 
AGO binding of miR-21 targets.  
 Focusing on miR-122 binding, we observed as in mice, that reduced AGO 
binding was not specific to 3'UTRs and was observed for both canonical and G-
bulged sites significantly in genic regions (Figure 5.18C). The miR-122 targetome 
in human liver constituted around 9% of all AGO clusters, slightly higher than the 
~6% in mice (Figure 5.18D). The miR-122 target network also skewed heavily to 
coding exons (>60%) and was generally similar to the global annotation of 
miRNA targeting in liver.  
 In the last analysis similar to that performed in mice, we investigated the 
conservation of miR-122 seeds using PhyloP scores and again observed that 
3'UTR and to a lesser extent coding exon canonical miR-122 targets were 
generally less conserved that the top 10 or all expressed miRNA (Figire 5.19).  
 Taken together, these results extend conclusions obtained in miR-122 KO 
mice with the human observation of a G-bulged miR-122 seed, extensive non-3-
UTR AGO binding, and importantly, poor conservation of miR-122 seeds that 
may point to high species specificity of miR-122 target regulation.  
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Figure 5.19. miR-122 CLIP targets are not well conserved in human. (A) Mean 
nucleotide conservation scores for human miR-122, bulged miR-122, the top 10 
miRNAs and all miRNA targets, denoted by genic region. PhyloP scores from 
placental mammals were averaged across the core miRNA 6mer and plotted. 
Shaded areas indicate statistical significance (P<10e-10, KS-test). (B) Per 
nucleotide PhyloP scores calculated as in (A) were further subdivided by codon 
position for coding exons. Shaded areas indicate statistical significance (P<10e-
10, KS-test). 
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Intersecting miR-122 target networks between mouse and human 
 Considering how well the miR-122 KO mouse appears to phenocopy the 
slow and chronic progression to HCC in humans, its reasonable to propose that 
miR-122 targets shared between mouse and human might be key drivers of the 
HCC phenotype. In this context, the high species specificity exhibited by miR-122 
target regulation between mouse and human can be seen as more of a feature 
than a bug: by intersecting these disparate datasets and focusing on common 
targets, we can filter out species specific noise to settle on a core set of 
conserved factors that presumably play the biggest roles in HCC. Of course, the 
alternative hypothesis, that much of the species specificity itself may drive 
pathogenesis is not without weight. This is especially true given the HCC cancer 
phenotype which strikes mice well past the age of sexual maturity, thus 
envisioning how natural selection acts to maintain miR-122 targets in this 
scenario is highly problematic, absent additional factors that affect individual 
fitness. This point will be addressed further in the discussion. For our purposes, 
we should simply consider the species specificity of miR-122 targets in the 
broader context of the multi-factorial nature of HCC. Or to use an analogy, let's 
say there are 1000 ways to get liver cancer. Far from miR-122 deregulation 
making that total 1001, the species specificity might make it more like 2001.  
 As of the writing of this chapter (mid-March 2015), RNAseq in matched 
normal and tumor samples has not yet been performed. So for the ensuing 
analysis, miR-122 target CLIP comparisons have been made with all transcripts 
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de-repressed in miR-122 KO livers. Irrespective of genic region, of the ~3900 
genomic loci harboring canonical and G-bulged miR-122 sites in mice roughly 
~15% (613) possessed any overlap with human targets in liver (Figure 5.20A). 
The human targetome, smaller than the mouse due to lower sequencing depth, 
overlapped considerably with all mouse targets. Focusing on the set of targets 
de-repressed in mice, only 76 targets (2% of mouse and 7% of human) were 
common among these datasets.  
 This theme is repeated when we zoom in on 3'UTR targets. Of the ~1200 
miR-122 3'UTR targets in mice, only 29 (or ~2%) were both de-repressed in 
mouse livers and found in human (Figure 5.20B). Focusing on miR-122 targets 
identified as HCV de-repressed in Huh-7.5 cells further reduces the overlap to 14 
targets with an additional 18 in common with de-repressed mouse targets (likely 
what remains to be found if human livers were sequenced deeper) (Figure 
5.20C). 
 It must be noted that even of the 29 targets in common in Figure 5.20B, 
nearly half can be considered co-incidental: miR-122 sites are not conserved 
between human and mouse paralogs. Thus in these targets, miR-122 regulation 
appears to have evolved independently. Such an example is shown in Figure 
5.21. This transcript encodes an alkaline phosphatase of unknown function that 
is expressed in liver, bone and kidney. In both mouse and human it clearly 
possesses AGO bound miR-122 sites, however the primary sequence and 
precise location relative to the stop codon are not conserved.  
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Figure 5.20. miR-122 target overlaps between human and mouse. (A) 
Proportional Venn diagram showing overlap of all CLIP identified canonical and 
bulged miR-122 targets in mouse or human liver, compared to all de-repressed 
miR-122 targets measured by RNAseq. (B) Diagram as in (A) focusing only on 
3'UTR targets. Genes found in all three categories are listed at right, in bold are 
any targets with an previous confirmatory data, in red are targets validated using 
either luciferase or single cell reporters from this thesis. (C) Diagram as in (B) 
displaying overlap with all CLIP derived miR-122 targets from Huh-7.5 cells.  
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Figure 5.21. miR-122 targeting ALPL 3'UTR is conserved while the binding site is 
not. AGO-CLIP data in mouse miR-122 or WT mouse liver (A) or human normal 
and tumor tissue (B). Zoom in view displays nucleotide conservation scores 
(PhyloP) and multi species alignments for indicated regions. miR-122 seed 
highlighted in gray. 
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 Of the number of genes that are conserved between human and mouse 
and that are derepressed in mouse KO livers, one novel miR-122 target stands 
out. Interleukin-1 receptor antagonist protein (IL1RN) is a well studied and potent 
negative regulator of IL-1B, a key pro-inflammatory signaling molecule (Gabay et 
al., 2010). Deficiency in IL1RN results excessive IL-1B signaling to produce acute 
and chronic inflammation in a variety of animal models and human disease 
contexts (Aksentijevich et al., 2009; Hirsch et al., 1996; Nicklin et al., 2000; 
Reddy et al., 2009). IL-1B has also been implicated as an important mediator in 
liver pathology, where increased IL-1B activity has been observed from patients 
with chronic liver diseases to fulminant hepatic failure (Sekiyama et al., 1994; Tilg 
et al., 1992).  
 IL1RN is a clear miR-122 target in both mouse and humans, with 
additionally conserved supplementary pairing (Figure 5.22). This identification of 
IL1RN as a miR-122 target in vivo raises numerous hypotheses. Conceivably, 
miR-122 could normally play a role in permitting IL-1B signaling by regulating 
IL1RN. Should an IL-1B driven inflammatory response overshoot, and reduce 
miR-122 levels as is typically seen in many liver diseases (see Introduction), de-
repressed IL1RN may work to dampen the IL-1B cascade. This feedback loop 
would make sense in the context of an acute HCV infection as a key axis to 
silence by potentially sequestering miR-122. As HCV replicates and induces an 
inflammatory response, reducing miR-122 would derepress IL1RN to suppress 
this exact immune response.  
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Figure 5.22. Conserved miR-122 targeting of the IL1RN 3'UTR in murine and 
human liver. AGO-CLIP data in mouse miR-122 or WT mouse liver (A) or human 
normal and tumor tissue (B). Zoom in view displays nucleotide conservation 
scores (PhyloP) and multi species alignments for indicated regions. miR-122 is 
highlighted in red, extensively conserved seed waiting highlighted in gray.  
 
In accordance with this, increased IL1RN (and IL-1B) expression has been 
observed in patients with acute and chronic active HCV infections (Gramantieri et 
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al., 1999; Libra et al., 2006). As an added wrinkle, IL1RN has also been identified 
as interferon induced in the context of HCV therapy (Cotler et al., 2002). And so 
we conclude with the following testable scenario, should HCV prevent the 
activation of an endogenous IFN response via NS3/4A inactivation of RIG-I 
signaling, derepression of a negative regulator of inflammation (IL1RN) by 
miRNA sequestration might be means to bypass IFN induction as suppress an 
inflammatory response. 
 The above hypothesis is one of many that can be made for the common 
targets shared between humans and mice as we begin to consider additional 
roles for miR-122 as a positive regulator for HCV proliferation in vivo. Clearly, 
much work remains to be done on this front.  
Chapter 5 summary and discussion 
 In this chapter, we've explored efforts to elucidate the miR-122 targetome 
in vivo using a miR-122 knockout mouse model and human liver tissue. We've 
uncovered both non-canonical G-bulged miR-122 sites and revealed widespread 
miR-122 dependent loci, well beyond the normal 3'UTR sites of miRNA function. 
Furthermore, we've revealed surprisingly low conservation of targets for such a 
highly conserved miRNA. In this section, we'll discuss how this might have come 
to be, and what we might expect from the miR-122 targetome if its deregulation 
contributes to a similar liver pathology in mice and humans despite regulating 
different target sets.  
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Redefining miRNA function: the Seitz hypothesis and target conservation 
 In 2009, Hervé Seitz pointed out that miRNAs present at least three 
apparent observational paradoxes (Seitz, 2009). The first paradox is how exactly 
a miRNA can have hundreds of targets, and yet many in vivo phenotypes of 
specific miRNA loss can be rescued by repressing a few, and often only single 
targets. Indeed, the developmental phenotypes for the pioneering miRNAs in C. 
elegans, lin-4 and let-7, can each be rescued by introducing complementary seed 
mutations in their respective targets lin-14 and lin-41 (Ambros, 1989; Slack et al., 
2000). One well-regarded explanation for this discrepancy is that many in vivo 
experiments tend to overlook, or not follow up, on subtle phenotypic changes 
associated with other targets. This dove-tails with another view that many miRNA 
loss-of-function phenotypes are context specific, and may not exist basally but 
require something to induce them. Indeed, a current evaluation of in vivo miRNA 
knockout studies agrees with these views, particularly in light of the fact that 
many miRNA knockouts possess no obvious phenotypes, often despite ample 
overexpression data (Vidigal and Ventura, 2015). On its face, this should strike 
fear in the heart of any miRNA researcher who relies on overexpressed miRNAs 
to repress luciferase reporters as a surrogate for miRNA target validation. But 
this is perhaps a separate discussion.  
 Compounding the miRNA:target discrepancy is the surprisingly modest 
repression exerted by miRNAs. This is the second major paradox. From a 
virologist's perspective, miRNA repression of target protein expression by less 
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than 2-fold is a pittance compared to the orders of magnitude of RNA replication 
and transcriptional regulation observed in viral infections and their counteracting 
innate immune responses. Seitz draws a more reasonable parallel by considering 
that 2-fold effects are well within intraindividual variations in gene expression and 
transcriptional noise (Seitz, 2009). Moreover, that only a fraction of human genes 
display haplo-insufficient phenotypes would only further support this argument 
(Huang et al., 2010). Fitting weakly repressive miRNAs within a complex and 
robust transcriptional control system that is largely buffered from fluctuations in 
gene expression is thus at odds with the clear importance of miRNA function.  
 To resolve these contradictions, Seitz proposed a redefinition of terms. 
Instead of positing that the primary function of miRNA is to repress mRNA by 
binding to seed sites, we should consider the obverse, that the function of mRNA 
seed targeting is to regulate miRNA activity. In other words, most mRNAs 
primarily function as miRNA sponges where the 2-fold repression is 
inconsequential for most targets except for the select few that are contextually 
very sensitive to gene dosage. This explanation provides a framework to resolve 
the both of the above paradoxes by predicting that most miRNA targets aren't 
functional in the sense that their repression has downstream consequences. 
Rather, they function more to set and continuously alter the effective miRNA 
concentration where, and this is the key, each targeted transcript responds 
uniquely but not independently of other targets. This interpretation is remarkably 
consistent at all scales of miRNA function: from thresholding effects on individual 
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transcripts thoroughly described and tested earlier (Mukherji et al., 2011), to in 
vivo phenotypes that appear only in specific contexts, such as genetic or 
environmental stress (Vidigal and Ventura, 2015).  
 For Seitz, the miRNA sponge or "pseudotarget hypothesis" also solves a 
third paradox: while many miRNA targets are conserved among closely related 
species, they differ considerably between distant species, even for highly 
conserved miRNAs (Chen and Rajewsky, 2006). This is essentially what we've 
confirmed for miR-122 targets between humans and mice, in that such targets 
are poorly conserved across these species, but often are retained in close 
neighbors such as macaques and rats, respectively. The pseudotarget 
hypothesis predicts such poor conservation among distantly related organisms 
precisely because repression is irrelevant for most targets. During evolution, the 
precise targetomes of a miRNA are free to diverge so long as pseudotargets are 
replaced with mRNAs with similar expression patterns (Seitz, 2009), or 
alternatively, by evolving exquisite control of miRNA transcription and 
degradation. As a consequence, this hypothesis strongly argues that target site 
conservation is a key feature of "real" targets.  
 Our results with miR-122 in liver would agree with this view, given that the 
vast majority of targets, while AGO associated, do not result in substantive 
repression. Still, it's possible that for many putative pseudotargets the right 
context for a visible phenotype remains elusive, but conceptually exists. Note 
also that the above discussion primarily revolves around conserved targeting in 
 262 
3'UTRs. Our CLIP data alongside other work would contest this narrow 
framework, given that AGO binding occurs well beyond 3'UTRs, can be 
conserved in these regions, and does not often behave according to strict seed 
pairing rules (Helwak et al., 2013; Loeb et al., 2012). Moreover, the 
demonstration of many species specific miRNA phenotypes in a variety of 
systems suggests that the pseudotarget hypothesis can be a source of neo-
functionalization for miRNA binding (Vidigal and Ventura, 2015). 
 The broadened framework originally proposed by Seitz has in large part 
underwritten the competing endogenous RNA (ceRNA) hypothesis as its more 
formalized and highly debated extension (Denzler et al., 2014; Ebert and Sharp, 
2010; 2012; Figliuzzi et al., 2013; Jens and Rajewsky, 2014; Salmena et al., 
2011). Critics rightfully point out that relatively minor fluctuations of individual 
target transcripts are unlikely to perturb global miRNA function, assuming that 
miRNA levels are in vast excess to the overall target abundance (Jens and 
Rajewsky, 2014). For highly abundant miRNAs such as miR-122, only when 
target abundance approaches or exceeds the miRNA expression level are 
ceRNA effects observed (Denzler et al., 2014). Nevertheless, as researchers are 
only beginning to appreciate the extent of AGO targeting outside of 3'UTRs and 
the prevalence of non-canonical binding, the general assumption that miRNA 
levels are in vast excess to target abundance will require revisiting. 
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The miR-122 knockout molecular phenotype and HCV: a proposed evolutionary 
connection 
 So where does the above discussion leave our results with miR-122 and 
HCV? I propose that the expansion of miR-122 bound loci defined by AGO-CLIP, 
combined with the relatively poor conservation observed for miR-122 target seed 
sites (as pseudo targets) may bear directly on two primary and unique features of 
this miRNA: its high abundance and its coercion by HCV.  
 At the outset, miR-122 is both an outlier for being highly liver specific and 
also the most abundant miRNA in any tissue measured, especially in humans 
(Ladewig et al., 2012; Lagos-Quintana et al., 2002). A sufficient explanaiton for 
these observations has yet to emerge. As mentioned earlier, the miR-122 cancer 
phenotype occurs after sexual maturity and KO mice display no apparent 
problems in breeding (K. Ghoshal, personal communication), unlike other 
miRNAs with critical roles in development or cellular differentiaion (de Pontual et 
al., 2011; Rodriguez et al., 2007; Vidigal and Ventura, 2015). Assuming that the 
the reproductive fitness of miR-122 KO mice is only mildly affected by miR-122 
loss, it is difficult to fathom how a miR-122 target network could not undergo 
genetic drift (Lynch and Hagner, 2015). Consider a small core set of targets that 
are sensitive to ~2-fold repression, among a pool of psuedo-targets which are 
insensitive. Absent strongly deleterious acquisition of miR-122 binding which is 
cleared though selective avoidance (Bartel and Chen, 2004), most pseudo-
targets and even non-targets are free to acquire miR-122 sites with no 
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deleterious effects. This would explain the the divergence of miR-122 targetomes 
between humans and mice and their relative evolutionary proximity to closely 
related species. Furthermore, this could also serve as the engine for neo-
functionalization which would be expected from such "evolutionary meandering" 
of intermolecular interactions (Lynch and Hagner, 2015). Even among highly 
conserved miRNAs, such a mechanism could also account for the emergence of 
species specific acquisition of sites that may then undergo positive selection as 
part of the neofunctionalization process, as has been observed in humans (Li et 
al., 2012; Saunders et al., 2007). 
 Now, one could imagine a scenario where at some point the expanded 
miR-122 targetome could negatively impact those core set of targets that must be 
repressed, due to the overall target abundance becoming inhibitory to repression. 
As a result, the hepatocyte may evolve a means to increase miR-122 abundance, 
and the cycle repeats. Notably, absolute miR-122 abundance per cell is well 
known in mouse (~66,000 copies / cell) and human, which contains nearly twice 
the amount of miR-122 (~135,000 copies per cell) (Chang et al., 2004; Denzler et 
al., 2014).  
 Overall, this hypothesis makes at least four testable predictions: that miR-
122 level should scale with its absolute target abundance across various 
organisms (measured by CLIP and not by informatic prediction), that targetomes 
should diverge between distant organisms (as is predicted in vertebrates (Xu et 
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al., 2013)), and that miR-122 promoter complexity as well as levels per 
hepatocyte should scale with organismal complexity. 
 If we consider HCV infection in this context, one reasonable argument for 
its acquisition of miR-122 dependence as a protective shield is due to the simple 
fact that miR-122 is both highly abundant in liver, but mostly irrelevant for most 
targets. In other words, HCV has evolved to use miR-122 precisely because it 
provides an unexploited niche relative to other miRNAs. At first glance, this 
appears to resemble a null hypothesis for any pro-viral role for the miR-122. 
However this need not be the case, especially if the substantial and species 
specific targeting in humans represents the right mix of targets that would make 
sense to de-repress. For conserved targets such as IL1RN (Figure 5.22), and 
non-conserved targets such as Drosha (Figure 5.9B), it is straightfoward to 
envision pro-viral paths for the HCV sponge in humans.  
 All of this is to say that many surprises are likely to continue to be in store 
for the myriad of roles that miR-122 plays in the livers of vertebrates. Expanding 
upon our results to test specific predictions in other organisms and model 
systems, using novel HCV variants (such as the U3 and miR-15 depdendent 
viruses), putative murine and equine cousins to HCV, and empowered by 
unbiased genomic methods such as CLIP, we are poised to unravel the complex 
host-viral interaction of information that is centered upon one 22 nucleotide 
snippet of RNA, life's indispensable molecule.  
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Chapter 6: Concluding remarks 
In this very short chapter, I aim less to provide a comprehensive model of 
the work presented in this thesis than to highlight the unanswered questions this 
work raises and point out viable paths forward. 
In succint terms, the following model is proposed that links HCV replication 
in the infected hepatocyte to outward manifestations of HCV induced disease. 
Mechanistically, miR-122 is positied as a central molecular player in this process. 
In normal hepatocytes, miR-122 target repression is required to maintain long-
term liver homeostasis. Upon HCV infection, viral RNA coercion of miR-122 
results in de-repression of host miR-122 targets (Figure 6.1). Due to this miRNA 
sponging by HCV RNA, liver homeostasis is perturbed and can result in a 
constellation of liver complications to include HCC. Indirect pro- or anti-viral 
benefits from the miR-122 sponge are possible, but currently unknown.  
At the outset, the miR-122:HCV sponge relies on a two part assumption: 
constant miR-122 levels and sufficiently high enough viral replication to impact 
the effective miR-122 concentration in the cell. As shown in this thesis and 
addressed in previous chapter discussions, mature miR-122 levels appear 
relatively constant in vitro and in vivo. Capturing the dynamic nature of 
cytoplasmic HCV replication that underlies long-term chonicity in the liver is the 
next major challenge. While the sponge effect decribed in this work can be 
thoroughly tested in cell culture systems, its ultimate validation in vivo will require 
appropriate model systems and technologies aimed at interrogating single cells.  
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Figure 6.1. A concise model for HCV:miR-122 sponge induced liver disese. In 
normal hepatocytes, miR-122 target repression is required to maintain long-term 
liver homeostasis. Upon HCV infection, viral RNA coercion of miR-122 results in 
de-repression of host miR-122 targets, which in turn de-stabilizes liver 
homeostasis. Indirect benefits (or road-blocks) to the virus as a result of miR-122 
target de-repression are possible but currently unknown. This figure adapted from 
(Luna et al., 2015).  
 
To this end, recently decribed hepaciviruses of rodents, as close 
homologs to HCV, might offer long sought after disease-causing surrogates for 
HCV infection. That these viruses have miR-122 sites in their 5'UTRs is highly 
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suggestive of their need for this miRNA and may point to potential sponge 
effects.  
But given that our data also pinpoint high species specificity to miR-122 
targeting between mice and humans, its possible that distinct human specific 
miR-122 targets, when de-repressed, might be key drivers for human disease. To 
this end, the application of single cell transcriptomic analysis to HCV infected 
human liver cells represents an alternative path forward, should murine 
hepaciviruses fail to phenocopy human disease. Additionally, the in vitro Huh-7.5 
cell context, where the sponge effect was discovered, can continue to play a role 
by exploring the stoichiometic requirements for a viral RNA to sponge miRNA. 
Testing other HCV genotypes with different replicative potentials, testing 
heterzygous miR-122 knockout mutant cells, and probing the sponge effect 
induced by the m15 virus offer proximal means to cement our observations while 
providing a roadmap for invesitgations of other RNA viruses.  
In sum, the genomic portrait I've outlined for HCV and miR-122 in this 
thesis is exactly that: a single perspective on the multifaceted relationship 
between host and virus. As biology matures in the post-genomic era, and static 
reductionist pictures yield to data-driven dynamism, the stage is set for further 
systems level views of viruses. Today as ever, Pasteur’s words remain as 
relevant as they did in the 19th century: "Messieurs, c'est les microbes qui auront 
le dernier mot." (Gentlemen, it is the microbes who will have the last word). 
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APPENDIX of OLIGOS 
Oligo name Sequence (5' to 3') 
miR-15 dependent HCV construct cloning 
Pos43_F CCTGTGAGGAACTACTGTCTTC 
Pos12343_F CGGCCAGTGAATTCTAATACGACTCA 
Pos1293_R CGGTGTCCAGTGATGGTACCAG 
Pos1358_R GCATCGCGTACGCCAAGATC 
m122to15_F 
CAGTGAATTCTAATACGACTCACTATAGACCTGCCC
CTAATAGGGGCGTGCTGCTGCCATGAATGCTGCTCC
TGTGAGGAACTACTGTC 
m122toU3_F 
CAGTGAATTCTAATACGACTCACTATAGACCTATACT
TTCAGGGATCATTTCTATAGTGTGTTACTAGAGAAGT
TTCTCTGAACGTGTAGAGCACCGATTGAATCACTCC
CCTGTGAGGAACTACTGTCTTC 
F S2p34 GATTGAATCACAGCCCTGTGAG 
R S2p34 CTCACAGGGCTGTGATTCAATC 
F S2p3 GATTGAATCACTGCCCTGTGAG 
R S2p3 CTCACAGGGCAGTGATTCAATC 
Luciferase reporter vector cloning 
miR-122_seed_F ATATCTCGAGTCTAGCCACATGACACTCCATATGCGGCCGCATTA 
miR-
122_seed_R 
TAATGCGGCCGCATATGGAGTGTCATGTGGCTAGAC
TCGAGATAT 
miR-
122_seedmut_F TCGAGTCTAGCCACATGACACAGCATATGC 
miR-
122_seedmut_R GGCCGCATATGCTGTGTCATGTGGCTAGAC 
miR-
17_4xseed_F 
/5Phos/TCGAGTCAAGGTCAGCTGCACTTTAGTACAG
TCTGTCATGCACTTTATAACGGCCCCGCTTGCACTT
TACAATCAGCAACCTTGCACTTTATATGC 
miR-
17_4xseed_R 
/5Phos/GGCCGCATATAAAGTGCAAGGTTGCTGATTG
TAAAGTGCAAGCGGGGCCGTTATAAAGTGCATGACA
GACTGTACTAAAGTGCAGCTGACCTTGAC 
miR-
17_4xseed_seed
mut_F 
/5Phos/TCGAGTCAAGGTCAGCTGCACaaTAGTACAG
TCTGTCATGCACaaTATAACGGCCCCGCTTGCACaaT
ACAATCAGCAACCTTGCACaaTATATGC 
miR-
17_4xseed_seed
mut_R 
/5Phos/GGCCGCATATATTGTGCAAGGTTGCTGATTG
TATTGTGCAAGCGGGGCCGTTATATTGTGCATGACA
GACTGTACTATTGTGCAGCTGACCTTGAC 
PKM2_3UTR_F1
881 ATATCTCGAGTGGACCCCAGAGCCCCTCC 
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PKM2_3UTR_R2
501 TAATGCGGCCGCGGTGCTTCAGCTGTTGTTTATTG 
PKM2_seedmut_
F GCAGCAAACACAGCACCCTCCACC 
PKM2_seedmut_
R GGTGGAGGGTGCTGTGTTTGCTGC 
CTDNEP1_3UT
R_F1183 ATATCTCGAGCAGCTGCTCCCCCTCCACCTG 
CTDNEP1_3UT
R_R1528 TAATGCGGCCGCTGACTTGGCTTCTCTTTGAGC 
CTDNEP1_seed
mut_F CGTGTTCACACAGCATGGAAACC 
CTDNEP1_seed
mut_R GGTTTCCATGCTGTGTGAACACG 
SFT2D1_3UTR_
F511 ATATCTCGAGAAATCAGAAACTTGTGGAAAAGAG 
SFT2D1_3UTR_
R699 TAATGCGGCCGCTTTAAAGTTACAAGCATTTAATGG 
SFT2D1_seedm
ut_F CCATAAAACACAGCAGGAACAAC 
SFT2D1_seedm
ut_R GTTGTTCCTGCTGTGTTTTATGG 
pTre3G fluorescent reporter vector cloning 
EcoRI-
nlsTagBFP_F 
CGGAATTCACCATGGGCCCTAAAAAGAAGCGTAAAG
TCATGAGCGAGCTGATTAAGGAGA 
NdeI-
nlsTagBFP_R 
GGAATTCCATATGTTATCCGGAATTAAGCTTGTGCC
C 
nlsTagRFP_F ATGGGCCCTAAAAAGAAGCGTAAAGTCATGGTGTCTAAGGGCGAAGAGC 
pT3G-MCS2-
BamHI-nls_F 
GGGGCCCAGATCTCCGCGGGGATCCACCATGGGCC
CTAAAAAGAAGCGTAAAGTC 
RFP-ClaI-N=1m-
EcoRV-pT3G_R 
CTGATTATGATCCTCTGGAGATATCCGGCTCCAGTC
TTGTATCCTGTTTCCGGCATCGATTTATCCGGAATTA
AGTTTGTGCCCC 
RFP-ClaI-N=1-
EcoRV-pT3G _R 
CTGATTATGATCCTCTGGAGATATCCGGCTGGAGTG
TTGTATGGTGTTTCCGGCATCGATTTATCCGGAATTA
AGTTTGTGCCCC 
RFP-ClaI-N=1pf-
EcoRV-pT3G _R 
CTGATTATGATCCTCTGGAGATATCCGGCTGGAGTG
TGACAATGGTGTTTCCGGCATCGATTTATCCGGAAT
TAAGTTTGTGCCCC 
RFP-end_R TTATCCGGAATTAAGTTTGTGCCCC 
RFP-ClaI-N=4-
EcoRV-pT3G  
GGGGCACAAACTTAATTCCGGATAAATCGATCGGCA
AACACCATACAACACTCCACTAGAAACACCATAAAA
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CACTCCAGATCAAACACCATACAACACTCCAGCATA
AACACCATAAAACACTCCACGGCGATATCTCCAGAG
GATCATAATCAG 
RFP-ClaI-N=6-
EcoRV-pT3G 
GGGGCACAAACTTAATTCCGGATAAATCGATCGGCA
AACACCATACAACACTCCACTAGAAACACCATAAAA
CACTCCAGATCAAACACCATACAACACTCCAGCATA
AACACCATAAAACACTCCAGTGCAAACACCATACAA
CACTCCACGAAAAACACCATAAAACACTCCACGGCG
ATATCTCCAGAGGATCATAATCAG 
pT3G-CS-
3UTR_F 
GGGGCACAAACTTAATTCCGGATAAAACTGGAGACT
GGGTGAAAGTG 
CS-3UTR-
BamHI-pT3G_R 
CTGATTATGATCCTCTGGAGATATCGGCTCAAGCAT
TGTTAATAAAAACATT 
pT3G-MASP1-
3UTR_F 
GGGGCACAAACTTAATTCCGGATAAGCTGACTTACT
TCCTCGGGGC 
MASP-3UTR-
BamHI-pT3G_R 
CTGATTATGATCCTCTGGAGATATCTTGGTTATCCAC
GAGGGTTTATTTCCAC 
pT3G-MAL2-
3UTR_F 
GGGGCACAAACTTAATTCCGGATAACACTCCTTAGA
AACTGGCAG 
MAL2-3UTR-
BamHI-pT3G_R 
CTGATTATGATCCTCTGGAGATATCATTATCAAATGA
ATACTTTATTAGAGACA 
pT3G-SFT2D1-
3UTR_F 
GGGGCACAAACTTAATTCCGGATAAAAATCAGAAAC
TTGTGGAAAAGAGC 
SFT2D1-3UTR-
BamHI-pT3G_R 
CTGATTATGATCCTCTGGAGATATCTTTAAAGTTACA
AGCATTTAATGGTTTAATC 
pT3G-PKM2-
3UTR_F 
GGGGCACAAACTTAATTCCGGATAATGGACCCCAGA
GCCCCTCC 
PKM2-3UTR-
BamHI-pT3G_R 
CTGATTATGATCCTCTGGAGATATCGGTGCTTCAGC
TGTTGTTTATTGAC 
pT3G-
CTDNEP1-
3UTR_F 
GGGGCACAAACTTAATTCCGGATAACAGCTGCTCCC
CCTCCACC 
CTDNEP1-
3UTR-BamHI-
pT3G_R 
CTGATTATGATCCTCTGGAGATATCTGACTTGGCTTC
TCTTTGAGCCTC 
pT3G-P4HA1-
3UTR_F 
GGGGCACAAACTTAATTCCGGATAACAAACAGGCTT
CCCTTTTTCTCCT 
P4HA1-3UTR-
BamHI-pT3G_R 
CTGATTATGATCCTCTGGAGATATCTTAAAAAAGATT
TAAGATCATAAATAGGTCATTG 
pT3G-AldoA-
3UTR_F 
GGGGCACAAACTTAATTCCGGATAAGCGGAGGTGTT
CCCAGGCTGC 
AldoA-3UTR-
BamHI-pT3G_R 
CTGATTATGATCCTCTGGAGATATCGCCGACTCCCC
CTTAAATAGCTGTTTA 
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CRISPR mutant cloning and sequencing 
122.sgRNA1a CACCGAGAGCTGTGGAGTGTGACAA  
122.sgRNA1b AAACTTGTCACACTCCACAGCTCTC 
122.sgRNA2a CACCGAGGAAACTCTGTAGCCACGA 
122.sgRNA2b AAACTCGTGGCTACAGAGTTTCCTC 
122Genomic_F GTTGCAAACAGAGTTCCTGTCC 
122Genomic_R GAGAGGCAGGGTTCAGCTAACC 
Drosha.sgRNA1a CACCGGAACTCTCTAACAGGGGTT 
Drosha.sgRNA1b AAACAACCCCTGTTAGAGAGTTCC 
Drosha.sgRNA2a CACCGAGGGCATAAAAACACGCACC 
Drosha.sgRNA2b AAACGGTGCGTGTTTTTATGCCCT 
DroshaGenomic_
F TCATGCCTATAATCCCAGCACTTTAGG 
DroshaGenomic_
R CAGTTTCAATACTAGGCAACATGTATCTTCTGAG 
Dicer.sgRNAEX1.
1a CACCGAACCCTGCATGATTGTGTAA  
Dicer.sgRNAEX1.
1b AAACTTACACAATCATGCAGGGTTC  
Dicer.sgRNAEX1.
2a CACCGTTATACGCCAAGAAAATATC  
Dicer.sgRNAEX1.
2b AAACGATATTTTCTTGGCGTATAAC  
DicerEX1_Genom
icF CACTGGGTAAGGTACAGAATGCTTGAC 
DicerEX1_Genom
icR TTAATCAGAAGTGGGAGGCCTGAAAG 
Dicer.sgRNAEX2.
1a CACCGCGTATAAAGACGTAGACTGT  
Dicer.sgRNAEX2.
1b AAACACAGTCTACGTCTTTATACGC  
Dicer.sgRNAEX2.
2a CACCGTATTTTATCAAGTTGTGCA  
Dicer.sgRNAEX2.
2b AAACTGCACAACTTGATAAAATAC 
DicerEX2_Genom
icF CATTTCAACACGTATTTACACAATACAGCTG  
DicerEX2_Genom
icR CAGAAGCAGAACATTTAAGAGAAACAGC  
Dicer.sgRNAEX1
9.1a CACCGAACCAGTATCTTCAAGTAA 
Dicer.sgRNAEX1
9.1b AAACTTACTTGAAGATACTGGTTC 
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Dicer.sgRNAEX1
9.2a CACCGTTCTTTCTGGCTGACTGCAC 
Dicer.sgRNAEX1
9.2b AAACGTGCAGTCAGCCAGAAAGAAC 
DicerEX19_Geno
micF GAGAGTTTTGTTTTTATACTTGGCCCATT 
DicerEX19_Geno
micR AGACTGAAAATGCTGATGCAGTAAC 
pX330 and pX458 
insert sequencing 
primer 
ACTATCATATGCTTACCGTAAC 
Small RNA northern probes 
miR-122-5p_AS AAACACCATTGTCACACTCCA 
miR-21-5p_AS TCAACATCAGTCTGATAAGCTA 
miR-16-5p_AS CGCCAATATTTACGTGCTGCTA 
U6_snRNA_AS GAATTTGCGTGTCATCCTTGCGCAGGGGCCATGCTAA 
Poly-G CLIP 
ND7C-
IndexGCAT 
/5phos/GNNNNNNNNTATGCGATCGTCGGACTGTAGA
ACTCT/idSp/CAAGCAGAAGACGGCATACGACCCCCC
CDN 
ND7C-
IndexGTCA 
/5phos/GNNNNNNNNTTGACGATCGTCGGACTGTAGA
ACTCT/idSp/CAAGCAGAAGACGGCATACGACCCCCC
CDN 
ND7C-
IndexACTG 
/5phos/GNNNNNNNNTCAGTGATCGTCGGACTGTAGA
ACTCT/idSp/CAAGCAGAAGACGGCATACGACCCCCC
CDN 
ND7C-
IndexAGCT 
/5phos/GNNNNNNNNTAGCTGATCGTCGGACTGTAGA
ACTCT/idSp/CAAGCAGAAGACGGCATACGACCCCCC
CDN 
DSFP5a AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGACG 
DSFP3a CAAGCAGAAGACGGCATA 
SSP2 GACAGGTTCAGAGTTCTACAGTCCGACGATC 
Multiplexed "Super-CLIP" primers 
Anchor_MiSeq_
CTAG_DP5_1 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTCTAGAGGGAGGAC
GATGCGG 
Anchor_MiSeq_
GATC_DP5_2  
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTGATCAGGGAGGAC
GATGCGG 
Anchor_MiSeq_
CGTA_DP5_3  
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTCGTAAGGGAGGAC
 274 
GATGCGG 
Anchor_MiSeq_
GCAT_DP5_4 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTGCATAGGGAGGAC
GATGCGG 
Anchor_MiSeq_
GTGC_DP5_5 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTGTGCAGGGAGGAC
GATGCGG 
Anchor_MiSeq_
ACCG_DP5_6 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTACCGAGGGAGGAC
GATGCGG 
Anchor_MiSeq_
CATG_DP5_7 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTCATGAGGGAGGAC
GATGCGG 
Anchor_MiSeq_T
GCA_DP5_8 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTTGCAAGGGAGGAC
GATGCGG 
Anchor_MiSeq_T
CAC_DP5_9 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTTCACAGGGAGGAC
GATGCGG 
Anchor_MiSeq_
AGTG_DP5_10 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTAGTGAGGGAGGAC
GATGCGG 
Anchor_MiSeq_T
ACG_DP5_11 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTTACGAGGGAGGAC
GATGCGG 
Anchor_MiSeq_
ATGC_DP5_12 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTATGCAGGGAGGAC
GATGCGG 
Anchor_MiSeq_
CCGA_DP5_13 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTCCGAAGGGAGGAC
GATGCGG 
Anchor_MiSeq_
CTCC_DP5_14 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTCTCCAGGGAGGAC
GATGCGG 
Anchor_MiSeq_
GGCT_DP5_15 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTGGCTAGGGAGGAC
GATGCGG 
Anchor_MiSeq_
GAGG_DP5_16 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTGAGGAGGGAGGAC
GATGCGG 
Anchor_MiSeq_
AACC_DP5_17 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTAACCAGGGAGGAC
GATGCGG 
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MSFP3 CAAGCAGAAGACGGCATACGAGATCCGCTGGAAGTGACTGACAC 
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